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Introduction 
In the Netherlands, 21.000 patients per year are struck by an ischemic stroke. 
Stroke is a major cause of death and an important cause of hospital admission 
and long-term disability. Although case-fatality rates have steadily declined 
over the past 25 years, this is mainly due to improved general stroke 
management but not to new strategies to halt or reverse the harmful effects of 
brain ischemia. Stroke as a clinical syndrome was recognized even before the 
time of Hippocrates, but it was not until I 995 that the first effective treatment, 
thrombolysis with recombinant tissue plasminogen activator, became available. 
However, this treatment can be applied only to a small percentage of patients. 
For all others cases no effective treatment is available. 
In this thesis I shall describe and discuss two types of treatment for acute 
ischemic stroke, that were studied in randomized controlled trials. Firstly, we 
evaluated the safety, efficacy and pharmacodynamics of the use of a 
hemoglobin solution, diaspirin cross-linked hemoglobin (DCLHb) in a 
multicenter trial of patients with acute ischemic stroke. Secondly, we studied 
the effect of heparin in patients with acute ischemic stroke in combination with 
atrial fibrillation (AF) entered in a large clinical study, the International Stroke 
Trial (IST). We had specific interest in the prevention of early stroke 
recurrence. 
Contents of this thesis 
Chapter 2 describes the rationale for using DCLHb and heparin in the treatment 
of acute stroke. The first part provides the background of the use of 
hemoglobin solutions with a more in-depth look at DCLHb in particular and 
reviews the available information, mostly based on experimental animal 
models. It continues with an evaluation of clinical studies that assessed the 
merits of anticoagulant treatment in acute stroke in combination with AF and 
justifies why we analysed a subgroup of 3 I 69 acute stroke patients with AF 
from the International Stroke Trial (IST). 
Chapter 3 covers the design, conduct and main results of the DCLHb in acute 
ischemic stroke (DIAS) trial in which we studied the safety and efficacy of the 
use ofDCLHb in acute ischemic stroke in humans. 
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In Chapters 4,5 and 6 we attempt to elucidate the pharmacodynamics of 
DCLHb and try to explain why DCLHb was not successful in reversing or 
halting the harmful effects of cerebral ischemia. In chapter 4 the induced 
elevation of blood pressure by DCLHb in acute ischemic stroke patients is 
described. In chapter 5 the role of vasoactive hormones in general and ET-1 in 
particular was explored by measuring BP and ET-1 plasma concentrations 
before and during administration of DCLHb. Chapter 6 focuses on the 
cardiovascular effects of DCLHb in our population. 
Chapter 7 provides the introduction to the second part of this thesis. One of the 
feared complications in the acute phase of ischemic stroke is early recurrence of 
stroke. This chapter aims to review the definition, epidemiology of and risk 
factors i.e. AF for early recurrent stroke and to focus on the benefits and risks of 
antithrombotic therapy in the prevention of this complication. 
In chapter 8 the additional diagnostic yield of long term Holter monitoring 
compared to repeated ECG recordings is calculated, in the identification of 
paroxysmal AF in the acute phase of stroke. 
Chapter 9 describes the effects of treatment with heparin in 3169 patients with 
atrial fibrillation and acute ischemic stroke from theIST. 
Finally chapters 10 and 11 provide a general discussion and summary of the 
studies presented in this thesis. 
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Treatment of acute ischemic stroke: the 
background and rationale of the studies 
presented in this thesis 
Chapter 2 
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Introduction 
The first adequate account of 'apoplexy' or stroke appeared in the Hippocratic 
writings. Apoplexy in Greek meant struck with violence, resulting in paralysis 
of some or all parts of the body. According to Hippocrates the causes of 
apoplexy varied, but in general, related to heating of the blood vessels of the 
head, which thereby attracted phlegm or caused the flow of black bile to the 
head. In the centuries to follow, many descriptions and concepts of apoplexy 
were presented, but little was added to the ancient descriptions. In the 
Eighteenth Century, Morgagni was the first to correlate pathological lesions on 
one side of the brain to clinical signs on the opposite side of the body. In 1828 
Abercrombie analyzed into great detail forty cases of apoplexy and suggested 
possible causes, amongst which were narrowing of the arteries.1 
Animal experimentation began early in the systematic investigation of 
cerebrovascular disease. In 1836 Cooper used the method of extrinsic ligation of 
the carotid and vertebral arteries in dogs, and by 1847 Flourens introduced 
intravascular injection techniques. It was also in 1847 that Virchow first 
reported occlusion of arteries of the brain by thrombi that seemed to have 
originated in the heart. Since then it became more and more apparent that 
obstruction to blood flow to the brain caused signs of apoplexy. All subsequent 
animal experiments on stroke have been variations of these two basic themes, 
either embolism or extrinsic compression of cerebral vessels. The next most 
significant advance in the study of apoplexy came with the elucidation of areas 
of vascular supply to the brain and in the demonstration of the common sites of 
lesions in the brain and specific symptoms following vascular occlusion. This 
was largely carried out by Henri Duret in 1873. 
In the Sixteenth Century the various form of treatment generally used in clinical 
medicine were also used in neurological diseases, and patients with apoplexy 
were treated with phosphorus, purgation or blood-letting. Since then, there has 
been very little progression.1 In the Twentieth Century, causes and 
consequences of stroke were largely elucidated, and strategies to for secondary 
prevention of stroke with aspirin and heparin proved to be successful, but there 
has been a almost complete lack of progression in finding a treatment for stroke. 
In the past decades numerous compounds have been shown to reduce infarct 
volumes in animal stroke models. Unfortunately these results could not be 
reproduced in human trials, except for thrombolysis with tissue plasminogen 
activator (tP A) within three hours after the onset of symptoms in carefully 
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selected patients has convincingly shown to improve outcome. This treatment 
however, is applicable to a small percentage of patients only. 
Background and rationale for using a blood substitute, 
diaspirin cross-linked hemoglobin (DCLHb) in acute 
ischemic stroke 
Viral contaminations, recurring shortages, cross-matching, typing, limited shelf 
life and problems in storage are some of the reasons for developing new oxygen 
carriers as a safe and effective alternative to blood. These blood substitutes can 
temporarily augment the oxygen-carrying capacity of the patient's red blood 
cells. 
Diaspirin cross-linked hemoglobin (DCLHb, HemAssist®) was originally 
developed as a blood substitute. When it was discovered that DCLHb enhanced 
oxygen delivery while increasing blood pressUte and organ perfusion, studies 
with animal stroke models were undertaken and showed favorable results. This 
eventually led to the start of oUt safety study: DCLHb in Acute Ischemic Stroke 
(DIAS). 
History of blood substitutes 
The search for an alternative to blood began almost as soon as people realized 
blood circulates through the body. Physicians petformed the first successful 
blood transfusion into a human in 1667, but stopped the practice when 
subsequent transfusion recipients died. Researchers have infused solutions 
containing hemoglobin, extracted from red blood cells with varying degrees of 
success since 1868. 
A breakthrough in the treatment of blood loss came in 1883, when it was found 
that blood pressUte could be restored by infusion of with Ringer's solution. 
FUtther blood-transfusion research stalled until scientists had a better 
understanding of issues critical to successful transfusion, including coagulation, 
bacterial contamination and the incompatibility of different blood types. By the 
early 1920s, health-care professionals widely practiced transfusion therapy, and 
interest in the search for a blood substitute waned. World War II rekindled 
intetest in research on blood and blood storage, culminating in the 
establishment of American Red Cross blood banks in 194 7. 
As blood must be refrigerated and can be stored for no more than six weeks it 
carmot be stockpiled for immediate use in disastet relief or for combat-casualty 
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care, nor can it be readily carried aboard ambulances or by field medical 
personnel. The need for typing and cross-matching of patients' blood means 
blood transfusions rarely can be given when such therapy might have its 
greatest value, during the first "golden hour" after a trauma event Type 0 
negative units are saved for such emergencies, but are always in short supply. It 
was during the Vietnam conflict, that these limitations on the use of blood for 
modern combat casualty care became apparent, and research on both 
hemoglobin solutions and synthetic oxygen carriers was renewed. 
Finally, safety remains a concern. Viral inactivation of red blood cells is not yet 
possible. Immune suppression and transfusion reactions, though often minor, 
still occur in 1 in 10 transfused patients. In the mid-1980s, the rising incidence 
of HIV and hepatitis infections, led scientists to intensify their work to improve 
the safety of the human blood supply2 
Physical, chemical and pharmaceutical properties and formulation 
DCLHb is prepared from packed red blood cells. The erythrocytes are lyzed to 
release hemoglobin and filtered to produced stroma-free hemoglobin and to 
remove contaminating viruses. The purified human hemoglobin is chemically 
stabilized to enhance intravascular persistence and oxygen delivery. 
Stabilization of hemoglobin as a tetrarneric protein is achieved by cross-linking 
the a subunits by means of a reaction with bis(3,5-dibromosalicyl) fumarate 
(DBBF). The heat treatment that follows results in virus inactivation. To 
achieve physiologic compatibility, the pH is adjusted and the final DCLHb 
solution is prepared in a balanced electrolyte solution. 
The solution has the following properties at 37°C: pH 7.4, oncotic pressure of 
42-44 mmHg (hyperoncotic compared with whole plasma), oxygen PSO affinity 
of 32 mmHg and a viscosity of <1.5 centistokes. Oxygen equilibrium binding 
measurements, as well as binding kinetic studies demonstrate that oxygen 
transport and release by DCLHb solutions is comparable to that of fresh human 
red cells containing an equivalent amount of hemoglobin.' 
Nonclinical studies regarding the pressor and perfusion effects 
Although the exact mechanism of action was unknown, historically hemoglobin 
solutions have been associated with a vasopressor action in both animals and 
man.'·' Consistent with this action DCLHb produces a predictable, rapid and 
sustained rise in mean arterial pressure (MAP), primarily through an increase in 
diastolic pressure. The pressure effect is reversible, non-linear, increases with 
the dose of DCLHb , and reaches a maximum at higher concentrations.0·7 The 
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pressure increase can be readily controlled by standard anti-hypertensive agents, 
such as nitroglycerine, labetolol, nicardipine and prazosin.8 
In a reciprocal response to the rise in blood pressure (BP), the heart rate (HR.) 
decreases. Contrary to typical hypertensive effects of catecholamines, the 
pressor response of DCLHb is accompanied by a rapid increase in perfusion as 
indicated in organ-flow measurements in hypervolemic (volume-load)7"9 as well 
as hypovolemic (hemorrhagic), animal studies. 10 In the latter, perfusion to vital 
organs such as the heart and brain exceeded pre-hemorrhage levels." 
Mechanism of the pressor effect 
The pressor response observed after hemoglobin infusion is not a unique 
property of DCLHb, but rather a general property of hemoglobin solutions. 
When conscious swine were given an infusion of 2000 mg/kg unmodified pig 
stroma-free hemoglobin, this produced a rapid rise in MAP with a temporal 
profile and magnitude similar to DCLHb. 12 
The pressor effect is maintained when administered to cervical spine-sectioned 
rats, suggesting that DCLHb primarily interacts with the peripheral vascular 
autoregulatory system, rather than the central nervous system. A simple 
explanation of the pressor effect would be that DCLHb stimulates the release of 
catecholamines from the adrenal glands. When administered to bilateral adrenal 
demedullated rates, however, DCLHb produced a pressor and heart rate 
response similar to that observed after infusion into normal rats." 
At the local level, vascular tone is normally maintained, at least in part, as a 
balance between the vasoconstrictive effects of endogenous catecholamines and 
endothelin (ET), and the vasodilatory effects of endothelium-derived relaxant 
factor, which has been identified as nitric oxide (N0)14"15 Hemoglobin in 
general, and DCLHb in particular have been shown to interact with NO and to 
induce contraction of vascular smooth muscle cells. 16"17 Studies in rats have 
shown that infusion ofDCLHb leads to an increase ofET-llevels along with an 
increase in BP.18·'9 This pressor effect was significantly attenuated by 
pretreatment with the ET-receptor antagonist, BQ-123, thus providing evidence 
for the hypothesis that the pressor effect of DCLHb is mediated, at least in part, 
through the increase ofET-llevels.20 
A study in rats with various pharmacological agents DCLHb potentiates 
adrenergic vasoconstriction, presumably through sensitization of both a 1- and 
a 1-adrenoceptors in the peripheral vascular system.Z'·22 
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Perfusion studies 
A rapid increase in BP as a result of vasoconstriction, could result in decreased 
tissue perfusion resulting in tissue ischemia and insufficient oxygenation. 
However, this effect does not occur with DCLHb as evidenced by several 
studies. While the commonly used pressor agents, such as the 
sympathomimetic amines, at best, divert blood from less vital to more vital 
tissues, DCLHb increases perfusion to above baseline levels in almost all 
organs, including the brain. The ability of DCLHb to increase tissue perfusion 
has been demonstrated in several volume-load and hemorrhage resuscitation 
animal studies. 
Administration of DCLHb in rats produced significant increases in blood flow 
to the heart, gastrointestinal tract, portal system and skin. The blood flow to 
kidney and brain increased slightly, but not significantly, while blood flow to 
the musculoskeletal system was not affected.7 
Rats that were lethally hemorrhaged demonstrated superior whole body 
perfusion after a small volume of DCLHb was infused. Infusion of 20% of the 
shed blood volume restored brain perfusion to pre-hemorrhage baseline levels 
and infusion of 50% of the shed blood volume the perfusion to the brain 
increased to far above baseline values. Comparative studies have shown that 
neither autologous blood nor clinically used oncotically matched colloids have 
the same beneficial effect.ll 
DCLHb in animal stroke models 
As DCLHb offered the potential advantage of enhancing oxygen delivery while 
increasing blood pressure and organ perfusion, this naturally led to experiments 
with animal stroke models. 
Cerebral blood flow (CBF) was assessed in a stroke-reperfusion model in rats 
undergoing temporary middle cerebral artery (MCA) occlusion. DCLHb was 
administered to achieve hemodilution and maintain hematocrits (HCT) of 37%, 
30%, 32%, 16% or 9%. Control animals received donor blood to achieve a 44% 
HCT. After 10 minutes of ischemia, brain sections were evaluated for CBF 
with radioactive microspheres. CBF to the ischemic area increased significantly 
in the DCLHb treated groups at HCT of 30% and lower. The greatest increase 
in CBF was observed in the non-affected hemisphere in the 30% and lower 
HCT groups. The same experiment showed that at HCT 30% and lower, 
oxygen delivery to the affected hemisphere increases significantly .23 
The effect of hemodilution with DCLHb on brain injury and edema was 
assessed during middle cerebral artery (MCA) occlusion (180 minutes) and 
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reperfusion (120 minutes) in rats. Prior to MCA occlusion animals received 
either donor blood to maintain a HCT of 44%, 10% albumin to reduce HCT to 
30%, or DCLHb to reduce HCTs to 30 or 9%. The percentage of ipsilateral 
hemispheric brain injury was greater in the blood (42±4%) and albumin 
(38±3%) groups versus the two DCLHb groups: 27±4% in the 30% HCT group 
versus 18±3% in the 9% HCT group. Cerebral edema, assessed by 
microgravimetry, was less in all hemodiluted groups versus the blood control 
'4 group.-
In a similar reversible stroke model, spontaneously hypertensive rats were given 
either donor blood to maintain a HCT of 45%, or DCLHb to achieve 
hemodilution and maintain HCTs of 30%, 16% or 9%. In addition, at HCTs of 
30 and 16%, some groups of animals were maintained normotensive (by giving 
DCLHb initially as an exchange, followed by a slow bolus), while other 
corresponding groups were allowed to become hypertensive (by giving DCLHb 
initially as a rapid bolus, followed by an exchange). Both edema and brain 
injury, as a percentage of the ischemic hemisphere were significantly reduced in 
a dose-dependent fashion 2 hours after DCLHb infusions (31±4% in 30% HCT 
group, 20±3% in 16% HCT group, 19±4% in 9% HCT group) compared to the 
blood 44% HCT group (43±5%). In HCT-matched groups, the most effective 
reductions in ischemic injury occurred when DCLHb was given in a manner 
that allowed the inherent hypertensive response to be manifested but reduced in 
all the groups of rats treated with DCLHb. Edema was not affected by 
hypertension.25 
Cerebral edema (measured via MRI) and brain tissue oxidation (measured via 
cytochrome aa3), were assessed in cats given either DCLHb 15ml/kg, Dextran-
40, perfluorocarbon (PFC) emulsion or no treatment 3 hours after stroke 
induction (MCA ligation plus 2 hours of carotid artery clamping followed by I 
hour of stabilization). Post-stroke cerebral edema in the DCLHb-treated 
animals was 74% less than the Dextran-treated animals, 52% less than the PFC-
treated animals and 73% less than the non-treated animals. DCLHb-treated 
animals showed relative tissue oxidation of the affected hemisphere that was 
significantly greater than the other groups except for the PFC group. However, 
the PFC group was maintained at an Fi02 of 1.0 while DCLHb-treated animals 
received an Fi02 0.4."6 
Finally, in a rabbit model of spinal stroke, DCLHb treatment before clamping of 
the aorta, significantly reduced the likelihood of paralysis, thus improving 
functional outcome.Z7 
In the early stage of cerebral infarction the ischemic area is thought to consist of 
a central core of densely ischemic tissue surrounded by a rim with less dense 
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ischemia, known as the ischemic penumbra. This penumbra is characterized by 
metabolic and ionic disturbances and a loss of functional activity, but with 
preserved structural integrity and the possibility to recover when blood flow is 
restored and/or so-called neuroprotective agents are administered. Restoration 
of blood flow is essential for recovery and reduces the volume of the infarct if 
instituted with undue delay. However, reperfusion may paradoxically lead to 
further tissue damage, which has been termed reperfusion damage. Nitric oxide 
(NO) is a free radical with vasodilatory effects, that plays a dual role in brain 
ischemia. NO is protective or destructive depending on the stage of evolution 
of the ischemic process and on the cellular source of N0.28 Since hemoglobin 
in general and DCLHb in particular is an extremely effective scavenger of nitric 
oxide (NO), inactivation of this endogenous vasodilator is one of the most likely 
mechanisms by which hemoglobin solutions induce a rise in BP.15"18 thereby 
possibly inhibiting NO-related neurotoxicity. 18•29 
In summary, in animal stroke models, hemodilution with DCLHb induced a 
hypertensive response and resulted in significant reductions in the extent of the 
brain injury and improved clinical outcome. It was anticipated that similar 
effects would occur in patients suffering acute ischemic stroke. 
Background and rationale for using heparin in acute 
ischemic stroke associated with atrial fibrillation 
Regardless of the Jack of convincing evidence of safety or efficacy physicians 
have been administering heparin to stroke patients for more than 50 years. 
Heparin is given to promote early clot lysis and to prevent thromboembolic 
events such as deep venous thrombosis, pulmonary embolism, stroke 
progression and early stroke recurrence.30 Since the recurrence rate is presumed 
by some to be even larger in patients with atrial fibrillation (AF),31 clinicians are 
even more inclined to treatment with heparin in ischemic stroke in the presence 
of AF.32·33 However, there are no conclusive data on this recurrence rate and on 
the effects of heparin to prevent these recurrences. 
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Early stroke recurrence 
One of the feared complications in the acute phase of ischemic stroke is early 
recurrence of stroke.34"35 Although nearly ail patients who survive an acute 
ischemic stroke eventually show some degree of clinical improvement, 
neurological symptoms are often unstable during the early phase. The diagnosis 
of early recurrent stroke is not always easy in patients with acute ischemic 
stroke, since 20-50% of these show spontaneous fluctuations,36-38 some of 
which may be caused by repeated embolism, but many of which have other 
causes, including systemic disorders, such as myocardial ischemia and 
metabolic disturbance." 
Very few studies have attempted to define recurrent stroke. Some have 
included worsening of a preexisting deficit, while others have accepted only 
new deficits that occurred in a different anatomic or vascular territory or were 
of a different stroke subtype than the index stroke. 32"4044 It is obvious that the 
lack of an uniform definition of recurrent stroke strongly influences the existing 
data. The incidence of, risk factors for and prevention of early recurrent stroke 
are discussed at length in chapter 7. 
Treatment of acute ischemic stroke with heparin 
Several surveys have shown that heparin is widely used to treat acute ischemic 
stroke, but without a clear consensus on whether it is effective or not. For 
instance a survey among physicians in the United Kingdom about 45% of 
physicians used heparin regularly in patients with acute ischemic stroke, 
whereas only 10-20% thought that heparin had been proven to be effective.33.45 
In the past few years several 4 randomized controiied trials, of which the 
primary aim was to demonstrate a beneficial effect on stroke outcome of 
anticoagulation in acute ischemic stroke have been reported Ail these trials also 
included patients with cardioembolic stroke. The only trial that showed a 
positive effect was published in 1995 by Kay et al.46 In this study, 312 Chinese 
patients with acute ischemic stroke were treated during 10 days with 
subcutaneous low molecular weight heparin (LMWH), either low-dose or high-
dose, or placebo. The main measure of outcome, clinical condition at 6 montha, 
was significantly improved in both actively treated groups. Early recurrent 
stroke during the treatment period occurred in 3 patient receiving the high-dose, 
3 in the low-dose and 6 in the placebo group. Early hemorrhagic transformation 
was found in 5 patients in the high-dose group, 7 in the low-dose, and 9 of the 
placebo patients. The risk of recurrent stroke per day during the treatment 
period was 0,1 %, 0,2% and 0,5% per day. 
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The 3 trials that failed to show a positive effect from heparin were the TOAST-
tria!,'7 theIST 48 and the FISS-bis study_49 In the trial of ORG 10172 in Acute 
Stroke Treatment (TOAST),'7 danaparoid administered intravenously was tested 
against placebo in 1275 patients with acute ischemic stroke, and turned out not 
to be associated with an improvement in favorable outcome at 3 months. The 
rate of recurrent stroke during the 7 day treatment period was 1,5% for both 
treatment groups, equaling a risk of 0.21% per day. In patients with AF the 
recurrence rate did not differ from those in sinus rhythm. In the FISS-bis study 
LMWH, again either low- or high-dose was tested against placebo in 766 
patients, treated during 10 days, starting within 24 hours of stroke-onset, also 
showed no positive effect from heparin_49 The International Stroke Trial (IST) 
48 
was the largest study to evaluate heparin in acute stroke. A total of 19435 
patients were randomized to receive heparin (5000 or 12500 W s.c. twice daily) 
or to "avoid heparin" and in a factorial design half were allocated aspirin and 
half to "avoid aspirin". Treatment was started within 48 hours after stroke onset 
and continued for 14 days or until hospital discharge. At 6 months neither 
heparin regimen offered any clinical advantage. The 14 day recurrence rate for 
all patients was 2,9% (0.21% per day) in the heparin treated group vs. 3,8% 
(0.27% per day) in the "avoid heparin" group, but there was an equally large 
increase in hemorrhagic strokes in the group treated with heparin. 
A recent systematic review by Gubitz et al50 included 23.427 patients (most of 
whom were from the trials mentioned earlier) also showed that immediate anti-
coagulant therapy in patients with acute ischemic stroke is not associated with 
net short- or long-term benefit, as the advantage of fewer recurrent ischemic 
strokes is completely offset by a similar sized increase in hemorrhagic strokes. 
Stroke and atrial fibrillation 
Non-valvular (non-rheumatic) AF is the most common cardiac arrhythmia, and 
the prevalence of AF in developed countries increases rapidly with age. 51 In 
patients aged 50 to 59 years, it occurs in only 0.5% of the population. 52 Between 
60 and 69 years, the prevalence is about 3.8% for men and slightly less for 
women, in those older than 70 years, the estimated prevalence is 9%.53 In a 
community-based Minnesota study, 16.1% of men and 12.2% of women older 
than 75 years had AF.54 A Dutch study of patients seen in a general practice 
setting confirms these findings. 55 
AF is found in about 15% of all strok\e patients 56•57, and is the most common 
cause of cardioembolic stroke as well as an independent and powerful risk 
factor for ischemic stroke and increased mortality.53 In the Framingham Cohort 
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Study, the risk of stroke was 5.6 times greater in patients with AF than that in 
comparably aged patients in sinus rhythm.57 
In developing countries, rheumatic heart disease accounts for most cases of AF, 
and the predominant incidence is in the young. In Western societies, however, 
when AF occurs in the young it is usually an isolated phenomenon, without 
predisposing structural heart disease, hypertension, or diabetes. These patients, 
usually younger than 60 years, have what is termed lone atrial fibrillation and 
are at low risk for systemic embolism. 58 
The overall risk of stroke among patients with AF without prior stroke or 
transient ischemic attack (TIA) is about 4% per year.59 The risk of developing a 
stroke varies with age. The cumulative incidence of stroke among patients 60 
years or younger with lone AF is not significantly different from that in a 
control population matched for age and sex: 0.5%/y.60 In the elderly group, 
however, the risk is much higher, often exceeding 10%/y."' 
Following an initial stroke patients are at an increased risk for recurrent 
cardioembolic stroke. The reported risk of recurrent stroke varies between 10 
and 20% during the first year62. 66 and the risk of very early recurrence has been 
investigated in several studies,31 ·34.42.43.63"64"67"69 and varies between 0.1% and 
1.3% per day during the first two weeks after the initial event.31•44·63•64•67·68 The 
consequences of these embolic strokes are often devastating, with either death 
or persistent neurological deficits in 40-70% of the affected patients:2•64•67•70-72 
Primary prevention of stroke in patients with atrial fibrillation 
Five studies have investigated the effect of anti-coagulation on the primary 
prevention of stroke in patients with AF. These studies were independently 
designed and include the Atrial Fibrillation, Aspirin, Anticoagulation Study 
from Copenhagen, Denmark {AFASAK),71 the Stroke Prevention in Atrial 
Fibrillation (SP AF I) study,73 the Boston Area Anticoagulation Trial in Atrial 
Fibrillation (BAATAF),74 the Canadian Atrial Fibrillation Anticoagulation 
{CAFA) study,75 and the Veterans Affairs Stroke Prevention in Non-rheumatic 
Atrial Fibrillation (SPINAF) study.76 Patients requiring anticoagulation for 
other reasons or having contraindications to warfarin or aspirin were excluded. 
The average length of follow-up ranged between 1.2 and 2.3 years. All trials, 
except the Canadian trial, were terminated early because of the benefit 
demonstrated with warfarin. The Canadian trial was terminated because of the 
defmitive results of the other studies. 
In a formal pooled analysis of these trials, conducted collaboratively by the 
principal investigators of each of the trials/9 the value of warfarin was 
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consistent among trials and, in aggregate, decreased the risk of stroke by 68% 
(4.5% to 1.4%/y) with virtually no increase in the frequency of major bleeding 
(the rates were 1.2%, 1.0%, and 1.0%/y for warfarin, aspirin, and placebo 
groups, respectively). It was further determined that increasing age and a 
history of hypertension, diabetes, and previous TIA or stroke were independent 
risk factors for developing a stroke among patients taking placebo. For patients 
younger than 65 years without these risk factors, even without anticoagulation, 
the stroke risk was I %/y. These patients would not benefit from warfarin 
therapy. All other warfarin-eligible patients would benefit from warfarin 
treatment (event rate reduction from between 3.5%-8.1%/y to 1.1%-1.7%/y). 
Aspirin was evaluated in 2 of these studies but in different doses: 75 mg/d for 
the AFASAK study71 and 325 mg/d for SPAF I.73 In the BAATAF study,74 
patients in the control group were allowed to take 325 mg/d of aspirin. Both the 
CAF A75 and the SPINAF76 studies excluded patients who used aspirin or 
nonsteroidal anti-inflammatory drugs. 
In the AF ASAK study, the incidence of thromboembolic complications and 
vascular mortality among patients taking aspirin was not significantly different 
from the incidence of these complications in the placebo group. In the SP AF I 
trial, aspirin use was associated with a 42% reduction in stroke. In the BAATAF 
study, patients in the control group were allowed to use aspirin, but no benefit 
was seen. Overall, the reduction of stroke afforded by aspirin compared with 
placebo was 36%.59 Hence, the primary prevention trials proved warfarin's 
superiority over both aspirin and placebo. 
Secondary prevention of stroke in patients with atrial fibrillation 
The only published randomized controlled secondary prevention trial is the 
European Atrial Fibrillation Trial (EAFT)."6 The cohort consisted of 1007 
patients from I 08 centers with non-rheumatic AF with a recent TIA or minor 
ischemic stroke. A total of 669 warfarin-eligible patients (group 1) were 
randomized to either open anticoagulation or further randomized to double-
blind treatment with either 300 mg/d of aspirin or placebo. The 338 patients 
with contraindications to anticoagulation (group 2) were randomized to receive 
only aspirin or placebo. The main outcome measures were death due to vascular 
disease, any stroke, myocardial infarction, or systemic embolism. Patients with 
chronic and poorly controlled hypertension, history of hemorrhagic cerebral 
infarction, retinopathy, chronic alcoholism, non-compliance, or refusal to use 
anticoagulants were not included in the study. 
During a mean follow-up of 2.3 years, the annual rate of outcome events was 
8%/y in patients in the anticoagulant group and 17%/y in the placebo group (in 
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group 1). Warfarin use reduced the risk of stroke from 12%/y to 4%/y (66% 
reduction). Among all patients assigned to aspirin, the incidence of outcome 
events was 15%/y compared with 19%/y among the patients receiving placebo 
(in group 2). The incidence of major bleeding complications was low in this 
study: 2.8%/y in the anticoagulant group, 0.9%/y in the aspirin group, and 
0.7%/y in the placebo group. Fatal intracerebral haemorrhage occurred in 3 
patients: I in the placebo and 2 in the aspirin group. 
This study shows that in patients with non-rheumatic AF and recent TIA or 
minor stroke, anticoagulant treatment reduces the risk of recurrent stroke by two 
thirds. The incidence of recurrent stroke was 12%/y in the placebo group, 
almost 3 times as high as in the placebo group of the primary prevention trials. 59 
The EAFT does not provide information on the balance between the risk and 
benefit of anticoagulant therapy in the early period after onset of symptoms. 
Treatment with heparin of acute ischemic stroke associated with atrial 
fibrillation 
Given the high efficacy of anticoagulation and the reported risk for early 
recurrence ofO.l-1.3% per day in the first 14 days after the initial event63•67•68•77 
should treatment be started as soon as possible? The risk of hemorrhagic 
transformation of the cerebral infarct has been stressed in patients with 
cardioembolic stroke. 62 The dilemma whether to withhold anticoagulants for a 
few days or start treatment immediately is a long-standing subject for debate. 
Some have recommended withholding anticoagulants during the first few days 
after suspected stroke, especially if the infarct is large, to prevent hemorrhagic 
transformation. 78 
To our knowledge there have been only 2 studies that focused solely on 
treatment with anticoagulants in the acute phase of an ischemic stroke of 
presumed cardioembolic origin, mostly AF. In 1983 an open randomized study 
compared immediate treatment with intravenous UFH to delayed (14 days) 
anticoagulation in patients with cardioembolic stroke. 45 Patients were included 
and of the 24 patients randomized to immediate heparin only 14 had AF. The 
study was terminated prematurely because of 2 recurrent strokes and 2 
asymptomatic hemorrhagic transformations occurred in the control group. In a 
recent study Berge et al investigated whether low-molecular-weight heparin 
(LMWH, dalteparin 1 OOIU/kg sc bid) is superior to aspirin for the prevention of 
recurrent stroke during the first 14 days in patients with AF. Treatment was 
started within 30 hours of stroke onset and cerebral tomographic (CT) scanning 
was mandatory before inclusion to exclude intracranial hemorrhages. AF had to 
be present on admission or documented within the 24 months before the stroke. 
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The results for the primary outcome event, recurrent ischemic stroke within the 
first 14 days were: 19/244 (8,5%) in dalteparin-allocated patients vs. 17/225 
(7 .5%) in aspirin allocated patients. The secondary events such as symptomatic 
and/or cerebral hemorrhage, progression of symptoms within the fust 48 hours, 
death and functional outcome at 14 days or 3 months also revealed benefit nor 
harm of dalteparin. The authors concluded that while the data could not provide 
any evidence that LMWH is superior to aspirin in this setting, the study could 
not exclude the possibility of smaller, but still worthwhile effects of either of 
the trial drugs. The trial was also not large enough to reliably estimate a 
significant increase in cerebral hemorrhage on dalteparin. 
Since 3169 patients with AF were randomized in theIST", we decided to study 
this subgroup in more detail. Even though this is a subgroup analysis, we 
considered it worthwhile still since many questions regarding AF in association 
with acute ischemic stroke are unanswered. We aimed to describe the effect of 
AF on early case fatality and the risk of recurrent stroke. We also wished to 
identify the main causative factors ofthe early case fatality, and study the effect 
of treatment with heparin compared with "no heparin" on these events. 
Diagnosis of paroxysmal atrial fibrillation in patients with 
acute ischemic stroke 
Both persistent and paroxysmal AF are a major source of cardiogenic embolism, 
thus an independent risk factor for acute ischemic stroke.53•57•59 The diagnosis 
of AF has therapeutical consequences since several large studies have 
demonstrated the superiority of warfarin compared to anti-platelet treatment in 
primary and secondary stroke prevention studies!6·71 '73' 76 In acute stroke 
patients the ECG is sufficient to detect patients with persistent AF, but generally 
unable to diagnose paroxysmal AF. 
Two retrospective studies failed to show any additional value of Holter 
monitoring. 79·80 One prospective study in 184 consecutive stroke and TIA 
patients did find a larger number of patients with (paroxysmal) AF with 48-hour 
automated arrhythmia monitoring (55 patients had an additional Holter 
registration) than with the combination of anamnesis, physical examination and 
ECG. 81 The current practice in the Netherlands is to perform ambulatory ECG 
monitoring in those patients with a history of cardiac disease, suspicious 
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standard ECG or complaints of palpitations or loss of consciousness preceding 
or during the stroke.'2 It is not known how many patients with P AF are missed 
with this practice. Other authors do recommend making a Holter in all stroke 
. 83 patJents. 
As a part of the safety study we monitored cardiac ftmction by means of 84 
hour Holter recording in the DCLHb in Acute Stroke Trial (DIAS) . We wanted 
to determine whether ECG-monitoring for 84 hours instead ofrepeated ECG' s, 
3 in 7 days, increased the likelihood of diagnosis of P AF in patients with acute 
ischemic stroke. 
The main questions addressed in this thesis 
Part 1 
• Is DCLHb safe when used in the acute phase of ischemic stroke? Are 
there indications that it is effective in halting or reversing the ischemic 
damage caused by the stroke? 
• DCLHb causes the BP to rise. Is this increase in BP tolerated by these 
stroke patients? 
• What are the specific cardiac effect ofDCLHb? 
• What is the role of various vaso-active hormones, such as 
catecholamines and ET-1, in the pressor effect ofDCLHb? 
Part2 
20 
• What is the definition of early recurrent stroke? How often does it 
occur and what are the risk factors associated with early recurrences? 
Do acute ischemic stroke patients with AF have a higher chance of 
early recurrent stroke? What are the risks and benefits of 
anti thrombotic therapy in the prevention of this complication. 
• What is the extra yield of long-term Holter-monitoring in the diagnosis 
ofPAF? 
• How does the risk of early death and recurrent stroke and effect of 
heparin in 3169 patients with acute ischemic stroke and atrial 
fibrillation in international stroke trial compare to these risks in patients 
in sinus rhythm? 
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Abstract 
Diaspirin cross-linked hemoglobin (DCLHb) is a purified cell-free human 
hemoglobin solution. In animal stroke models it produced both an increase in 
blood pressure and tissue perfusion and a significant reduction in the extent of 
brain injury. The primary objective of this study was to evaluate the safety of 
DCLHb in patients with acute ischemic stroke. 
This multi-center, randomized, single-blind, controlled safety trial consisted of 
3 parts. Twelve doses of 25, 50 and lOOmg/kg DCLHb or equal volumes 
normal saline were administered over 72 hours ·to 85 patients with acute 
ischemic stroke in the anterior circulation, within 18 hours of symptom onset. 
DCLHb caused a rapid rise in mean arterial blood pressure. The duration of 
which was dose-dependent. The pressor effect was not accompanied by 
complications, nor an excess need for anti-hypertensive treatment. All 
laboratory abnormalities were clinically asymptomatic and disappeared within a 
week. Two patients, in the 100 mg/kg group, had an adverse event which was 
possibly drug-related: one of fatal brain and puhnonary edema, the other of 
transient renal and pancreatic insufficiency. Jaundice and hemoglobinuria were 
minor adverse drug reactions that predominantly occurred in the 100 mg/kg 
group. Although patients in the DCLHb group tended to have more severe 
strokes at baseline than the control group, multivariate logistic regression 
analysis showed that a severe stroke at baseline (odds ratio (OR) 
20.9;confidence interval (CI) 4.1-102.4) and treatment with DCLHb (p=O.Ol5; 
OR 3.9; CI 1.4-12.0) were independent predictors of a worse outcome (Rankin 
3-6) at 3 months. 
In conclusion, outcome scale scores were worse in the DCLHb group and more 
serious adverse events and deaths occurred in DCLHb-treated patients than in 
controls. We recommend thst additional safety studies be performed, preferably 
with a second generation, genetically engineered hemoglobin. 
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Introduction 
Diaspirin cross-linked hemoglobin (DCLHb) is a cell-free hemoglobin based 
oxygen carrying solution. In animal studies DCLHb causes an increase in blood 
pressure (BP) and tissue perfusion.'·2 In animal stroke models, hemodilution 
with DCLHb resulted in significant reductions in the extent of the brain injury 
and cerebral edema. These reductions were most profound when DCLHb was 
given in a manner that induced its inherent hypertensive response.3•4 The 
viscosity of DCLHb is lower than that of whole blood and it offers the potential 
advantage of hemodilution without a decrease in oxygen delivery.' In addition, 
experimental data suggests that DCLHb scavenges nitric oxide (N0),6 thereby 
possibly inhibiting NO-related neurotoxicity.7 Hypertension has been used in 
the treatment of stroke to increase blood flow, but it has not been widely 
adopted.'·' An increase in BP and improved perfusion with an oxygen carrier in 
tissues at risk of ischemia may improve outcome for these patients. 
In the phase I study 24 healthy volunteers received a single dose ofDCLHb (25, 
50 or 100 mg/kg), dose-dependent increases in mean arterial pressure (MAP). 10 
In another smaii study 18 subjects receiving chronic hemodialysis therapy were 
given the same dose." No significant adverse events nor toxicity occurred in 
either study. At the time our study took place, DCLHb was being developed as 
a hemoglobin therapeutic for abdominal aortic aneurysm surgery, 12 sepsis, 13 
cardiac surgery14 and trauma.15 
The aim of our study was to assess the safety and tolerability of repeated low 
dose infusions of DCLHb in acute ischemic stroke patients started within 18 
hours of symptom onset. 
Subjects and methods 
The trial was conducted in compliance with the Declaration of Helsinki and 
Good Clinical Practice for Trials on Medicinal Products. For participation 
written informed consent from the patients or their family was required. The 
Medical Ethics Committees of the participating hospitals approved the protocol. 
The participating centers were the departments of Neurology in the University 
Hospitals of Heidelberg, Helsinki, Leuven and Rotterdam. Patients received ail 
standard care and treatment with increased clinical monitoring and assessment, 
including prophylactic medication such as acetylsalicylic acid and heparin. 
33 
Chapter 3 
Patients 
Patients with clinical symptoms of an acute ischemic stroke, with motor 
disturbance, consistent with localization in the anterior cerebral circulation were 
eligible to participate in the study if they were older than 20 years; could be 
treated within 18 hours after start of symptoms; and were likely to survive for at 
least 3 months. Patients had to be alert or at least arousable by stimulation to 
obey, answer or respond to verbal commands and a brain computed tomography 
(CT) scan had to be normal or compatible with a recent infarction. Exclusion 
criteria were: any major disabling disorder interfering with the assessments; 
pregnancy or lactation; an evident hematological cause of the symptoms; 
congestive heart failure or acute myocardial infarction; systolic BP > 230 
mmHg or diastolic BP > 130 mmHg; renal or liver disease; spontaneous 
improvement of symptoms by at least 2 grades on the modified Rankin scale;16 
and previous enrollment in this study or enrollment in another investigational 
trial within 30 days. Eighty-five patients were enrolled at four centers between 
August 1994 and November 1996. 
Drugs 
DCLHb is a hemoglobin based oxygen carrier derived from human 
erythrocytes. Outdated human erythrocytes are washed, filtered and lysed. 
DCLHb is produced by cross-linking of molecular hemoglobin between the 
alpha- subunits by means of a reaction with the diaspirin compound, bis (3,5-
dibromosalicyl) fumarate5 and is subjected to rigorous viral inactivation and 
removal procedures17 The cross-linking gives the hemoglobin biochemical 
stability and a favorable oxygen dissociation curve. DCLHb is provided as a 
solution that is electrolyte balanced and has the following properties at 37°C: 
pH 7.4, oncotic pressure of 42-44 mmHg (hyperoncotic compared with whole 
plasma), oxygen PSO affinity of 32 mmHg and a viscosity of <1.5 centistokes5 
The solution was kept frozen at -20°C until needed, when it was passively 
thawed to 5°C. DCLHb was prepared and provided by Baxter Healthcare Corp., 
Deerfield, IL, USA (lot numbers 94A21AD II through 95L08AD II). 
Treatment regimen 
Patients were randomly assigned to DCLHb or equal volume of 0.9% normal 
saline (placebo) in a I: I ratio. The study was single blind because of the 
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prominent color of the drug and the difficulty to manufacture a proper placebo. 
Three doses were tested: 25, 50 and 100mg/kg 10% DCLHb (n=10, 10 and 20 
respectively) or equal volume of saline (n=45) (17, 35 and 70ml per infusion in 
a 70kg person) every 6 hours for 72 hours (12 doses) intravenously at a rate of2 
mllminute. Each successive increased-dose segment was initiated only after 10 
patients had received the preceding dose of DCLHb. 
Assessments 
Baseline assessment consisted of a medical history, general physical and 
neurological examinations, ECG, CT scan, urine analysis, hematological and 
biochemical tests. 
Neurological status was assessed by means of the modified National Institutes 
of Health Stroke Scale (NIHSS)18 Functional ability was scored by means of 
the Barthel Activities of Daily Living (ADL) index.19 The Modified Rankin 
scale was used to score handicap. 16 BP and HR and digital pulse oximetry were 
recorded immediately prior to each infusion and 15, 30 and 45 minutes after 
start (where applicable), at the end of infusion and 30 minutes and 1,2,3,4 and 5 
hours after each infusion. Baseline BP and HR were measured during one hour, 
also every 15 minutes, and these values were averaged. We used an automatic, 
oscillometric blood pressure device (Accutor 3SAT, Datascope Corp. Paramus, 
NJ). 
The physical examination was repeated at day 3, 7, 14 and at the 3 month 
follow-up. The NlliSS was assessed again at day 1, 3, 14 and 3 months. 
Rankin and Barthel scores were measured at day 14 and at the 3 month follow-
up. 
Blood samples for complete blood count (CBC) and sedimentation rate (ESR) 
were collected pre-infusion (before the first infusion) and day 1,2,3,7 and 14. 
Hematocrit, fibrinogen and blood viscosity were measured preinfusion and 
twice daily before infusions and on day 7. Blood urea nitrogen, serum 
creatinine, total creatine kinase (CK, total and fractionated), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), total serum bilirubin, 
electrolytes, serum amylase, lactate dehydrogenase (LDH, total and 
fractionated) and glucose were measured prior to infusion and on day 1,2,3 and 
7. Transferrin was measured preinfusion and on day 7. Activated partial 
thromboplastin time (APTT) and prothrombin time (PT) were measured 
preinfusion and on day 1,3 and 7. Plasma hemoglobin concentrations were 
determined when possible immediately prior and at the end of each infusion for 
all twelve infusions and 2, 4, 6, 12, 24 and 36 hours after the fmal infusion. 
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Antibody titers to DCLHb were measured once at the 3-month visit. Urinalysis 
was performed pre-infusion and on day 1, 2 and 3. Fluid intake and output was 
measured for the first three days. 
ECG' s were repeated on day I and once between day 3 and 7. Continuous 
Holter ECG monitoring was started before the first infusion and continued for 
84 hours. 
The CT scan was repeated approximately 14 days after the first infusion and a 
Magnetic Resonance Imaging (MRI) scan was done once between 7 and 14 
days. 
Statistics 
The analysis included all randomized subjects. Values are expressed as mean± 
SD unless otherwise indicated. For comparison between two groups Student's 
unpaired t-test, chi-square or Fisher's exact test were used as appropriate. 
Regression analysis was used to identify factors independently related to 
outcome at 3 months. A p value<0.05 was considered statistically significant. 
Results 
Patient characteristics are presented in table 1. The groups were well-matched 
with respect to all baseline variables, although patients receiving control 
treatment patients tended to have less severe strokes. The average time to 
treatment was the same for both groups: 11±5 hours from onset of symptoms. 
Adverse events 
Two patients in the I OOmg/kg group had unexpected adverse events, possibly 
related to DCLHb. The first was a 65-year old male with a severe cortical 
stroke (NIHSS 23), cardiomegaly, slightly elevated SGOT (41, normal 5-37), 
SGPT (55,normal 5-40) and GGT (128, normal 11-50), and obstructive 
breathing at baseline. The patient received 5 doses DCLHb of 80ml each. 
Subsequently scleral icterus, hypertension, fever, two episodes of pulmonary 
and cerebral edema developed, leading to death. The other patient was a 53-
year-old female with a moderately severe lacunar stroke (NIHSS 9), and a 
medical history of untreated hypertension. Baseline examinations showed a 
slightly elevated amylase 171 U/1 (normal 30-130 U/1). She was treated 12 
doses DCLHb of 50ml each. She developed renal and pancreatic insufficiency, 
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Table 1 Characteristics of patients with acute ischemic stroke randomized to 
DCLHb or normal saline. 
Saline DCLHb P-value 
Number of patients 45 40 
Age (years) 65 ± 15 68 ± 13 0.40 
Female!Male ratio 22123 (49/51) 24/16 (60/40) 0.42 
Stroke subtype 
Cortical 32 (71) 26 (67) 0.84 
Lacunar 13 (29) 12 (33) 0.84 
Stroke side (R/L) 19/26 (42/58) 25/15 (63/37) 0.10 
Rankin score pre-infusion 
2 2 (4) 2 (5) 0.69 
3 16 (36) 7 (17) 0.10 
4 11 (24) 17 (43) 0.12 
5 16 (36) 14 (35) 0.86 
Medical History 
Angina pectoris 4 (9) 8 (20) 0.25 
Atrial fibrillation 7 (16) 6 (15) 1.00 
Diabetes mellitus 9 (18) 9 (23) 0.79 
Hypercholesterolemia 1 (2) I (3) 1.00 
Hypertension 18 (40) 20 (50) 0.48 
Myocardial infarction 6 (13) 3 (8) 0.49 
Smoking 19 (42) 12 (30) 0.35 
Stroke 12 (27) 13 (33) 0.73 
Systolic BP 155±20 158±24 0.52 
Diastolic BP 85±13 84±13 0.72 
Heart rate 75±15 80±13 0.18 
Values in parentheses are percentages 
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nausea and anemia within 24 hours. Additional tests did not reveal the cause of 
these symptoms. All signs and symptoms resolved within 7-10 days, except for 
the amylase level, which was still asymptomatically, elevated (215 Ull) at the 3-
month follow-up. 
Various adverse events occurred more frequently in the DCLHb treated 
patients, as sununarized in Table 2. Multivariate analysis however, showed that 
the adverse events of cerebral coning, nausea and pneumonia were related to 
stroke severity rather than with DCLHb. Insomnia occurred more often in the 
control group. Adverse events that were independently related to DCLHb were 
jaundice and hemoglobinuria. Jaundice occurred in 0110, 1/10 and 17/20 
patients in the 25, 50 and 100mg!kg groups respectively versus 0/45 in controls 
(p=O.OO). Jaundice typically appeared within 24 hours after start of treatment 
and disappeared without sequelae around day 5. There was no evidence of 
associated hepatotoxicity and the jaundice was considered to be a discoloration 
due to the extravasation of DCLHb and the rise in bilirubin, which is a 
metabolic product of DCLHb. Hemoglobinuria was found in 22/40 patients in 
the treatment group vs. 13/45 in controls (p=0.03). There were no associated 
renal function changes and the signs resolved by day 7. 
Table 2 Univariate analysis of adverse events in the DCLHb and control 
group 
Saline DCLHb P-value 
Cerebral coning 0 4 (10) 0.05 
Hemoglobinuria* 13 (40) 22 (69) 0.03 
Insomnia 8 (18) 1 (3) 0.03 
Jaundice* 0 17 (43) 0.00 
Nausea 3 (7) 11 (28) 0.02 
Pneumonia 3 (7) 10 (25) 0.04 
Values in parentheses are percentages 
* Differences still statistically significant in the regression analysis 
Laboratory parameters 
Dose-dependent increases of LDH, CPK, bilirubin, AST and plasma 
hemoglobin were found. Amylase was elevated in the lOOmg/kg group only. 
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LDH levels were elevated by 39, 61 and 77% respectively for the increasing 
doses ofDCLHb; increases of CPK were !28, 222 and 280%; for bilirubin: 100, 
!81 and 263%; for serum ASAT: 44, 63 and 166% and for amylase only in the 
!OOmg/kg group 170%. The subfractions LDH-1 and CPK-MB were not 
increased. All laboratory abnormalities were clinically asymptomatic and 
disappeared within a week. Maximum plasma hemoglobin concentrations were 
achieved around 24 hours after start of treatment for doses 25 and 50 mg!kg and 
around 42 hours for 100 mg/kg and were 74 (52-160), 229 (149-267) and 419 
(331-632) vs. 3.9 (0-139) mg/dl (median and range). 
All other laboratory measurements (BUN, creatinine, electrolytes, AL T, 
glucose, CBC, ESR, PT, APTT, transferrin, blood viscosity, hematocrit, 
fibrinogen, APTT, PT) showed no difference between groups. At 3 months no 
DCLHb anti-bodies were found. 
Blood pressure 
DCLHb produced a rapid rise in mean arterial pressure (MAP), from 113±14 at 
baseline to 134±20, vs. !09±16mmHg in controls. The magnitude of the 
increases caused by the different doses was similar, but the duration of the 
pressor was dose-dependent.20 The hypertensive reaction was not accompanied 
by adverse events. The hypertensive reaction was not accompanied by clinical 
signs of hypertensive encephalopathy, nor did the CT and MRl-scans show 
occipital edema or brain swelling. Severe hypertension that needed 
pharmacological intervention occurred in 3 patients treated with DCLHb vs. 3 
in the saline group. Fluid intake and output during the first 3 days did not differ 
between treatment groups. 
Outcome 
Outcome, measured by means of the Rankin score at 3 months was significantly 
worse in the treatment group. Thirty-four (85%) patients had an unfavorable 
outcome (Rankin score of3-6) vs. 23 (51%) in controls (p=0.002). The Rankin 
score at 14 days was also worse in DCLHb treated patients: 90% vs. 68% 
(p=0.04). Multivariate logistic regression analysis showed that a severe stroke 
at baseline (Rankin 4-5; p<O.OOl; odds ratio 20.9; confidence interval 4.1-
102.4) and treatment with DCLHb (p=0.015; odds ratio 3.9; confidence interval 
1.4-12.0) were independent predictors of a worse outcome (Rankin 3-6). 
Outcome was not related to the dose of DCLHb. The Barthel scale and NIHSS 
showed similar results (figure 1). 
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Figure 1 Clinical outcome at 3 months according to treatment 
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Discussion 
Following the beneficial treatment effects of DCLHb in animal models of focal 
cerebral ischemia, we initiated this phase II trial, to investigate the safety of this 
hemoglobin therapeutic in patients with acute ischemic stroke. In keeping with 
animals studies as well as in healthy volunteers and hemodialysis patients 
DCLHb produced a rapid rise in blood pressure, the duration of which was 
dose-dependent. The hypertensive effect was not accompanied by 
complications, such as excess need for anti-hypertensive treatment, nor did we 
find any signs or symptoms of hypertensive encephalopathy or hemorrhagic 
transformation of the infarction. Immediate side effects that were 
independently related to the use of DCLHb were jaundice and hemoglobinuria. 
These were all transient and not associated with morbidity. Cerebral coning and 
pneumonia were related to a severe stroke at baseline, rather than with DCLHb. 
The dose-dependent increases of LDH, CPK, bilirubin, AST and amylase were 
clinically asymptomatic and disappeared within a week. The subfraction 
analysis of LDH and CPK iso-enzymes revealed that the elevated enzyme levels 
did not originate from the heart. The rise in bilirubin was expected, since this is 
a metabolic product ofDCLHb. The rise in ASAT was not accompanied by a 
rise in AL T; therefore it probably did not arise from the liver. Except for one 
patients, the rise in amylase was also asymptomatic and not accompanied by 
any evidence of pancreatic insufficiency. 
However, treatment with DCLHb was an independent predictor of an 
unfavorable outcome at 3 months. The cause of the worse outcome is unclear. 
Endothelin-1 (ET-1, a potent vasoconstrictor) and NO (a vasodilator) may well 
have played an important role, although we cannot be sure how exactly. We 
have reported elevated ET-1 levels in response to DCLHb21 which may have 
contributed to the ischemic damage through the potent vasoconstrictor effect of 
ET -1. (See chapter 5)22 On the other hand, there is also evidence that a systemic 
increase in endothelin causes a vasodilator effect in the brain?' The dose-
dependent increase in ET -1 may have been promoted by the duration of 
treatment of 72 hours or by the treatment delay of 18 hours. DCLHb is also a 
scavenger ofN0,6 a free radical that plays a dual role in brain ischemia. NO is 
protective or destructive depending on the stage of evolution of the ischemic 
process and on the cellular source ofN0 7 
Alternative explanations of the worse outcome in DCLHb patients are the play 
of chance in this small study, the imbalance, although not statistically 
significant, of stroke severity at randomization, or bias due to the single-blind 
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nature of the study. Furthermore, in analogy with other stroke treatments,24"25 it 
may be beneficial to administer DCLHb immediately after the onset of 
ischemia, but harmful if given during a later phase. In most animal experiments 
a highly favorable response was found after a single high dose exchange 
transfusion of DCLHb, either before or within one hour after initiation of 
ischemia. After our study had finished, such high doses were found to be safe 
in patients after undergoing coronary by-pass surgery14 On the other hand, a 
North-American15 and European study26 in trauma patients were prematurely 
terminated due to higher mortality in the treatment group. 15 
In conclusion, this was the first study in which the effects of low doses DCLHb 
over three days were studied in acute ischemic stroke patients. As far as we are 
aware this is also the frrst randomized study in which the blood pressure of 
stroke patients was deliberately elevated. DCLHb affected outcome adversely. 
We recommend that the safety of a hemoglobin therapeutic in the treatment of 
stroke be further explored, preferably using a second generation, genetically 
engineered hemoglobin. We suggest that treatment should include a single high 
dose given earlier after stroke onset. 
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Abstract 
Blood pressure (BP) is often elevated in the acute phase of stroke. Lowering BP 
is commonly discouraged as this may adversely affect outcome. Controlled 
evidence on the safety and value of induced hypertension is lacking. In healthy 
volunteers, infusion of diaspirin cross-linked hemoglobin (DCLHb) produced a 
dose-dependent increase in BP. The aim of our study was to study the safety of 
induced hypertension with DCLHb in the acute phase of ischemic stroke. 
DCLHb in a dose increasing fashion (25, 50 and 100 mg/kg, n=10, 10 and 20, 
respectively) or placebo (n=45) was infused intravenously every 6 hours for 72 
hours in patients with an acute ischemic stroke in the setting of a randomized 
controlled trial. We measured BP and heart rate every 15 minutes. Safety was 
further monitored by repeated physical and neurological examinations and by 
CT- and l\1Rl scans. 
DCLHb caused a rapid rise in mean BP from 113±14 at baseline to 129±21, 
135±11 and 135±24 for the 25, 50 and 100mg/kg respectively, vs. 
109±16mmHg in controls. The duration of this effect on BP was dose-
dependent. The pressor effect was not accompanied by complications such as 
hemorrhagic transformation of the infarct, brain edema or hypertensive 
encephalopathy and there was no excess need for anti-hypertensive treatment. 
However, clinical outcome at 3 months was worse in the treatment group. 
Even though the pressor effect was well tolerated, clinical outcome was worse 
in patients treated with DCLHb. Further studies should try and evaluate other 
methods of induced hypertension and explore their clinical efficacy. 
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Introduction 
Blood pressure (BP) is often elevated in the acute phase of stroke. Possible 
reasons are: previous hypertension, a pathophysiological response to ensure 
perfusion in the ischemic penumbra through the Cushing reflex or increased 
catecholamines through sympathetic nervous system activation, or a reaction to 
the mental and physical stress of hospitalization. The course of BP following an 
acute stroke has been extensively studied, and typically shows a spontaneous 
decline during the first week1 "5 
Decreasing BP in the acute phase of stroke can have a deleterious effect on 
outcome!·7 The general consensus among neurologists is not to treat high BP 
during the first week, except for a consistently elevated systolic BP over 250 
mmHg or diastolic BP over 140 mmHg, which can cause hemorrhagic 
transformation, brain edema or hypertensive encephalopathy through failed 
autoregulation. 8 Other reasons for lowering BP are cardiovascular 
complications such as myocardial ischemia or aneurysma dissecans.' 
While lowering BP may be harmful, the safety and efficacy of increasing BP is 
completely unknown. Hypervolemia and induced systemic hypertension are 
generally considered the standard approach to the treatment of ischemia due to 
vasospasm after subarachnoid hemorrhage. 10 Early reports in humans/1.12 and 
recent experimental work, 13"14 have shown a beneficial effect on outcome of 
treatment with induced hypertension. However, this therapy is very rarely used 
in acute ischemic stroke15·16 and it has never been studied in a randomized 
controlled fashion. The rationale for this therapy is that it may help to restore 
the blood flow to the ischemic area of which the perfusion is passively 
dependent on systemic BP because of the loss of local autoregulation, or it may 
induce dilatation of the leptomeningeal collateral circulation in case of an 
embolic occlusion. 
In animal stroke models, diaspirin cross-linked hemoglobin (DCLHb), a 
purified cell-free human oxygen-carrying hemoglobin solution, produced both 
an increase in BP and in tissue perfusion and a significant reduction in the 
extent of brain injury. This reduction was most profound when DCLHb was 
given in a manner that induced its inherent hypertensive response.17. 19 We 
recently performed a safety study of DCLHb in patients with acute ischemic 
stroke (see chapter 3).20 In the present study, we have investigated the 
tolerability of induced hypertension with DCLHb in the acute phase of ischemic 
stroke. We have specifically focused on the commonly feared complications of 
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this therapy, that is, hypertensive encephalopathy, hemorrhagic transformation, 
brain edema, myocardial infarction and congestive heart failure.21 
Subjects and methods 
DCLHb in a dose increasing fashion (25, 50 and 100 mg!kg, n=lO, 10 and 20, 
respectively) or placebo (n=45) was infused intravenously every 6 hours for 72 
hours in patients with an acute ischemic stroke in the anterior circulation, within 
18 hours of onset of symptoms, in the setting of a randomized controlled, 
single-blind trial.20 (See chapter 3). The volumes infused per 24 hours were 
approximately 70 ml for the lowest, 140 ml for the intermediate and 280 ml for 
the highest dose ofDCLHb. 
Prophylactic medication such as acetylsalicylic acid was permitted. If patients 
were already on anti-hypertensive medication, this medication was continued, 
without change, throughout the study. New anti-hypertensive therapy was not 
initiated unless BP exceeded 220/135 mmHg for an hour. 
Assessments 
During the study BP and heart rate (HR) were measured at 15-minute intervals 
with an automatic, oscillometric BP device (Accutor 3 SAT, Datascope Corp. 
Paramus, NJ, USA) and a 3-lead ECG was recorded continuously. Baseline BP 
and HR were measured during one hour, also every 15 minutes, and these 
values were averaged. 
CT scan was performed on admission and after 2 weeks and a MRI scan around 
day 7. 
Physical examination were performed at baseline, day 3, 7, 14 and at the 3-
month follow-up. Neurological examinations using the NIH stroke scale22 at 
baseline, day I, 3, 14 and 3 months. Patients were checked for adverse events 
on a daily basis while admitted and again at 3 months. Outcome at 3 months 
was measured by means of the Modified Rankin scale?' 
Statistics 
The analysis included all randomized subjects. Since a similar protocol was 
followed for all patients, the data of the three groups of patients randomized to 
saline infusion, referred to as the placebo group, were averaged. 
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Values of MAP and HR are presented as mean and 95% confidence interval. 
Comparison of data between tbe four groups of patients was done by analysis of 
variance (ANOVA). For comparison between two groups Student's unpaired t-
test, chi-square or Fisher's exact test were used as appropriate. A p value< 0.05 
was considered statistically significant 
Results 
Clinical characteristics of the patients randomized to treatment witb DCLHb or 
placebo are summarized in Table L There were no significant differences 
between groups. BP was elevated (> 150/90 mmHg) in 64% of tbe patients on 
admission, whereas 45% were known to have hypertension. 
In tbe control group (n=45), BP on admission was 155±20/85±12 mmHg. The 
systolic and diastolic BP were significantly lower at 24 hours: 140±25 mmHg 
(p=0.01) and 78±16 mmHg(p=0.01) and did not fall further during the 2 weeks 
of observation (see table 2). There were no significant changes in heart rate. 
After tbe first infusion, DCLHb produced a rapid rise in blood pressure, which 
depended more on a elevation of tbe systolic tban the diastolic pressure. It 
reached a maximum within two hours after tbe first infusion. For the treatment 
group as a whole (n=40) the systolic pressure increased from 159±24 mmHg at 
baseline to 172±27 mmHg, vs. 156±24 mmHg in controls (p=0.005). The 
diastolic pressure increased from 83±17 mmHg to 94±15 mmHg, vs. 84±17 
mmHg in controls (p=0.008). The magnitude of tbe increases caused by tbe 
different doses was similar, but tbe duration of the pressor effect was dose-
dependent, despite tbe repeated infusions (see figure 1). 
The mean arterial pressure during tbe treatment phase was dose dependently 
higher in the DCLHb treated groups. Heart rates in the 4 groups were similar 
(see table 3 and figure 2). In the patients treated witb DCLHb (n=40), tbe BP 
on admission (158±23/83±14 mmHg) did not fall during tbe treatment period of 
72 hours. By day 7 tbe BP had significantly decreased to 130±7/78±9 (p=0.05) 
(see table 2). 
51 
Chapter4 
Table 1 Characteristics of patients randomized to DCLHb or saline 
Saline DCLHb P-valne 
Number of patients 45 40 
Age (years) 65 ± 15 68± 13 0.40 
Sex 
Female 22 (49) 24 (60) 0.42 
Male 23 (51) 16 (40) 0.42 
Stroke subtype 
Cortical 32 (71) 26 (67) 0.84 
Lacunar 13 (29) 12 (33) 0.84 
Blood pressure (mmHg) 
Systolic 155±20 158±24 0.52 
Diastolic 85±13 84±13 0.72 
Medical History 
Angina pectoris 4 (9) 8 (20) 0.25 
Atrial fibrillation 7 (16) 6 (15) 1.00 
Diabetes mellitus 9 (18) 9 (23) 0.79 
Hypercholesterolemia I (2) I (3) 1.00 
Hypertension 18 (40) 20 (50) 0.48 
Myocardial infarction 6 (13) 3 (8) 0.49 
Smoking 19 (42) 12 (30) 0.35 
Stroke 12 (27) 13 (33) 0.73 
Cause of stroke 
Large vessel 10 (22) 9 (23) 1.00 
Small vessel disease 13 (29) 12 (30) 1.00 
Cardioembolic 9 (20) 10 (25) 0.71 
Other 13 (29) 9 (23) 0.67 
Time to treatment (hours) 11±5 11±5 1.00 
Values in parentheses are percentages 
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Table 2 Systolic and diastolic blood pressure values for the 4 treatment groups 
Systolic blood pressure in mrnHg 
Time Saline DCLHb DCLHb DCLHb 25mglkg 50mglkg lOOmglkg 
n 45 10 !0 20 
0 hours !55± 20 149 ± 23 !64 ± 19 161 ± 26 
24 hours 140 ± 25 * 146 ± 21 169 ± 23 167 ± 24 
48 hours 140±20* 141 ± 22 160 ± 27 164 ± 18 
72 hours 140 ± 26 * 147 ± 22 !51± 24 163 ± 24 
day7 137±20 * 130±7* 140±24* 142 ± 27 * 
day 14 139 ± 20 * 136±14* 134± 11 * 136± 17 * 
Diastolic blood pressure in mrnHg 
Time Saline DCLHb DCLHb DCLHb 25mglkg 50mglkg lOOmglkg 
n 45 10 10 20 
0 hours 85 ± 12 77±11 86± 14 88± 13 
24 hours 78 ± 16 * 80 ± 14 86 ± 8 92± 16 
48 hours 79 ± 13 * 73 ± 14 80 ± 11 91 ± 11 
72 hours 79 ± 15 * 85 ± 11 77± 12 93 ± 16 
day 7 78 ± 12 * 78± 5 73 ± 10 * 80 ±II * 
day 14 81 ± 12 * 85 ± 11 75 ± 9 * 81 ± 6 * 
* denotes a significant change from baseline 
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Figure 1 Relative changes in mean arterial pressure (MAP) in relation to 
baseline values in percentage of baseline values. 
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Figure 1 Relative changes in mean arterial pressure (MAP) in relation to 
baseline values in percentage of baseline values, continued. 
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Table 3 Blood pressure in mmHg during the treatment period of 72 hours 
Saline DCLHb DCLHb DCLHb 25mglkg 50mglkg lOOmg!kg 
n 45 10 10 20 
MeanMAP±SD 99 ± 11 102± 9 112± 10 * 117±13*# 
95% CI for MAP 95- 102 96- 108 105- 120 111- 123 
MeanSBP±SD 141 ± 17 146 ± 13 163 ± 21 * 166±20 *# 
95% CISBP 136- 146 137- 155 148- 178 157- 176 
MeanDBP±SD 78 ± 10 80± 9 87±7 92± 11 
95% CI for DBP 75-81 74-86 81-92 87-97 
MeanHR±SD 73 ± 13 79 ± 17 74± 14 74± 13 
95% CiforHR 69-77 67-92 64-84 68-80 
* denotes a significant change from saline 
• denotes a significant change from DCLHb 25mg/kg 
Table 4 shows the adverse events that could be expected after induced 
hypertension. Cerebral edema/coning occurred in 4 patients treated with 
DCLHb vs. 0 in the placebo group (p=0.05), but multiple regression analysis 
showed this was related to a misbalance in severe stroke at baseline, rather than 
to treatment with DCLHb (see chapter 3).Z0 Hemorrhagic transformation 
occurred in 2 patients treated with DCLHb vs. 6 in the saline group (p=O.l7). 
There were no significant differences in the prevalence of myocardial ischemia 
or cardiac failure. Hypertensive encephalopathy, did not occur at alL Severe 
hypertension that needed pharmacological intervention (BP>220/135 mmHg for 
one an hour) occurred in 4 patients treated with DCLHb vs. 5 in the saline 
group. 
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Figure 2 Mean arterial pressure during the treatment period of 72 hours in 
patients treated with DCLHb and in controls 
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Table 4 Adverse events that might be expected with induced hypertension 
Saline DCLHb P-value 
Cerebral edema 0 4 0.05 
Myocardial ischemia 3 0 0.10 
Hypertension >220/135 for an hour 5 4 0.58 
Congestive heart failure 2 3 0.44 
Hypertensive encephalopathy 0 0 0.99 
Hemorrhagic transformation 6 2 0.17 
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Discussion 
Experimental data to support the value of induced hypertension in stroke are 
abundant. 13"14 Human data are more scarce, 11 "12 and there are no reports of 
randomized controlled studies. We have studied the effect of DCLHb on BP in 
the setting of a randomized controlled trial in which the safety and efficacy of 
DCLHb in acute ischemic stroke was investigated. Administration of DCLHb 
was started within 18 hours after the onset of symptoms. DCLHb caused a 
pressor effect that delayed the typical fall in blood pressure in stroke patients 1-5 
as also seen in our control group. The magnitude of the pressor effect was 
similar in the 3 treatment groups. However, the duration of this effect was dose 
dependent, resulting in dose-dependent higher MAP values during the treatment 
phase of 72 hours. The induction of hypertension did not lead to complications 
such as hemorrhagic transformation, brain edema or hypertensive 
encephalopathy. 
It is noteworthy that the BP in the control group stabilized within 24 hours, 
which was sooner than described in other studies, in which this varied between 
4,3.4 7/ and 105 days. One explanation might be that our patients had lower BP 
at stroke onset than the ones described in other studies. This could be explained 
by the use of an automatic oscillometric BP device, which is known to yield 
lower values than manual measurements, partly due to the avoidance of the 
white coat effect Furthermore, we measured BP every 15 minutes during the 
first 72 hours, and the baseline BP was defmed as the average of the first hour 
recordings. Finally, our study population was more homogeneous, since all 
patients in our study had had an ischemic stroke and were randomized within 18 
hours after the insult, than those of the abovementioned studies in which 
patients with cerebral hemorrhages and long intervals after stroke onset were 
also accepted. 
Our study suggests that induction of hypertension can be performed in the acute 
phase of stroke without complications such as hemorrhagic transformation, 
brain edema or hypertensive encephalopathy. However, it is impossible to draw 
conclusions regarding the clinical effect on outcome since DCLHb is an agent 
with more effects than just hypertension. In a previous paper, we reported a 
dose-dependent increase in endothelin-1 (ET-1) levels in our patients (see 
chapter 5)24 and in another the worse outcome in the treatment group which 
seemed to be independently related to the use of DCLHb (see chapter 3)?0 In 
addition, a North-American25 and European26 study in trauma patients were 
terminated prematurely terminated due to higher mortality in the treatment 
group. Further studies should therefore try and evaluate other methods of 
induced hypertension and explore their clinical efficacy. 
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Abstract 
For almost 50 years it has been known that hemolyzed blood can increase blood 
pressure (BP). Although pre-clinical studies suggest that this pressor response 
is due to interaction of hemoglobin with endothelium-derived vasoactive 
substances, its mechanism in humans is unknown. We investigated the 
involvement of endothelin-1 (ET-1) in the BP response to the oxygen carrier 
diaspirin cross-linked hemoglobin (DCLHb) in stroke patients. 
In a randomized phase II study, DCLHb in a dose increasing fashion (25, 50 
and 100 mg/kg, n=8, 8 and 11, respectively) or placebo (n=26) was infused 
intravenously every 6 hours for 72 hours to patients with an acute ischemic 
stroke. BP and heart rate (every 15 minutes) and plasma concentrations ofET-
1, catecholamines, renin, vasopressin and atrial natriuretic peptide (before and 
24 and 66 hours after the start of infusions) were measured. 
In the placebo group, mean arterial pressure (MAP) of 112 (109-115) mmHg 
(mean and 95%Cl) at baseline decreased spontaneously by 11.4 (5.4 -17.5) and 
12.5 (5.4-19.5) mmHg after 24 and 66 hours, respectively. This decrease in 
MAP was attenuated in patients treated with DCLHb, reaching statistical 
significance in the highest dose group. Plasma ET -1 concentration decreased 
slightly in the placebo group from 4.2 (3.1-5.3) pg/ml (median and range) at 
baseline to 2.4(1.9-3.7) pg/ml after 24 hours (p=0.0044) and 2.8 (1.9-3.7) pg/ml 
after 66 hours (p=0.0042), but increased dose-dependently in response to 
DCLHb infusion. With the highest dose ofDCLHb, plasma ET-1 concentration 
rose from 4.8 (0.1-7.8) pg/ml at baseline to 21.2 (13.4-53.2) pg/ml after 24 
hours (p<0.001) and to 27.6 (11.9-47.8) pg/ml after 66 hours (p<0.001). 
Increments in plasma ET-1 concentration and in MAP were correlated (r=0.30, 
p=0.02). Other vasoactive hormones were not affected by DCLHb infusion. 
Infusion of DCLHb in patients with acute ischemic stroke is associated with a 
dose-dependent increase in plasma ET -1 concentration. We suggest that this 
increase prevents the natural decrease in BP in these patients. 
64 
DCLHb, ET-1 and blood pressure 
Introduction 
Diaspirin cross-linked hemoglobin (DCLHb) is a hemoglobin-based oxygen 
carrying solution that is derived from human red blood cells osmotically lyzed 
to release hemoglobin. In a phase I study, performed in healthy volunteers, a 
single intravenous infusion of a 10% DCLHb solution in doses of25, 50 or 100 
mg/kg was associated with a dose-dependent increase in blood pressure (BP) 1• 
Increments in BP have also been observed with other hemoglobin solutions, and 
do not appear to be unique to DCLHb2 Despite this consistent pharmacological 
effect, the mechanism has not been studied in human subjects or patients. 
Since hemoglobin is an extremely effective scavenger of nitric oxide (NO), 
inactivation of this endogenous vasodilator is one of the most likely 
mechanisms by which hemoglobin solutions induce a rise in BP .'-' 
Interestingly, recent in vitro studies 5·6 and experiments in rats 4'7 and pigs 8 have 
provided evidence that endothelin-1 (ET-1) may also be a mediator of the 
pressor response observed with DCLHb. 
In animal studies, DCLHb causes an increase in BP and tissue perfusion. Since 
the viscosity of DCLHb is lower than that of whole blood, it offers the potential 
advantage of hemodilution without a concomitant decrease in oxygen delivery 9 . 
In animal stroke models, hemodilution with DCLHb resulted in sigoificant 
reductions in the extent of the brain injury and cerebral edema. These 
reductions were most profound when DCLHb was given in a manner that 
induced its inherent hypertensive response. 10' 12 In addition, experimental data 
suggests that DCLHb scavenges NO, thereby possibly inhibiting NO-related 
neurotoxicity.'·" Considering these experimental results administration of 
DCLHb to patients in the acute phase of ischemic stroke may improve outcome. 
In the present study the involvement ofET-1 in DCLHb-induced increase in BP 
was further explored by measuring BP and ET -1 plasma concentrations before 
and during administration of DCLHb to patients with an acute ischemic stroke. 
Understanding the mechanism by which DCLHb increases BP in humans will 
likely provide useful information concerning the optimal utilization of this 
hemoglobin therapeutic. 
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Patient and methods 
Patients 
Patients with clinical symptoms of an acute ischemic stroke, consistent with 
localization in the anterior cerebral circulation, who were admitted to the 
Department of Neurology of the University Hospital Dijkzigt, were eligible to 
participate in the study. The age of the patients had to be over 20 years, the 
duration of symptoms less than 18 hours, and they had to be likely to survive 
for at least 3 months. The patients had to be alert or at least arousable by 
stimulation to obey, answer or respond, and a brain computed tomography scan 
had to be normal or compatible with a recent infarction. Exclusion criteria 
were: pregnancy or lactation, an evident hematological cause of the symptoms, 
congestive heart failure or an acute myocardial infarction, systolic BP > 230 
mmHg or diastolic BP > 130 mmHg, renal or liver disease or spontaneous 
improvement of symptoms by at least 2 Rankin grades. 14 All patients received 
standard care and treatment with increased clinical monitoring and assessment, 
and prophylactic medication such as acetylsalicylic acid was permitted. If 
patients were already on anti-hypertensive medication, this medication was 
continued, without any change, throughout the study. New anti-hypertensive 
therapy was not initiated unless systolic BP increased above 240 mmHg. For 
participation written informed consent from the patients or their family was 
required. The protocol was approved by the Medical Ethics Committee of the 
University Hospital Dijkzigt. 
Drug and study design 
DCLHb was prepared and provided by Baxter Healthcare Corp., Round Lake, 
IL, USA (lot numbers 94A21AD11 through 95L08AD11). DCLHb is a 
hemoglobin based oxygen carrier derived from human erythrocytes and is 
produced by cross-linking of molecular hemoglobin between the alpha-subunits 
by means of a reaction with the diaspirin compound, bis (3,5-dibromosaiicyl) 
fumarate and is subjected to rigorous viral inactivation and removal procedure. 
The cross-linking gives the hemoglobin biochemical stability and a favorable 
oxygen dissociation curve. DCLHb is electrolyte balanced and has the 
following properties at 37°C: pH 7.4, oncotic pressure 42-44 mmHg (iso-
oncotic with whole blood and hyperoncotic with plasma), oxygen affinity 32 
mmHg and a viscosity <1.5 centistokes. The solution was kept frozen at -20°C 
until needed, when it was passively thawed to 5°C? 
Stroke patients fulfilling the entry criteria were randomized to receive a low (25 
mg/kg), intermediate (50 mg/kg) or high (100 mg/kg) intravenous dose of a 
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10% DCLHb solution or equal volumes of normal saline (placebo). Because 
this was a safety study each successive increased-dose segment was initiated 
only after 8 patients had received the preceding dose of DCLHb. The infusion 
rate was 2 mllmin. Infusions of DCLHb or saline were repeated every 6 hours 
for a total duration of 72 hours. The volumes infused per 24 hours were 
approximately 70 ml for the lowest, 140 ml for the intermediate and 280 ml for 
the highest dose ofDCLHb. 
During the study BP and heart rate (HR) were measured at 15-minute intervals 
with an automatic, oscillometric blood pressure device (Accutor 3SAT, 
Datascope Corp. Paramus, NJ, USA) and a 3-lead ECG was recorded 
continuously. Baseline BP and HR were measured during one hour, also every 
15 minutes, and these values were averaged. Before and 24 and 66 hours after 
start of infusions blood was sampled through an indwelling intravenous cannula 
for the measurement of plasma concentrations of ET-1, catecholamines, N-
terminal pro-atrial natriuretic peptide (NtproANP), renin, and vasopressin 
(A VP). In addition, blood was sampled for routine laboratory evaluation, 
including measurement of liver enzymes, BUN, serum creatinine, creatine 
phosphokinase and a complete blood count. 
Analytical methods 
Blood for measurement of ET-1, NtproANP, renin and vasopressin was 
collected in chilled 10-m! tubes containing EDTA (19 mg), whereas blood for 
measurement of catecholarnines was collected into chilled heparinized I 0-ml 
tubes containing 12 mg of glutathione. Within 30 minutes after sampling, blood 
was centrifuged at 3000 x g for I 0 minutes at 4 °C and the plasma was stored at -
80° C until assay. 
Plasma catecholamines were determined with fluorimetric detection after HPLC 
separation.15 ET -I was measured after SepPak extraction by means of a 
radioimmunoassay using a commercially available kit (Nichols Institute 
Diagnostics, San Juan Capistrano, CA, USA). Normal plasma values ofET-1 in 
healthy volunteers range from 1.6 - 4.9 pg/ml and intra- and inter-assay 
coefficients of variation were respectively, 4.5 and 6.8 %. In vitro addition of 
various concentrations of DCLHb to plasma samples had no effect on the 
measured concentration of ET-1. NtproANP was measured by means of a 
radioimmunoassay with a commercial kit (Biotop, Oulu, Finland). Normal 
values of NtproANP in healthy elderly subjects range from 1.6-6.6 ng/m1. 16·17 
Vasopressin was measured after SepPak extraction by means of a 
radioimmunoassay (INCSTAR, Stillwater, MN, USA). Normal plasma values 
in healthy volunteers range from not detectable to 4.7 pg/ml. 
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Active plasma renin concentration was measured according to a previously 
described method.18 Normal values range from 14-51 flU/mi. 
Statistics 
Since a similar protocol was followed for all patients, the data of the 
three groups of patients randomized to saline infusion, referred to as the 
placebo group, were averaged. 
Values of MAP and HR are presented as mean and 95% confidence interval. 
Values of neurohormones were not normally distributed and are presented as 
median and range. Comparison of data between the four groups of patients was 
done by analysis of variance (ANOV A) for MAP and HR or the Kruskal-Wallis 
non-parametric ANOVA for the neurohormones. For comparison between two 
groups Student's unpaired t-test or chi-squared analysis was used as 
appropriate. A p value < 0.05 was considered to indicate a statistically 
significant difference. 
Results 
Clinical characteristics of the patients randomized to administration of DCLHb 
or placebo are given in Table 1. 
Baseline values of MAP, HR and plasma concentrations ofET-1, noradrenalin, 
ac]renalin, renin, vasopressin and NtproANP of patients did not differ between 
the four groups (Table 2). 
lr1 the placebo group MAP decreased from 112 (109-115) rnmHg at baseline by 
11.4 (5.4 -17.5) rnmHg at 24 hours and 12.5 (5.4-19.5) rnmHg at 66 hours after 
stwt of infi,lsions. This decrease was attenuated in the patients treated with 
.QCLHb, reaching statistical significance in the group randomized to 100 mg/kg 
(fig.!). 
In contrast to the marked fall in MAP, HR did not change in the placebo group 
24 and 66 hours after start of infusions, whereas it decreased by 7.1 (0.9-13.3) 
bpm at 24 hours and 6.2 (-2.8-12.2) bpm at 66 hours after infusion of 100 
mg/kg DCLHb (Fig. I). 
Considering an ET -1 level of 4.9 pg/ml as the upper limit of normal, 16 patients 
had increased baseline values (median 6.5 pg/ml, range 5.0-26.1 pg/ml). 
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Table 1 Baseline characteristics of patients randomized to DCLHb or saline 
DCLHb Saline P-value 
Number of patients 27 26 
Age (years) 69±12 63±16 0.69 
Sex: female/male (n) 17/10 14/12 0.15 
Stroke subtype 
Cortical 18 (67) 18 (69) 1.00 
Lacunar 9 (33) 8 (31) 1.00 
Stroke side (right/left) 18/9 10116 0.07 
Rankin score 
3 6 (22) 10 (38) 0.32 
4 10 (37) 8 (31) 0.85 
5 11 (41) 8 (31) 0.64 
Medical history 
Hypertension 14 (52) 10 (38) 0.66 
Myocardial infarction 2 (7) 4 (15) 0.32 
Angina pectoris 6 (22) 1 (4) 0.06 
Atrial fibrillation 5 (19) 2 (8) 0.23 
Diabetes mellitus 7 (26) 4 (15) 0.2,7 
Stroke 11 (41) 7 (27) 0.13 
Hypercholesterolemia 1 (4) 1 (4) 0,75 
Smoking* II (41) 7 (27) 0.44 
Cause of stroke 
Large vessel disease 4 (15) 7 (27) 0.46 
Small vessel disease 8 (30) 8 (31) 1.00 
Cardioembolic 7 (26) 4 (15) 0.54 
Other 8 (30) 7 (27) 1.00 
Time to treatment (hours) 11±5 11±5 1.00 
Values in parentheses are percentages; other values are mean± SD 
* More than 5 cigarettes per day 
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Table 2 Pre-infusion values of mean arterial pressure and heart rate, and plasma concentrations of endothelin-1, 
adrenalin, noradrenalin, renin, N-tenninal-proANP and vasopressin in patients randomized to saline or DCLHb infusions 
Saline DCLHb 
25 mg/kg 
Number of patients 26 8 
Mean BP (mm Hg) 112 (106-118) 106 (96-116) 
Heart rate (bpm) 74 (69-79) 83 (68-98) 
Endothelin-1 (pg/ml) 3.7 (0.5-10.6) 5.2 (3.2-7.4) 
Adrenalin (pg/ml) 64 (7-344) 61 (16-99) 
Noradrenalin (pg/ml) 277 (169-705) 423 (189-959) 
Renin (JlU/ml) 11.3 (3.6-220) 6.9 (0-34.4) 
NtproANP (ng/ml) 4.3 (2.6-21.5) 4.9 (2.0-23.2) 
Vasopressin (pg/ml) 0.7 (0.2-8.8) 1.4 (0.2-2.8) 
Values of mean BP and heart rate: mean (95% CI) 
Values ofneurohormones: median (ranges) 
DCLHb 
50 mg/kg 
8 
123 (117-129) 
79 (72-86) 
4.1 (2.6-26.3) 
34 (23-79) 
314 (185-1295) 
7.0 (2.0-10.9) 
2.8 (1.6-37.8) 
0.6 (0.3-9.4) 
DCLHb 
100 mgll<g 
11 
116 (109-123) 
80 (69-91) 
4.2 (0.1-7.1) 
62 (3-157) 
244 (119-526) 
8.4 (1.9-15.0) 
6.4 (3.7-23.1) 
0.7 (0.2-8.8) 
P-value 
0.32 
0.25 
0.33 
0.53 
0.08 
0.5 
0.24 
0.53 
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Figure 1 Bar-diagrams showing changes in MAP and HR as compared to 
baseline values 24 hours and 66 hours after start of infusions for the four groups 
of patients randomized to receive saline or DCLHb infusions 
Changes in heart rate (HR) 24 and 66 hours after start of 
infusions compared to baseline 
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Figure 2 Line-plots showing pre-infusion values of plasma ET-1 concentration and values 24 and 66 hours after 
start of infusions in the individual patients of the four treatment groups 
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In the group of patients randomized to placebo, ET -I values slightly decreased 
from 4.2 (3.1-5.3) to 2.5 (1.9-3.7) pg/ml after 24 hours (p=0.0044) and to 2.8 
(1.9-3.7) pg/ml after 66 hours (p=0.0042), whereas values increased markedly 
and dose-dependently in response to DCLHb (Fig.2). With the highest dose of 
DCLHb plasma ET-1 concentration rose from 4.8 (0.1-7.8) pg/ml at baseline to 
21.2 (13.4-53.2) pg/ml after 24 hours (p<0.001) and to 27.6 (1 1.9-47.8) pg/ml 
after 66 hours (p<0.001). The DCLHb-induced increments in ET-1 
concentration and MAP were correlated (r =0.30, p=0.02, Fig. 3). 
Figure 3 Scatterplot showing the relation between DCLHb-induced changes in 
plasma ET -1 concentration and mean arterial pressure 24 hours and 66 hours 
after start of infusions 
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In contrast to the marked rise in plasma ET-1 concentration, plasma 
concentrations of noradrenalin, adrenalin, renin, NtproANP and vasopressin did 
not change in response to DCLHb. 
Changes in serum creatinine, BUN, liver enzymes, creatine phosphokinase, 
erythrocytes, leukocytes or platelets as observed in the groups of patients 
randomized to DCLHb treatment did not differ from changes in the control 
group. 
Side effects that were directly related to DCLHb were transient yellow 
discoloration of the skin and sclerae (0/8, 1/8 and 11/11 in the low, medium and 
high dose group respectively) and hemoglobinuria (2/8, 6/8 and 11/11). The 
hemoglobinuria occurred due to excretion of DCLHb in the urine and was not 
associated with any impairment of renal function as assessed by serum 
creatinine. 
The DCLHb induced effects on MAP were well tolerated. There was no excess 
need for anti-hypertensive treatment in comparison with the control group, nor 
were there any signs or symptoms of hypertensive encephalopathy or 
hemorrhage into the infarct. The number of fatal outcomes at three months was 
3126 (0/8, 0/8 and 3/1 0) in the patients randomized to placebo and 7/27 (3/8, 1/8 
and 3111) in those treated with DCLHb (dose A, Band C respectively; p=O.l6). 
Treatment with DCLHb did not have a favorable effect on neurological 
outcome as assessed by the Rankin disability score. 
Discussion 
In this safety study, patients with an acute ischemic stroke were treated with 
DCLHb. DCLHb could be of potential benefit to these patients because of its 
ability to increase cerebral perfusion pressure as well as oxygen delivery to the 
brain.9-12 DCLHb also scavenges NO, thereby possibly further reducing NO 
related neurotoxicity.'·13 We investigated the involvement of ET -1 in the effect 
on MAP in stroke patients in response to the oxygen carrier DCLHb. Of the 
pressor hormones measured, only ET -1 increased progressively with increasing 
doses of DCLHb. In addition DCLHb-induced changes in plasma ET-1 
concentration and MAP were correlated. 
Observational studies have shown that hypertension occurs in three-fourths of 
the patients in the acute phase of a cerebral infarction. 19•20 In most instances the 
elevated BP decreases spontaneously in the first few days and this decrease is 
often most marked in the first 24 hours after the infarction?1-23 A similar course 
of the BP was observed in the control patients. In the DCLHb groups this fall in 
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BP was attenuated and in the highest treatment group BP remained above 
baseline during the entire treatment period of 72 hours. The absence of fall in 
BP was well tolerated, but did not have a beneficial effect on survival or degree 
of disability. 
That hemolyzed blood or hemoglobin solutions can increase BP has been 
known for almost 50 years," but only recently evidence has accumulated that 
this rise in BP is mainly due to an interaction of hemoglobin with endothelium-
derived vasoactive substances! Oxyhemoglobin (1-3 Jlmo1/L) has been shown 
to stimulate the release of ET-1 in cultured endothelial cells.5' 6"24 In awake 
Sprague-Dawley rats an intravenous bolus injection of DCLHb (280 mg/kg) 
was associated with a rapid rise in BP, which could almost completely be 
prevented by pre-treatment with phosphoramidon, an agent known to inhibit the 
conversion of inactive proendothelin to ET-1.5 However in another study, also 
performed in rats, this could not be confmned?5 Recently, Gulati and co-
investigators showed that infusion of DCLHb in rats induced a rise in the 
plasma and tissue concentration of ET -I. The same authors also showed that 
most of the hemodynamic effects of DCLHb could be blocked by the specific 
endothelin-A receptor antagonist BQ123.7 These experimental studies indicate 
that the BP elevation induced by DCLHb, and probably also other hemoglobin 
solutions, is mediated at least in part by ET -1. 
There is evidence from studies in man 26"27 and animals 28"29 that a modest, also 
called pathophysiological increase in plasma ET-1 concentration induced by 
exogenous administration ofET-1 is associated with a rise in BP due to a rise in 
vascular resistance. For example in a study performed in hypertensive subjects 
reported by Kaasjager eta!. 27 a 4-fold increase in plasma ET-1 concentration 
was associated with an increase of BP of about 10 mmHg and a rise in 
calculated systemic vascular resistance of about 27%. With the highest infusion 
rate of DCLHb currently used plasma ET-1 concentration rose 4 to 5-fold. 
Considering the results of the aforementioned studies, it is possible that plasma 
ET -1 concentrations obtained in the present study were high enough to explain, 
at least in part, the observed rise in MAP. The fact that the correlation 
coefficient between DCLHb-induced increments in ET-1 and MAP was not 
very strong does not contradict such a contention. BP depends on numerous 
variables and ·an induced rise in BP is counteracted by the arterial baroreflex to 
a different extent in different patients. More information about the precise role 
of ET -1 in the DCLHb-induced rise in BP could have been obtained if a 
complementary study had been done in the absence and presence of an ET -1 
receptor antagonist. Unfortunately, ET-1 receptor antagonists are not freely 
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available for clinical research at this moment, so we did not have the 
opportunity to perform such a study. 
Although not investigated in the present study, interaction of DCLHb with the 
endothelium-derived relaxing factor NO is likely an additional mechanism by 
which this compound maintained BP at higher levels than in the placebo group. 
NO reacts rapidly with oxyhemoglobin and deoxyhemoglobin, yielding nitrite 
and methemoglobin and nitric oxide-hemoglobin, respectively.''·" This 
interaction of NO with hemoglobin results in a shift in vascular tone towards 
vasoconstriction due to an imbalance between endothelium derived 
vasoconstrictor and vasodilator substances. This imbalance may cause an 
increase in vascular resistance and BP. The rise in BP may involve ET-1 since it 
has been shown that this effect is blocked by ET-1 receptor antagonism." 
The mechanism by which DCLHb induces a rise in plasma ET-1 concentration 
remains to be established. It is tempting to speculate that this rise is caused by a 
DCLHb-induced decline in the concentration of NO. In vitro studies with 
cultured human endothelial cells have shown a substantial increase in ET -1 
gene expression and ET -1 production after inhibition of endothelium-derived 
N0.33 Furthermore, Richard et al. reported increased plasma concentrations of 
ET-1 after NO synthase inhibition.34 However, these increments were only 
modest as compared to the striking increments in plasma ET-1 concentration 
observed in the present study. 
Besides oxyhemoglobin, vasopressin, angiotensin II and thrombin are other 
factors known to stimulate the release of ET-1 from endothelial cells. In the 
present study plasma vasopressin levels were not affected by DCLHb, nor did 
the plasma concentration of renin, the rate-limiting enzyme in the biochemical 
cascade of the formation of angiotensin II, change. Plasma thrombin levels were 
not measured, but changes in the number of platelets, the main source of 
thrombin, did not differ from controls. 
Elevated plasma ET -1 levels have been noted in serious clinical insults 
including eclampsia,35 cardiogenic shock, and acute myocardial infarction.36 
The results of studies in patients in patients with acute ischemic stroke are 
variable. Some studies have shown a moderate increase 37"38 , but in another 
study no rise in plasma ET-1 concentration was found.39 In our study 16 of 53 
patients (30%) had elevated baseline plasma ET-1 levels, but, with the 
exception of two patients, the elevations were very modest. In the patients 
randomized to placebo, plasma ET -1 levels significantly decreased in the 
successive days, which agrees with previous observations.37"38 
The 4 to 5-fold increase in plasma ET-1 concentration, observed in the highest 
dose of DCLHb is considerably higher than the increase observed in patients 
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with an acute myocardial infarction or heart failure.'0.41 With ET -I being a 
potent and long-lasting vasoconstrictor, one may wonder whether the elevated 
ET -I concentrations associated with the use of DCLHb may be cardiotoxic. In 
our study, ECG recording and monitoring of serum creatine phosphokinase 
levels showed no evidence of myocardial damage. Still, we think that clinical 
investigators should be aware that DCLHb, and probably other hemoglobin 
solutions as well, can induce high plasma ET-1 concentrations. Future studies 
should demonstrate whether high plasma ET-Ilevels are cardiotoxic, especially 
in subjects with a compromised coronary circulation and in situations where 
vasoconstrictor mechanisms are already activated as for example hemorrhagic 
shock, a clinical condition where treatment with a hemoglobin solution seems a 
logical option. 
In conclusion, this study provides the first data regarding the mechanism of the 
hemodynamic effects in man. Infusion of DCLHb in patients with acute 
ischemic stroke is dose-dependently associated with high increments in plasma 
ET-1 levels. Though not investigated in the present study, there is experimental 
evidence suggesting that most likely, this increase in plasma ET-1 concentration 
in combination with the inactivation of NO by DCLHb underlies the observed 
prevention of the natural decrease in BP in these patients. 
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Chapter 6 
The influence of a hemoglobin based 
oxygen carrier, DCLHb, on cardiac 
parameters in patients with acute 
ischemic stroke 
Chapter 6 
Abstract 
Cardiac disease is a well-known risk factor for stroke. Conversely, cardiac 
disorders can be caused by stroke itself or its treatment. We have previously 
shown that diaspirin cross-linked hemoglobin (DCLHb ), a purified human 
hemoglobin solution, was not beneficial when given to patients with acute 
ischemic stroke. The aim of our study was to determine whether the adverse 
effect on outcome was caused by the effect ofDCLHb on cardiac parameters. 
DCLHb in a dose increasing fashion (25, 50 and 100 mg/kg, n=lO, 10 and 20, 
respectively) or placebo (n=45) was infused intravenously every 6 hours for 72 
hours in patients with an acute ischemic stroke in the setting of a randomized 
controlled trial. We measured BP and heart rate every 15 minutes. Continuous 
ECG monitoring was performed during 84 hours. Standard 12 lead ECG's were 
made at entry, after 24 hours and once between day 3 and 7. Patients were 
checked for adverse events on a daily basis. A repeated physical examination 
was performed at 3 months. Plasma levels of CK and LDH including sub-
fractions were determined regularly. 
DCLHb caused a rapid rise in mean arterial blood pressure that was not 
accompanied by complications or excess need for anti-hypertensive treatment. 
Cardiac functions as assessed by ECG' s, Holter registration, and physical 
examination were not affected. Cardiac adverse events, such as heart failure, 
dysrhythmias occurred equally in both groups. Dose-dependent increases of 
LDH and CPK were found, but without an increase in CK-MB or LDH-1 sub-
fractions. 
Although the clinical outcome of patients was adversely affected by treatment 
with DCLHb, this was not caused through adverse effect on the heart. 
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Introduction 
Diaspirin cross-linked hemoglobin (DCLHb) is a cell-free hemoglobin based 
oxygen carrying solution.' Until recently, it was developed as a hemoglobin 
therapeutic for high blood loss, surgery, sepsis, hemodialysis, cardiac surgery 
and trauma. In several phase ill clinical trials, DCLHb was not found to be 
efficacious and did not meet the predefined level ofsafety.2· 6 We have recently 
reported on our phase II study in which we assessed the safety and efficacy of 
DCLHb in patients with acute ischemic stroke. Outcome scale scores were 
significantly worse in the DCLHb group and more serious adverse events and 
deaths occurred in DCLHb-treated patients than in controls.7 
A major toxicity fmding in the pre-clinical studies in swine and primates had 
been the occurrence of focal and multi-focal myocardial lesions. These lesions 
were typically found 24-48 hours after volume-load doses as low as 200 mg/kg 
in rhesus monkeys and 700 mg/kg in pigs. Incidences in the most sensitive 
animal model, the rhesus monkey, were 5/5 at 700 mg/kg, 3/3 at 500 mg/kg, 3/5 
at 350 mg/kg, 1/5 at 200 mg/kg and 0/5 at both 100 and 50 mg/kg. CK-MB and 
LDH-1 levels did not increase. No electrocardiographic (ECG) changes, 
dysrhythmias, decrease in cardiac output or other physiologic consequences 
have been associated with these lesions. Histologically the lesions are similar to 
those occurring after high doses catecholamines.[investigator's brochure] 
In a double-blind, cross-over phase I study involving 24 healthy volunteers, 
participants received a single infusion DCLHb of 25 mg!kg (n=7) 50 mg/kg 
(n=8) and 100 mg/kg (n=7). The evaluation of cardiac function by 12-lead 
ECG, echocardiography and 48-hour Holter monitoring revealed no treatment 
related abnormalities. Dose dependent increases in mean arterial pressure 
(MAP), were reported with a concomitant decrease in heart rate.' 
Recent studies in humans in different populations, such as patients undergoing 
cardiac surgery or abdominal aortic surgery, have shown that DCLHb increases 
BP, systemic vascular resistance index (SVRi) and slightly decreases cardiac 
output.2"4 
The primary aim of our study was to assess whether the adverse effect of 
DCLHb on clinical outcome in patients with acute ischemic stroke, was 
mediated through adverse effects on the heart. 
85 
Chapter 6 
Patients and methods 
The trial was conducted in compliance with the Declaration of Helsinki and 
Good Clinical Practice for Trials on Medicinal Products. For participation, 
written informed consent from the patients or their family was required. The 
participating centers were the departments of Neurology in the University 
Hospitals of Heidelberg, Helsinki, Leuven and Rotterdam. The Medical Ethics 
Committees approved the protocol. Patients received all standard care and 
treatment, including prophylactic medication such as acetylsalicylic acid and 
heparin. If patients were already on anti-hypertensive medication, this 
medication was continued, without any change, throughout the study. New 
anti-hypertensive therapy was not initiated unless BP exceeded 220/135 mmHg 
for an hour. 
Patients 
Patients with clinical symptoms of an acute ischemic stroke, in the anterior 
circulation were eligible if they were older than 20 years; could be treated 
within 18 hours after start of symptoms; and were likely to survive for at least 3 
months. Patients had to be alert or arousable by stimulation to obey, answer or 
respond to verbal commands. Brain computed tomography (CT) scan had to be 
normal or compatible with a recent infarction. Exclusion criteria were: any 
major disabling disorder interfering with the assessments; pregnancy or 
lactation; an evident hematological cause of the symptoms; congestive heart 
failure or acute myocardial infarction; systolic BP > 230 mmHg or diastolic BP 
> 130 mmHg; renal or liver disease; spontaneous improvement of symptoms by 
at least 2 grades on the modified Rankin scale; and previous enrollment in this 
study or enrollment in another investigational trial within 30 days. Eighty-five 
patients were enrolled between August 1994 and November 1996. 
Drugs 
DCLHb was derived from human erythrocytes and subjected to rigorous viral 
inactivation and removal procedures.' DCLHb was prepared and provided by 
Baxter Health care Corp., Deerfield, IL, USA (lot numbers 94A21AD 11 through 
95L08AD11). 
Treatment regimen 
Patients were randomly assigned to DCLHb or saline (placebo) in a l: 1 ratio. 
The study was single blind because of the prominent color of the drug and the 
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difficulty to manufacture a proper placebo. Three doses were tested: 25, 50 and 
IOOmg/kg 10% DCLHb (n=lO, 10 and 20 respectively) or equal volume of 
saline (n=45) every 6 hours for 72 hours (12 doses) intravenously at a rate of 2 
mllminute. The volumes infused per 24 hours were approximately 70 ml for the 
lowest, 140 ml for the intermediate and 280 ml for the highest dose ofDCLHb. 
Assessments 
Baseline assessment consisted amongst others of a medical history, general 
physical and neurological examinations and an ECG. Blood pressure and HR 
were measured every 15 minutes with an automatic, oscillometric blood 
pressure device during the 72-hour treatment period. 
The physical examination was repeated at day 3, 7, 14 and at 3 months. At the 3 
month follow-up, the presence of an irregular pulse was interpreted as the 
presence of AF. Patients were checked for adverse events on a daily basis 
during their hospitalization and again at the 3 month visit. Creatine kinase (CK, 
total and fractionated) and lactate dehydrogenase (LDH, total and fractionated) 
were measured prior to infusion and on day 1,2,3 and 7. Safety was further 
monitored by ECG' s on day 1 and once between day 3 and 7 and 84-hour 
Holter monitoring, started at study entry. 
The ECG's and Holter-tapes were assessed by cardiologists who were blinded to 
treatment. ECG's were assessed as normal or abnormal. The latter was further 
specified into new ischemia, non-specific ST- and T wave changes, left 
ventricular hypertrophy, AF, supraventricular dysrhythmias other than AF, 
ventricular dysrhythmias, conduction disorders and a category other. The latter 
consisting mainly of old infarctions and atrial enlargement. A single ECG 
could carry any number of diagnoses. 
Holler-analysis consisted of rhythm-analysis as well as ST-analysis. Holter-
registrations were also judged to be normal or abnormal. When abnormal, the 
results were further specified into ST-segment depressions and/or ischemia, AF, 
atrial or ventricular arrests flutter, Q-T interval prolongation, and a category 
other in which mostly of many premature atrial or ventricular complexes 
(PAC's or PVC's), significant sinustachycardia or sinusarrythmia. A chest X-
ray was performed once during the study period. 
Statistics 
For statistical analysis we used SPSS, version9.0. Values are expressed as mean 
± SD unless otherwise indicated. Values of MAP and HR are presented as mean 
and 95% confidence interval. Comparison of data between the four groups of 
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patients was done by analysis of variance (ANOVA) for MAP and HR. Cardiac 
enzymes were not normally distributed and were analyzed using the Wilcoxon 
signed-rank test. For comparison between two groups Student's unpaired t-test 
or chi-squared analysis was used as appropriate. A p-value < 0.05 was 
considered to indicate a statistically significant difference. 
Results 
Patient characteristics 
Relevant patient characteristics are presented in table 1. More extensive 
baseline characteristics were published in an earlier paper (see chapter 3).7 The 
groups were well-matched with respect to cardiovascular baseline variables. 
Table 1 Characteristics of patients with acute ischemic stroke randomized to 
DCLHb or normal saline 
Saline DCLHb P-value 
Number of patients 45 40 
Age (years) 65 ± 15 68± 13 0.40 
Cause of stroke 
Large vessel 10 (22) 9 (23) 1.00 
Small vessel 13 (29) 12 (30) 1.00 
Cardioembolic 9 (20) 10 (25) 0.71 
Other 13 (29) 9 (23) 0.67 
Medical History 
Angina pectoris 4 (9) 8 (20) 0.25 
Atrial fibrillation 7 (16) 6 (15) 1.00 
Hypertension 18 (40) 20 (50) 0.48 
Myocardial infarction 6 (13) 3 (8) 0.49 
Systolic BP 155±20 158±24 0.52 
Diastolic BP 85±13 84±13 0.72 
Heart rate 75±15 80±13 0.18 
Values in parentheses are percentages 
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Prior Medication 
Twenty patients did not use any medication in the two weeks prior to study 
entry. Six had been allocated to receive DCLHb, 14 to saline. There were no 
significant differences in medication used at study entry, specifically no 
difference in use of anti-hypertensive medication, diuretics, anti-coagulants 
such as heparin and warfarin, platelet aggregation inhibitors, anti-arrhythmic 
and inotropic medication. 
Medication used during the first week 
Anti-hypertensive medication such as aldosterone antagonists, beta blocking 
agents, calcium channel blockers, clonidine, converting enzyme blockers) were 
used by 30 DCLHb patients and 35 saline patients and coronary vasodilators by 
3 patients in each group. Diuretics for heart failure and hypertension were used 
at baseline in 9 DCLHb vs. 6 control patients, and during treatment in 16 versus 
8, respectively (p=0.04) .. We found no relationship between the occurrence of 
clinical adverse events and the use or type of co-medication. 
ECG's and Holter analysis 
There were no significant differences between the treatment and control group 
in the baseline ECG' s, or in the follow-up ECG's. The results are given in table 
2. 
The results of the Holter analysis are summarized in table 3. Again there were 
no differences in incidences between the two groups. ST-dysfunction or 
ischemia occurred in 5 saline and 3 DCLHb patients, but mostly subclinically. 
See also under adverse events. 
Adverse events 
Cardiac arrests did not occur in either group. 
Heart failure occurred in 3 DCLHb and 3 saline within the first 14 days. In all 
but one (saline) patient, heart failure was not present at baseline and newly 
developed during the study. Cardiac failure was of mild to moderate severity, 
resolved in 3 and persisted in 2 (one in each group) patients. Another seven 
patients ( 4 DCLHb, 3 saline) already had heart failure at the time of admission. 
Myocardial ischemia or mJury, defined as the development of 
electrocardiographic evidence ofT-wave inversion, ST-segment elevation or 
depression in leads corresponding to or opposite the area of involvement or 
elevated CK with elevated CK-MB, occurred in 4 saline and 0 DCLHb patients. 
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Table 2 Results of the repeated ECG recordings 
ECG pre-treatment 
Saline DCLHb 
Number of patients* 45 40 
Result abnormal 28 27 
Supraventricular rhythm disorder ** 2 1 
Atrial fibrillation 4 6 
Ventricular rhythm disorder 0 l 
Conduction delay 9 9 
New ischemia 1 0 
Left venh·icular hypertrophy 3 3 
Non-spec. ST-and T-wave changes 14 16 
Other*** 14 12 
ECG at 24 hours 
Saline DCLHb 
45 38 
26 23 
1 1 
5 5 
1 0 
8 7 
1 0 
0 1 
12 14 
12 10 
Q 
{l 
~ 
0, 
ECG between day 3-7 
Saline DCLHb 
45 35 
27 25 
2 0 
5 8 
0 0 
10 5 
3 
1 2 
10 14 
11 12 
* At 24 hours: ECG not done in 4 saline and 7 DCLHb patients, so last observation was catTied forward. 2 DCLHb 
patients were dead, of whom 1 had AF. At day3-7: ECG not done in 9 saline and 4 DCLHb patients, so last 
observation was carried forward. 5 DCLHb patients were dead, of whom 2 had AF 
** Other than atrial fibrillation 
*** PVC's, PAC's, old ischemia, atrial enlargement 
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Table3 Results of 84 hour Halter-registration 
Saline DCLHb P-value 
Number of patients* 41 40 
Result abnormal 13 18 .25 
ST -dysfunction, ischemia 5 3 .71 
Atrial fibrillation 4 10 .08 
Ventricular or atrial arrests 1 3 .35 
Q-T interval prolongation 5 1 .20 
Supraventricular arrhythmia 3 2 1.00 
Ventricular arrhythmia** 0 5 0.02 
Other disorders*** 3 7 0.19 
* Due to technical failure reports in four saline patients are missing, and 2 of 
these had AF on their ECG 
* * 4 Ventricular tachycardia, 1 ventricular flutter 
*** Many PAC's or PVC's, marked sinustachycardia, sinus arrhythmia 
Cardiac laboratory parameters 
During the first 3 days, concentrations of CPK were increased in the active 
treatment groups, see figure 1. CK-MB levels were also elevated, but remained 
within the normal range of 0-14 U/1. LDH levels were elevated pre-infusion in 
the low and intermediate dose group, but further increased after treatment. The 
LDH sub-fraction originating from the heart, LDH-1, however, was dose-
dependently decreased compared with controls. All laboratory abnormalities 
were clinically asymptomatic and disappeared within a week. 
Blood pressure and heart rate 
DCLHb produced a rapid rise in mean arterial pressure (MAP). The magnitude 
of the increases caused by the different doses was similar, but the duration of 
the pressor was dose-dependent. Severe hypertension that needed 
pharmacological intervention occurred in 3 patients treated with DCLHb vs. 3 
in the saline group. Heart rates were similar in both groups and did not change 
significantly from baseline. We have reported this in more detail elsewhere (see 
chapter 4). 9 
91 
'0 
N 
Figure 1 Median values ofCK, CK-MB, LDH and DH-1 levels during the first week 
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Discussion 
We conducted a safety study of DCLHb in patients with acute ischemic stroke. 
We have previously reported that treatment with DCLHb was an independent 
predictor of an unfavorable outcome at 3 months, but the cause of this 
unexpected adverse effect remained unclear.7 We also showed that DCLHb 
caused a rise in ET -1 levels and blood pressure, but did not find evidence that 
this caused stagnation of recovery stagnate.10 In the present study, we wished to 
determine whether the adverse effect on outcome was mediated through an 
adverse effect on the heart. We studied cardiac functions extensively through 
ECG's, 24-hour Holter monitoring, laboratory tests and patients were checked 
for adverse events. We found that none of the cardiac function parameters 
differed between treated patients and controls. The Holter-analysis revealed 
more ventricular arrhythmias in the treated group, but these were mostly 
ventricular tachycardias not leading to discomfort or sequelae. We found a 
dose-dependent transient increase in LDH en CPK, but without an increase of 
the cardiac sub-fractions. The previously reported increase in BP was well 
tolerated. 
These results are in concordance with experimental evidence and clinical trials 
in humans. Lamy et a!. performed a trial in which DCLHb was infused as an 
alternative to blood transfusion after cardiac bypass surgery in 104 patients, and 
the control group (n=105) received packed red blood cells. Although the 
number of deaths was balanced in this study, there were more adverse and 
serious adverse events in DCLHb recipients. However, myocardial iso-
enzymes (CK-MB and LDH-1) and Troponin T increase from baseline was 
smaller in the DCLHb group. These results suggested that there was no 
evidence that DCLHb caused myocardial stress or damage. DCLHb caused a 
rise in systemic and pulmonary artery pressures, but no adverse clinical 
sequelae were reported as a consequence of the increase in blood pressure.4 
In a controlled, randomized, dose-incremental trial by Garrioch et. a!., 34 
patients undergoing elective repair of an abdominal aortic aneurysm, the effects 
of a single infusion with 50, 100 or 200 mg/kg DCLHb or Ringer's lactate was 
studied. DCLHb caused an increase in arterial pressure, with a small decrease 
in cardiac index, while heart rate did not change? 
In conclusion, infusion of low doses of DCLHb over 3 days did not harm the 
cardiac functions as assessed in this study. Therefore, the adverse effect of 
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DCLHb on outcome among patients with acute ischemic stroke can not be 
explained by an adverse effect on the heart. 
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Abstract 
The diagnosis of early recurrent stroke is not always easy in patients with acute 
ischemic stroke, since up to 20% of patients show spontaneous fluctuations, 
some of which may be caused by repeated embolism, but many have other 
causes, including systemic disorders. The risk of recurrent stroke seems to be 
higher in patients entered in clinical trials than in population based studies or 
stroke data banks. The aggregate results of randomized clinical trials of heparin 
in acute ischemic stroke suggest that this treatment reduces the risk .of early 
recurrence by about one quarter, but also that this benefit is completely offset by 
an equal risk of hemorrhage. Present data neither suggest a clear subgroup, in 
particular those with cardioembolic stroke, with a higher risk of early 
recurrence, nor one that specifically benefits from early treatment with 
anticoagulants. Findings from two large trials show that aspirin is effective in 
reducing death and early recurrence (10 events prevented per 1000 treated) and 
safe. 
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Introduction 
One of the feared complications in the acute phase of ischemic stroke is early 
recurrence of stroke. The frequency of early recurrent stroke varies in different 
studies and is often believed to be higher in patients with a potential cardiac 
source of embolism. It has also been suggested that recurrent stroke is often 
more severe than the initial event and is associated with increased mortality and 
disability. The value of antithrombotic treatment, especially heparin and 
aspirin, has recently been addressed in several studies. This chapter aims to 
review the definition and epidemiology of early recurrent stroke and to focus on 
the benefits and risks of antithrombotic therapy in the prevention of this 
complication. 
Definition of early stroke recurrence 
Although nearly all patients who survive an acute ischemic stroke eventually 
show some degree of clinical improvement, neurological symptoms are often 
unstable during the early phase. Patients may show rapid deterioration 
('progressive stroke'), fluctuations ('stuttering stroke') or secondary 
deterioration after initial improvement ('recurrent stroke'). These various forms 
of worsening are difficult to define and often overlap. Several studies have 
shown that spontaneous fluctuations occur in about 20% of carotid territory 
ischemic stroke and in up to 50% of vertebrobasilar ischemia.1·3 Systemic 
disorders, such as myocardial ischemia and metabolic disturbance, are thought 
to play a role in fluctuation and late deterioration. Surprisingly, the large 
majority of studies focusing on early recurrent stroke reviewed in this chapter 
have not addressed this diagnostic problem. In fact, this issue is briefly 
discussed in only one study4 and very few studies have attempted to define 
recurrent stroke (see table 1)5 "10 Some have included worsening of a 
preexisting deficit, while others have accepted only new deficits that occurred in 
a different anatomic or vascular territory or were of a different stroke subtype 
than the index stroke. It is obvious that the lack of an uniform definition of 
recurrent stroke strongly influences the existing data on the epidemiology and 
medical prevention of this complication. 
99 
Chapter 7 
Table 1 Definition of recurrent stroke in various studies 
Author 
CESG (1983)5 
Ramirez-Lassepas (1986)6 
Sacco (1989)" 
Sandercock (1992)8 
Hornig (1993)9 
Berge (2000/0 
Table continued on next page 
100 
Definition 
Clinical evidence of recurrent systemic or cerebral 
embolism (no furtber details 
New infarct and no extension of index cerebral 
infarct (no furtber details) 
A cerebrovascular event within 30 days after the 
index stroke that clearly resulted in a new deficit 
and occurred in a different anatomic or vascular 
territory or was of a different subtype than the 
index stroke 
Clear clinical evidence of the sudden onset of a 
new neurological deficit, or an increase in an 
existing deficit, for which no explanation other 
than a recurrent stroke could be found 
Sudden worsening of preexisting focal deficit, or 
new symptoms without other reasons, e.g. 
epileptic sei=e 
A clinical sudden and persistent (>48h) 
deterioration occurring after the first 48h 
foil owing stroke onset, which equals a loss of 3 or 
more points in the SSS, excluding cerebral 
hemorrhage, intercurrent iiiness and effect of 
medication 
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Table 1 Definition of recurrent stroke in various studies, continued 
Author 
Petty (2000)17 
Other publications on the 
subject 
Definitiou 
A new neurological deficit fitting the definitions 
of ischemic or hemorrhagic stroke, occurring after 
a period of unequivocal neurological stability or 
improvement lastiog~4h and not attributable to 
edema, mass effect, brain shift syndrome, or 
hemorrhagic transformation of the incident 
cerebral infarction 
Not explicitly stated 
Incidence of early recurrence 
The frequency of early recurrence has recently been reported in several large 
acute stroke trials, in which the efficacy of aspirin and/or heparin was 
investigated. Table 2 sununarizes the early stroke recurrence rate. Because of 
the inherent methodological drawbacks of retrospective, non-randomized and 
uncontrolled studies only prospective, randomized, controlled studies, in which 
recurrent stroke was a predefined outcome event are shown. Data for untreated 
groups are presented if available or otherwise data for patients treated with 
aspirin. Patients were randomized within 24-48 hours of stroke onset and the 
observation period varied between 7 and 28 days after the index stroke. The 
International Stroke Trial (IST), 11 Chinese acute stroke trial (CAST)12 and the 
Trial ofORG 10172 in Acute Stroke Treatment (TOAST)13 and FISS14 included 
all types of ischemic strokes. However, physicians were free to exclude patients 
whom they believed to require anticoagulation, for instance patients with atrial 
fibrillation (AF) and a presumed high risk of stroke recurrence. ln the Heparin 
in Acute Embolic Stroke trial (HAEST) only patients with acute ischemic stroke 
and AF were randomized. 10 Table 2 shows that the risk of early recurrence 
varies between 0.09% per day in CAST patients (7% AF) and 0.68% per day in 
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the small CESG triaL In the HAEST study the recurrence risk was also high 
(0.53%/day). In that study, recurrent ischemic stroke was a primary outcome 
event and patients were assessed for neurological deterioration every day during 
the frrst week and every other day during the second. Another important factor 
is the time between stroke onset and inclusion in studies. In IST and CAST, 
patients could be randomized up to 48 hours after onset of symptoms, so some 
very early recurrences may have been missed. 
Since patients from clinical trials in general represent a selected gtoup, 
information from stroke data banks and population based studies are important. 
These are also summarized in table 2. The disadvantage of some of these 
studies is, however, that they were retrospective, leading to potential 
underreporting of recurrent stroke and to uncertainty regarding dose, duration 
and the clinical gtounds of antithrombotic therapy. The observation period in 
all these studies was 30 days. 
Sacco eta! studied 1,273 patients with acute ischemic stroke who were entered 
into the NINDS-Stroke Data Bank, a prospective, observational study7 The risk 
of early recurrence was 3.3% in 30 days. Gustafsson followed 276 consecutive 
patients admitted to a population-based stroke unit in Stockholm." Within 1 
month, 2.9% had a recurrent stroke. In the Rochester Epidemiology Project 
(REP), 1,382 patients with first ever cerebral infarction between 1960 and 1984 
were tracked. 16 The recurrence risk within 30 days was 2%. In a second report, 
patients between 1985 and 1989 were studied retrospectively and the 30 day 
recurrence rate was 4.8%17 In the Oxfordshire Community Stroke Project 
(OCSP), 545 patients with frrst ever ischemic stroke were followed.' The risk 
of early recurrence within 30 days was 3.5%. However, some recurrences may 
have occurred unnoticed as many of these patients stayed at home and were not 
carefully studied in the acute phase. 
In conclusion, the risk of recurrent stroke seems to be higher in patients entered 
in clinical trials than in population based studies or stroke data banks. Patients 
in trials were randomized early after stroke onset and probably followed more 
carefully. On the other hand, they probably represent a selected gtoup of high 
risk patients. It is also possible that the longer observation period in the 
population based and stroke data bank studies has diluted the early recurrence 
rate. 
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Table 2 Risk of early stroke recmTence in untreated or aspirin-treated patients from randomized, controlled acute 
stroke trials and patients from stroke data banks and community studies, with unspecified treatment 
Study Patients Observation Recurrences (%) Time to 
(n) Period During Per day inclusion (h) 
(days) observation 
Clinical trials 
CESG (198305 21 14 9.5 0.68 48 
FISS (1995} 14 105 10 5.7 0.57 48 
IST (1997) 11 9718* 14 3.8 0.27 48 
CAST (1997) 12 10552 28 2.5 0.09 48 
TOAST (1998) 13 631 7 1.4 0.20 24 
HAEST (2000) 10 225" 14 7.5 0.53 30 
Stroke data banks and community studies' 
NINDS-SDB (1989)7 1273 30 3.3 0.11 unknown ? Gustafsson (1991) 15 276 30 2.9 0.10 unknown 
REP '60-'84 {1992)16 1382 30 2.0 O.o? unknown !'l 13· 
OCSP (1992}8 545 30 3.5 0.12 unknown " ~ 
REP'85-'89 (2000) 17 442 30 4.81 0.161 unknown g 
... 
* Half were treated with aspirin ~ 
# All were treated lvith aspirin ~ t Procedure related strokes were excluded g 
- " 0 iJi w 
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Risk factors for early recurrence 
All of the abovementioned population studies have also tried to identifY risk 
factors for early stroke recurrence. Some authors have compared the recurrence 
rate for specific etiological stroke subtypes. Sacco et a! prospectively studied 
determinants of early recurrence in 1,273 patients with ischemic stroke from 
various causes7 A total of 40 patients (3.3%) had a recurrence within 30 days. 
Procedute related strokes were not included. Patients with atherothrombotic 
infarction (ATH) had the highest risk of very early recurrence (7 .9% ), followed 
by patients with presumed catdioembolic stroke (CES, 4.3%), infarction of 
undetermined cause (IUC, 3.0%), and lacunar infarcts (LAC, 2.2%). Petty et al 
reviewed records of 442 patients with first ever ischemic stroke from the 
Rochester Epidemiology Project and used the same etiological 
subclassification.17 Twenty-five patients (5.6%) had a recurrent ischemic stroke 
within 30 days and there was a significant difference between stroke 
mechanisms and the recurrence rate: ATH: 18.5%; CES: 5.3%; IUC: 3.3% and 
LAC: 1.4%. Procedute related strokes were included and it is noteworthy that 4 
of the 13 recurrences in the ATH group were iatrogenic (angiography, carotid 
endarterectomy). 
As the early recurrence rate is often believed to be higher in patients with a 
potential cardiac somce of embolism, data for patients with presumed cardio-
embolic stroke, compared to those without catdioembolic stroke ate shown in 
table 3. In IST, 3,169 (17%) of 18,451 acute stroke patients had AF at study 
entry.u Patients with AF had a higher risk of early death, which could be 
explained by older age and larger initial strokes in AF patients, but not by a 
higher risk of early recurrent ischemic stroke, although slightly more patients 
with AF died from a fatal recurrent stroke of ischemic or unknown type (1.3% 
vs. 0.9%; Odds Ratio 1.7, 95% Confidence Interval 1.2-2.4) (unpublished data). 
Three quarters of IST patients received heparin and/or aspirin and one quarter 
no antithrombotic therapy. The rate of early recurrent stroke was equally 
frequent in both groups (3 .9% in AF against 3.3% in SR; Odds Ratio 1.2, 95% 
Confidence Interval 1.0-1.5) when all treatment groups were combined. The 
IST data ate potentially weakened by the possibility of selection bias, since 
patients with AF and a high risk may have been treated with anticoagulants and 
not have been entered into the study. On the other hand, the frequency of AF of 
18%, which is very similar or even higher than that found in other series of 
stroke patients, does not point in that direction. The data for the patients who 
did not receive heparin ate given in table 3. In these patients (balfreceived no 
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antithrombotic treatment and the others received aspirin) the risk of stroke 
recurrence was somewhat higher than in patients without AF. 
In the TOAST trial no difference between patients with and without CES was 
found. 13 
The HAEST and CESG studies are not mentioned in table 3, as all patients had 
a cardioembolic stroke. In the HAEST study all patients had AF and the 
recurrence rate was high (7.5%/14 days).10 Furthermore, recurrent stroke was a 
primary outcome event in this trial and patients were rigorously checked for 
recurrences. In CESG, 2 of21 patients (9.5%) had a recurrence.' In CAST,12 
7% of patients had AF and in FISS, 14 13% had a CES , but recurrence rates 
were not reported separately for these groups. 
Epidemiological studies have also focused on differences in the risk of early 
recurrence between patients with presumed cardioembolic stroke and those with 
a likely vascular cause (see table 3). Two population studies discussed earlier, 
OCSP and REP, showed no clear evidence of a higher risk in patients with a 
cardiac cause.7·" In the Oxfordshire Community Stroke Project, the prevalence 
of AF was 98 (18%) among 545 patients with first ever stroke.' Twenty-one 
patients with AF received anticoagulants at some time after the stroke. The risk 
of early recurrence within 30 days was 1% in AF patients against 4% in patients 
with sinus rhythm. A potential weakness of the study is that cardiac screening 
was very rarely performed which may have led to an underestimation of the 
prevalence of cardiac disease. Furthermore, some recurrences might have been 
missed as many patients stayed at home and were not carefully studied in the 
acute phase. In the first study from the Rochester Epidemiology Project, 318 
(23%) of 1,382 patients with first ever cerebral infarction had at least one major 
potential cardiac source of emboli. 16 AF was present in 19% of all cases. The 
recurrence risk within 3 0 days was 2%, both in patients with or without a 
cardiac abnormality. Details on antithrombotic treatment were known only in 
the subgroup of patients who survived the first week. Slightly less than half of 
them were treated with heparin, warfarin or both within the first 7 days. The 30 
day stroke recurrence rate was 3% for treated vs. 2% in untreated patients. 
Gustafsson also did not find a significant difference in the 14 day recurrence 
rate: 4/88 in AF patients versus 4/188 in patients with sinus rhythm." 
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Table 3 Risk of early stroke recurrence in patients with or without cardio-
embolic stroke (CES) in untreated patients or aspirin-treated patients from 
randomized, controlled trials and patients from stroke data banks and community 
studies, with unspecified treatment 
Study Cardio-embolic Non-cardio- Observation 
stroke embolic stroke Period (days) 
Clinical trials 
IST (1997)11 1612 (all AF) 8105" 14 
TOAST (1998)13 123 (52 AF) 508 7 
Stroke data banks and community studiest 
NINDS-SDB (1989}" 246 958 30 
Gustafsson (1991) 88 (all AF) 188 30 
REP '60-'84 (1992)16 318 1064 30 
OCSP (1992)8 76 (all AF) 448 30 
REP'85-'89 (2000)17 132 310 30 
# Half were treated with aspirin 
t Procedure related strokes were exclude 
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Table 3 Risk of early stroke recurrence in patients with or without cardia-
embolic stroke (CES) in untreated patients or aspirin-treated patients from 
randomized, controlled trials and patients from stroke data banks and community 
studies, with unspecified treatment, continued 
Recurrence rate CES Recurrence rate non-CES 
(%) (%) 
During Per day During Per day OR(95% CI)* 
observation observation 
4.9 0.35 3.6 0.26 1.38 (1.06-1.79) 
1.6 0.23 1.4 0.20 1.18 (0.26-6.25) 
4.1 0.14 3.1 0.10 1.31 (0.59-2.84) 
4.5 0.15 2.1 0.07 2.2 (0.46-10.94) 
2.0 0.07 2.0 0.07 0.96 (0.34-2.5) 
1.0 0.03 4.0 0.13 0.25 (0.02-1.7) 
4.851 0.161 5.2t 0.171 0.91 (0.34-2.56) 
* Cardia-embolic stroke (CES) vs. non-cardia-embolic stroke 
107 
Chapter 7 
There may also be differences in the recurrence rate between various types of 
underlying cardiac disease, but the available data are insufficient to determine 
major differences with the possible exception of rheumatic heart disease, which 
carries a higher risk, and atrial fibrillation, which is more benign.18 Yasaka and 
colleagues studied risk factors for early recurrence in 227 patients with 
cardioembolic stroke, none of whom were treated with anticoagulants. 19 
A quarter of the study population had rheumatic heart disease. Recurrent brain 
or systemic embolization within 14 days occurred in 31 (13.7%) and 19 (8.4%) 
patients, respectively, and was associated with a higher mortality. The presence 
of rheumatic heart disease, prosthetic valves and intracardiac thrombi were 
associated with recurrent emboli. The incidence of rheumatic heart disease, 
however, has strongly declined in the western world. In the Rochester 
Epidemiology Project '60-'84 cardiac valve disease and congestive heart failure 
(but not AF) were independent predictors of recurrent stroke.16 
In conclusion, there is contradictory evidence whether a cardiac source of 
embolism, especially AF, is associated with a higher risk of early stroke 
recurrence. The main disadvantage of clinical trials is that they represent a 
selected group, whereas the potential impact of antithrombotic treatment is an 
uncertain factor in epidemiological studies. 
Some other factors have been found to be associated with the risk of early 
recurrence. Sacco found that a history of hypertension and diabetes mellitus as 
well as diastolic hypertension and an elevated blood sugar on admission and 
increased weakness scores were associated with early recurrence in a logistic 
regression analysis. 7 Yasaka also reported low plasma levels of antithrombin 
III, dehydration to be associated with recurrent stroke.19 Studies concentrating 
on late stroke recurrence have found that a history of hypertension, ischemic 
heart disease, diabetes and previous thromboembolism were associated with a 
higher risk?a-22 These data suggest that risk factors for early and late recurrence 
are strikingly similar. 
Prevention of early recurrence 
Immediate use of antithrombotic therapy might reduce the risk of early 
recurrent stroke, but may also increase the risk of intra- and extracranial 
hemorrhage. Older clinical trials, mostly non-randomized and retrospective, 
have suggested a reduction of the absolute risk of early recurrence by 
anticoagulants from 15% to 5% during the first month.18 We shall concentrate 
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on prospective, randomized, controlled trials addressing the safety and efficacy 
of antithrombotic treatment in acute stroke, in which recurrent stroke and 
intracranial hemorrhage were predefmed endpoints and patients were 
randomized within three days of stroke onset. The results are summarized in 
figures 1-3. 
In 1960, Marshall and Shaw published a clinical trial of 51 patients with a 
clinical diagnosis of ischemic stroke of less than 72 hours duration and without 
a potential source of embolism in the heart.23 Patients were randomized to open 
label treatment with 3 doses of 12,500 units un:fractionated heparin plus the oral 
anticoagulant phenindione twice daily aiming at PT ratio between 2 and 3, or to 
no treatment. Two patients in the control group and none in the anticoagulants 
group had an early recurrent event within 6 weeks after randomization. Three 
treated patients died of cerebral hemorrhage vs. 1 untreated patient. 
Low-molecular-weight heparins (LMWH) were tested in the FISS'", TOAST13 
and FISS-bis study.Z4 In1995, Kay et al published the double-blind, placebo-
controlled FISS trial in which 312 Chinese patients with acute ischemic stroke 
were treated with subcutaneous LMWH, either low-dose or high-dose, or 
placebo within 48 hours of stroke onset. 14 Patients were younger than 80 years 
and did not have valvular heart disease necessitating anticoagulant therapy. 
Treatment lasted I 0 days. The main measure of outcome, clinical condition at 6 
months, was significantly improved in both actively treated groups. Early 
recurrent stroke during the treatment period occurred in 1 patient receiving the 
high-dose, 2 in the low-dose and 5 in the placebo group. Early hemorrhagic 
transformation was found in 5 patients in the high-dose group, 7 in the low-
dose, and 9 of the placebo patients. Symptomatic hemorrhagic transformation 
occurred in respectively 0,2 and 1 patients. 
In an attempt to reproduce the results of FISS, a replication study with a larger 
number of patients (placebo: n=250; low-dose LMWH: n=271; high-dose 
LMWH: n=245) was undertaken.Z4 In 1998 FISS-bis was published and there 
was no overall benefit of either heparin dose on clinical condition at 6 months. 
Recurrent stroke was not a specified outcome event and was not reported in the 
publication. 
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Figure 1 The efficacy of anticoagulant treatment in the prevention of early recurrent stroke in patients 
with acute ischemic stroke 
Events/patients 
Study Treatment Control OR(95% CI) 
CESG (1983) 0/24 2/21 0.11 (0.01-1.85) 
Marshall ( 1960) 0/26 2/25 0.12 (0.01-2.05) 
FISS (1995) 3/203 5/105 0.27 (0.06-1.20) 
HAEST (2000) 19/224 17/225 1.13 (0.55-2.36) 
TOAST (1998) I 0/638 1!1628 0.89 (0.35-0.28) 
IST (1997) 283/9716 370/9717 0.76 (0.65-0.89) .. 
Total 315/10831 407/10721 0.76 (0.65-0.88) OR=0.76 ... 
-
Q 
{l 
~ 
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0,01 0, I I 10 
Log odds ratio and 95% 
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Figure 2 Number of symptomatic intracranial hemorrhages in patients with acute ischemic stroke 
and anti-coagulant treatment 
Events/patients 
Study Treatment Control OR(95% CI) 
CESG (1983) 0/24 0/21 not applicable 
Marshall ( 1960) 3/26 1/25 3.13 (0.26-330) 
FISS (1995) 2/203 1/105 1.04 (0.92-1.16) 
HAEST (2000) 6/224 41225 1.52 (0.42-5.46) 
TOAST (1998) 14/638 4/628 3.5 (1.07-12.64) 
-
IST (1997) 120/9716 41/9717 2.95 (2.04-4.16) ---;a 
. 
Total 145/10831 51/10721 2.83 (2.03-3.96) 
• . 
OR=2.84 
0,1 Log 0dds ratio and 9S% confidence interval 10 
J 
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Figure 3 Number of recunent ischemic strokes and symptomatic intracranial hemorrhages in patients 
with acute ischemic sh·oke and anticoagulant treatment 
Events/patients 
Study Treatment Conh·ol OR(95% Cl) 
CESG(l983) 0/24 2/21 not applicable 
Marshall (1960) 3/26 3/25 0.96 (0.13-6.86) 
FISS (1995) 5/203 6/105 0.42 (0.11-1.59) 
HA EST (2000) 25/224 21/225 1.22 (0.64-2.35) 
TOAST (1998) 24/638 25/628 1.59 (0.79-3.23) 
1ST (1997) 403/9716 4ll/9717 0.97 (0.4-1.13) 
4- OR=0.95 
Total 460/10831 458/10721 0.95 (0.83-1.09) 
g 
{l 
~ 
" 
0,1 1 10 
Log odds ratio and 95% confidence interval 
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The Trial of ORG I 0172 in Acute Stroke Treatment (TOAST) evaluated the 
LMWH danaparoid among I ,281 patients with ischemic stroke treated within 
24 hours of stroke onset.13 Danaparoid was given intravenously and treatment 
was continued for 7 days. The primary measures of were the Glasgow Outcome 
Scale and the Barthel Index at 3 months. Within I 0 days of onset of treatment, 
the risk of recurrent ischemic stroke was similar in both groups (10/638 
vs.ll/628 in controls). Serious intracranial bleeding events occurred in 14 
patients given ORG 10172 (15 events) and in 4 placebo-treated patients (5 
events, p=.05). Treatment with ORG 10172 was not associated with an 
improvement in favorable outcome at 3 months. 
The efficacy of antithrombotic treatment in the long-term prevention of stroke 
recurrence has been firmly established in patients with AF by the European 
Atrial Fibrillation Trial.25 Only two trials have studied the value of heparin in 
the acute treatment of CES. In 1983, the Cerebral Embolism Study Group 
published the results of a small open randomized trial in 45 patients with acute 
cardioembolic stroke of less than 48 hours duration.' The trial was primarily 
designed to assess the safety, and not efficacy, of early treatment with 
continuous intravenous heparin (APTT 1.5-2.5) compared with no treatment 
during I 0 days. Early recurrent stroke occurred in 2/21 control patients and 
none of the 24 treated patients. Symptomatic intracranial hemorrhage did not 
occur, but intracranial bleeding on a control CT -scan was found in 2 control 
patients. The recently published HAEST trial randomized 449 patients with 
acute ischemic stroke (within 30 hours after onset) and AF to treatment with 
aspirin (160mg/day) or a high dose of the LMWH dalteparin (IOOIU/kg sc bid). 
No difference in the frequency of early recurrent ischemic stroke or cerebral 
hemorrhage was detected. 
By far the largest trial to date is the IST which involved 19,435 patients with 
acute stroke, randomized in 467 hospitals." Three quarters of the patients were 
randomized to anti thrombotic therapy, i.e. to one of the three regimens: aspirin, 
subcutaneous unfractionated heparin (low dose or medium dose) or the 
combination, and one quarter to control. Patients with mild, moderate and 
severe deficits, presenting within 48 hours of the onset of suspected acute 
ischemic stroke were eligible for the study. Duration of treatment was 14 days. 
Nearly all patients had a CT-scan either before or after randomization. The 
primary outcomes were death within 14 days and death or dependency at 6 
months. Symptomatic intracranial hemorrhage and recurrent ischemic stroke 
within 14 days were protocol-specified secondary outcome events. Patients 
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allocated to heparin had significantly fewer recurrent ischemic strokes within 14 
days (2.9% vs. 3.8%) but this was completely offset by an increase in 
hemorrhagic strokes (1.2% vs. 0.4%). A total of3,169 (17%) patients were in 
AF, 784 of whom were allocated to 12,500 ill heparin sc bid, 773 to 5,000 ill 
heparin sc bid, and 1612 to avoid heparin. The proportion of AF patients with 
further fatal or non-fatal events within 14 days allocated to 12,500 ru heparin, 
5,000 ru heparin and to avoid heparin were respectively: ischemic stroke 2.3%, 
3.4%, 4.9% (p for trend=O.OOI); hemorrhagic stroke 2.8%, 1.3%, 0.4% 
(p<0.0001); and any stroke or death 18.8%, 19.4% and 20.7% (p=0.3). No 
effect of heparin dose on the proportion of patients who were dead or dependent 
at 6 months was found.26 
In acute ischemic stroke, a majority of patients show evidence of in vivo platelet 
activation, which can be inhibited by aspirin.27.28 The only antiplatelet agent 
that has been evaluated for the treatment of acute ischemic stroke is aspirin. In 
CAST, aspirin treatment (160 mg/day) was started within 48 hours of the onset 
of suspected acute ischemic stroke and continued in hospital for up to 4 
weeks. 12 In total, 20,000 patients were randomized. The primary outcome 
events were death from any cause during the 4-week treatment period and death 
or dependence at discharge, the secondary fatal or non-fatal recurrent 
hemorrhagic or ischemic stroke. There was a significant 14% (SD 7) 
proportional reduction in mortality during the scheduled treatment period (343 
[3.3%] deaths among aspirin-allocated patients vs. 398 [3.9%] deaths among 
placebo-allocated patients; 2p = 0.04). Significantly fewer recurrent ischemic 
strokes occurred in the aspirin-allocated than in the placebo-allocated group 
(167 [1.6%] vs. 215 [2.1%]; 2p = 0.01) but slightly more hemorrhagic strokes 
(115 [1.1%] vs. 93 [0.9%]; 2p > 0.1). In IST, aspirin-allocated patients had 
significantly fewer recurrent ischemic strokes within 14 days (2.8% vs. 3.9%) 
with no significant excess of hemorrhagic strokes (0.9% vs. 0.8%), resulting in 
a significant reduction in death or non-fatal recurrent stroke with aspirin (11.3% 
vs. 12.4%).11 
With the results ofiST and CAST combined, aspirin produces a small reduction 
of about I 0 early deaths or recurrent strokes per 1000 patients treated. Both 
trials suggest that aspirin should be started as soon as possible after the onset of 
all subtypes of ischemic stroke. 
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Summary 
The diagnosis of early recurrent stroke is not always easy in patients with acute 
ischemic stroke, since up to 20% of patients show spontaneous fluctuations, 
some of which may be caused by repeated embolism, but many have other 
causes, including systemic disorders. The risk of recurrent stroke seems to be 
higher in patients entered in clinical trials than in population based studies or 
stroke data banks. The aggregate results of randomized clinical trials of heparin 
in acute ischemic stroke suggest that this treatment reduces the risk of early 
recurrence by about one quarter, but also that this benefit is completely offset by 
an equal risk of hemorrhage. Present data neither suggest a clear subgroup, in 
particular those with cardioembolic stroke, with a higher risk of early 
recurrence, nor one that specifically benefits from early treatment with 
anticoagulants. Findings from two large trials show that aspirin is effective in 
reducing death and early recurrence (10 events prevented per 1000 treated) and 
safe. 
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Detection of paroxysmal atrial 
fibrillation in the acute phase of stroke 
by means of 84-hour Holter-ECG 
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paroxysmal atrial fibrillation in the acute phase of 
stroke by means of 84-hour Holter-ECG. (Submitted) 
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Abstract 
Atrial fibrillation (AF), both continuous and paroxysmal (P AF), constitute a 
major risk factor for stroke. The most effective way to diagnose P AF in acute 
stroke patients without a history of AF is still uncertain. We compared the yield 
of 84-hours (h) Holter-ECG recording with that of a single Holter-ECG during 
the first 24 hours and of repeated ECG's during the first 7 days. 
We prospectively studied 85 patients with ischemic stroke in the anterior 
circulation ofless than 18 hours duration by means of continuous ECG 
monitoring during 84 hours within the setting of a multi-center stroke trial. 
Medical history, including AF, was assessed from patients, general practitioners 
and available hospital information. Standard 12 lead ECG's were made at 
entry, after 24 hours and once between day 3 and 7. 
Twenty-one patients had AF, including 11 patients with a history of AF. Eight 
of21 patients had PAF. Five of these 8 patients did not have a history of AF. 
Seven of eight were identified by 84-h Holter-ECG recording, 5 by repeated 
ECG's, and none by Holter-ECG recording during the first 24 hours only. 
P AF is commonly present in patients with acute ischemic stroke, and often 
newly discovered. It can be most effectively identified by 84-h Holter-ECG 
recording and only slightly less effectively by repeated ECG' s. The yield of 
Holter-ECG monitoring during the frrst 24 hours only is extremely low. 
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Introduction 
Atrial fibrillation (AF), both continuous and paroxysmal (P AF), are a major 
cause of cardiogenic embolism to the brain. 1"3 An accurate identification of AF 
is important since several large studies have demonstrated the superiority of 
warfarin compared to anti-platelet treatment in primary and secondary stroke 
prevention studies.""10 The best way to identify P AF is still uncertain. 
Common practice in the Netherlands, and probably also in other countries, is to 
perform a single 24-h Holter-ECG monitoring in stroke patients with a history 
of cardiac disease, abnormal standard ECG or palpitations or loss of 
consciousness preceding or during the stroke. II It is not known how many 
patients with P AF are missed with this practice. 
The Framingham study and retrospective reviews have found that P AF accounts 
for 14-24% of strokes associated with AF and that the P AF likely precedes the 
event. 12. 15 Studies in consecutive stroke patients have found that ifP AF is not 
detected on the initial ECG, 24-h Holter-ECG recording can identify P AF in 1-
5% ofpatients. 16-22 Schuchert et aL evaluated the additional yield of72-h 
ambulatory ECG monitoring in 82 consecutive stroke patients without a history 
of AF and with sinus rhythm (SR) on initial ECG. Five patients with AF were 
detected, but only I within 24h.23 Another study found that in patients whose 
initial ECG showed normal sinus rhythm (SR) follow-up 12-lead ECG on 2 
successive days detected AF in an additional 9%.24 
We wanted to determine whether ECG-monitoring during 84 hours instead of 
24 hours or repeated ECG' s, 3 in 7 days, increases the likelihood of identifying 
P AF in patients with acute ischemic stroke, in particular in those without a 
history of AF. We used the setting of an acute stroke trial in which the safety of 
administration of diaspirin cross-linked hemoglobin (DCLHb) was studied."' 
DCLHb did not cause any kind of arrhythmia, or other adverse effects on the 
heart (see chapter 6), so the data for the control and treatment groups were 
combined. 
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Subjects and methods 
Patients 
Details regarding the trial are provided elsewhere (see chapter 3). In short, it 
was a single-blind, randomized controlled trial in which the safety and efficacy 
ofDCLHb administered within 18 hours of symptom onset was studied in acute 
ischemic stroke patients. Posterior circulation strokes, congestive heart failure, 
acute myocardial infarction and systolic blood pressure (BP) > 230 mmHg or 
diastolic BP > 130 mmHg were exclusion criteria. All patients received 
standard care and treatment, including prophylactic medication such as 
acetylsalicylic acid and heparin. If patients were already on anti-hypertensive 
therapy, this treatment was continued throughout the study. New anti-
hypertensive therapy was not initiated during the first week unless BP exceeded 
220/135 mmHg for more than an hour. 
Assessments 
For the purpose of this study P AF was defined as one or more episodes of AF 
documented on the 12-lead ECG's or Holter-ECG made during the study period 
or AF discovered after sinus rhythm on the initial ECG. 
Medical history was assessed from patients, referring general practitioners and 
available hospital computerized information. 
Three ECG's were performed in each patient: the first on admission, the second 
on the next day and the third between the 3'd and 7"' day. Holter-ECG 
monitoring was started at study entry and continued for 84 hours. The ECG's 
were assessed by different cardiologists than those who assessed the Ho1ter-
ECG recordings and all were blinded to treatment. 
A general physical examination was performed on admission, and on day 3, 7, 
14. Pulse was checked for irregularity on these occasions. 
Statistics 
For statistical analysis we used SPSS, version 9.0. For comparison between two 
groups Student's unpaired t-test or chi-squared analysis or Fisher's exact test 
were used as appropriate. A p-value < 0.05 was considered to indicate a 
statistically significant difference. 
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Results 
A total of 85 patients were randomized in the study. There were no differences 
in any of the cardiac parameters, in particular history of AF and cardiovascular 
history, between patients treated with DCLHb or in controls (see chapter 6), so 
the data for these 2 treatment groups were combined.25 A total of 21 patients 
had AF. Eleven patients (13%) were already known to have AF, and of the 
remaining 74 patients without a history of AF 10 patients (14%) had newly 
discovered AF. Demographic data and selected cardiovascular risk factors are 
shown in table I. 
Of the 11 patients with a history of AF, 5 had continuous AF, 3 had PAF and 3 
did not show AF during the study. Of the 10 patients with recent AF, it was 
continuous in 5 and firstly recognized on the admission ECG, and paroxysmal 
in the other 5 (see table 2). One patient (with recent AF) had just one single 
episode of P AF lasting one hour, all others had episodes lasting from more than 
7 hours till days. 
Table 1 Characteristics of patients with acute ischemic stroke with recent 
AF, known AF or without AF 
NoAF KnownAF RecentAF 
Number of patients 64 11 10 
Age 63±14 80±6 * 74±5 * t 
Male 31 (48%) 4 (36%) 4 (40%) 
Cortical stroke 40 (63%) 9 (82%) 9 (90%) 
Treatment with DCLHb 28 (42%) 6 (55%) 6 (60%) 
Medical history 
Hypertension 27 (42%) 6 (55%) 5 (50%) 
Myocardial infarction 8 (13%) 0 (0%) 1 (10%) 
Angina pectoris 9 (14%) I (9%) 2 (20%) 
Hypercholesterolemia 2 (3%) 0 (0%) 0 (0%) 
' Stroke 16 (25%) 5 (45%) 4 (40%) 
* p<O.OOI compared to controls 
t p<0.02compared to controls 
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The diagnostic yield of the repeated ECG's and of prolonged Holter-ECG 
monitoring of the patients with P AF was as follows. None of the 8 patients 
with P AF had the arrhythmia on their admission ECG, 5 had AF on the 
subsequent ECG's as well as on 84-h Holter-ECG monitoring, and in 2 patients 
AF was discovered by Holter-ECG-monitoring only (after 72 hours) and not 
seen on ECG's. In 1 patient with recent AF, the arrhythmia was not detected by 
the protocol-specified tests, but by finding an irregular pulse on day 7 and 
subsequent confirmation by an extra ECG. In none of the 7 patients with AF on 
Holter-ECG monitoring P AF appeared within the first 24 hours. These data are 
summarized in table 2. 
Table 2 Yield of the protocol specified ECG's and 84-h Holter-ECG 
monitoring 
KnownAF RecentAF 
Paroxysmal AF 3 5 
On admission ECG 0 0 
Only on repeated ECG's 0 0 
Only on Holter-ECG monitoring I I 
On repeated ECG's 2 3 
On Holter-ECG within 24 h 0 0 
On Holter-ECG between 24-48 h 1 1 
On Holter-ECG between 48-72 h 0 2 
On Holter ECG after 72 h 2 1 
Not detected by protocol specified testing 0 I 
Continuous AF 5 5 
On all ECG's and on Holter-ECG 5 5 
No AF during study period 3 not applicable 
Total number of patients with AF 11 10 
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Discussion 
The objective of this study was to evaluate whether Holter-ECG recording of 84 
hours detects more patients with paroxysmal AF after an acute ischemic stroke 
than Holter-ECG recording only during the first 24 hours or than repeated 
ECG's (3 ECG's during the first 7 days). Of the 8 patients with P AF, 5 did not 
have a history of AF. The 84-h Holter-ECG recording had the highest yield by 
identifying 7 of 8 patients. By means of repeated ECG's 5 of 8 patients were 
identified. The results of ECG monitoring during the first 24 hours only were 
disappointing as none of the patients had their paroxysms of AF within that 
period. 
The results of the single 24-h ECG recording is in agreement with those in 
several other studies: 1 .. 22 the identification of patients with P AF is inadequate, 
and even nil in our study, whereas the yield of the 84-h recordings is much 
better. This confirms the findings of Schuchert et al. who found that during 24-
h recording only 1 of 82 patients showed P AF, whereas 4 more were discovered 
with the longer (72-h) recording.Z3 None of these patients had a history of AF. 
The results of these studies are provided in table 3. Most of these studies also 
included patients with known AF, so the efficacy is even lower. Repeated 
ECG' s proved to be better than 24-h Holter ECG since 3 of 5 patients with 
previously unknown AF were identified. Lindgren and colleagues also 
discovered a substantial number of stroke patients with P AF: 12 of 131 patients 
who's initial ECG showed SR. However, a large proportion of these patients 
had a history of AF.Z4 
It has been suggested tbat when AF is recognized for the first time during the 
acute phase of ischemic stroke, so-called recent AF, the arrhythmia may have 
been the consequence rather than the cause of stroke.Z6 Others have shown, 
however, that in nearly all such patients AF ultimately becomes persistent." 
Whether AF is caused by the stroke or vice-versa was beyond the scope of our 
study. 
In conclusion, recent AF was found in 14% of patients with acute ischemic 
stroke and no history of AF. PAF was effectively discovered by 84-h Holter-
ECG recording and only slightly less effectively by repeated ECG's. The yield 
ofHolter-ECG monitoring during the first 24 hours only was nil. 
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Table 3 Patients with stroke or TIA undergoing Holter-ECG recording and 12-lead ECG* 
Study Patients AF P AF not detected 
(n) (n) on initial ECG (n/%) 
Consecutive stroke or TIA patients, some of whom had a histOIJ' of AF 
Koudstaal 15 100 4 1 (1%} 
Britton16 100 23 2 (2.6%) 
Richardt17 135 161 7 (5.6%)1 
Non·is 18 312 36 15 (5.4%) 
Mikolich19 30 2 I (3.6%) 
Homig20 300 33 10 (3.6%) 
Rem21 184 13 4 (2.3) 
Consecutive stroke patients without a histOI)' of AF and SR 011 initial ECG 
Shucheti22 82 5 5 ( 6.1%) 
* Table adapted from Bell et al (2000}27 
t Arrytlunias, not only AF 
Comments 
2 did not have admission ECG 
Only 87% received Holter testing, 4 
of 10 had a history of AF 
2 did not have admission ECG 
72-hour recording, 4 of 5 discovered 
after 24 hours 
Detection of paroxysmal AF 
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Abstract 
We wished to investigate the apparently high risk of early death after an 
ischemic stroke among patients with atrial fibrillation (AF), identify the main 
factors associated with early death, and to assess the effect of treatment with 
different doses of subcutaneous unfractionated heparin (UFH) given within 48 
hours. 
We studied the occurrence of major clinical events within 14 days among 
18,451 patients from the International Stroke Trial, firstly for all treatment 
groups combined and then, among patients with AF, we examined the effects of 
treatment with subcutaneous unfractionated heparin (UFH) started within 48 
hours and continued till 14 days after stroke onset. 
3,169 (17%) patients were in AF. A total of784 patients were allocated to UFH 
12,500 IU sc bid, 773 to UFH 5,000 IU sc bid, and 1612 to "no heparin". 
Within each of these groups, half of the patients were randomly assigned to 
aspirin 300 mg once daily. Compared with patients without AF, patients with 
AF were more likely to be: female (56% vs. 45%), old (mean 78 vs. 71 yrs), 
have an infarct on the pre-randomization CT (57% vs. 47%), and impaired 
consciousness (37% vs. 21 %). The initial ischemic stroke type was more often 
a large artery infarct (36% vs. 21 %). A lacunar stroke syndrome was less 
common (13% vs. 26%). Death within 14 days was commoner in patients with 
AF (17% vs. 8%) and more often attributed to neurological damage from the 
initial stroke (10% vs. 4%). The frequency of recurrent ischemic or undefmed 
stroke was not significantly different (3.9% vs. 3.3%). The proportion of AF 
patients with further events within 14 days allocated to UFH 12,500 IU 
(n=784), UFH 5,000 IU (n=773) and to "avoid heparin" (n=1612) respectively, 
were: ischemic stroke 2.3%, 3.4%, 4.9% (p=0.001); hemorrhagic stroke 2.8%, 
1.3%, 0.4% (p<0.0001); and any stroke or death 18.8%, 19.4% and 20.7% 
(p=0.3). No effect of heparin on the proportion of patients dead or dependent at 
6 months was apparent. 
Acute ischemic stroke patients with AF have a higher risk of early death, which 
can be explained by older age and larger infarcts, but not by a higher risk of 
early recurrent ischemic stroke, although slightly more patients with AF died 
from a fatal recurrent stroke of ischemic or unknown type (1.3% vs. 0.9%). In 
patients with AF the absolute risk of early recurrent stroke is low, and there is 
no net advantage to treatment with heparin. These data do not support the 
widespread use of intensive heparin regimens in the acute phase of ischemic 
stroke associated with AF. 
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Introduction 
Atrial fibrillation (AF) is found in 6 to 20% of patients with acute stroke.1· 8 The 
reported risk of recurrent stroke varies between 10 and 20% during the first 
year."·13 The risk of very early recurrence has been investigated in several 
studies4-6•10"11.14-17 and varies between 0.1% and 1.3% per day during the first 
two weeks after the initial event.6. 10"14"15 The striking variation between studies 
can be explained partly by differences in study design (some studies were 
retrospective and others prospective), and by differences in the study 
populations (some studies included AF patients with co-existent cardiac 
abnormalities and others only patients with "lone" AF). Several studies have 
reported higher case fatality and morbidity after an ischemic stroke among AF 
patients compared with patients in sinus rhythm.5·6·11 ·18.20 The underlying cause 
of this high case fatality is unclear. Possible factors include a higher frequency 
of large, especially cortical, infarcts, 11"17"19.21 the presence of concomitant 
ischemic heart disease, 15 and a high frequency of early recurrent stroke. 
Analysis of primary prevention studies in patients with AF have shown that oral 
anticoagulant therapy reduces the risk of stroke by 60-70%?2•22 In the European 
Atrial Fibrillation trial (EAFT)13, a secondary prevention study, the relative risk 
reduction with oral anticoagulation was of similar magnitude, but the best time 
to start anticoagulant therapy was not clear. In the EAFT, half of the patients 
were randomized more than two weeks after stroke onset, and effective 
anticoagulation was not obtained within the first weeks, when the risks 
(hemorrhagic transformation of the infarct) and benefits (prevention of recurrent 
ischemic stroke) are probably highest. Only two studies have focused on 
treatment with anticoagulants in the acute phase of stroke, but they showed no 
evidence of benefit of heparin compared with aspirin24 or no antithrombotic ,, 
treatment.-
The data from the International Stroke Tria1,26 a large randomized controlled 
trial of heparin, aspirin, both, or neither in patients with acute ischemic stroke 
provided an opportunity to study these questions further. In the main phase of 
the trial, data on the presence of absence of AF at baseline were recorded, and 
over 3000 patients with this arrhythmia were included. The aim of this paper 
was to compare the early case fatality in patients with AF and those without AF, 
and to examine whether any difference in case fatality was chiefly related to 
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clinical features at baseline, or to the difference in the frequency of recurrent 
stroke in the acute phase. We also wanted to study the effect of different 
heparin doses on the risk of recurrent ischemic stroke and intracranial 
hemorrhage in patients with AF. 
Subjects and Methods 
Patients and treatment 
We studied data available for the 18,451 patients entered during the main phase 
of the International Stroke Trial (IST) between March 1993 and May 1996. (AF 
status at baseline was not recorded in the 984 patients entered during the pilot 
phase.) The IST was a multicenter, multinational randomized open trial which 
aimed to assess the effectiveness of early antithrombotic treatment in patients 
with acute stroke.' Patients with mild, moderate and severe deficits, presenting 
within 48 hours of the onset of suspected acute ischemic stroke were eligible for 
the study, provided that the responsible physician did not initially consider there 
to be any clear indications for, or clear contraindications to, any one of the trial 
treatments (aspirin or heparin). Patients were randomized in a 3 x 2 factorial 
design, i.e. to subcutaneous UFH (5000 IU bid or 12,500 IU bid), aspirin 300 
mg, both, or neither. Coagulation times were monitored at the discretion of the 
treating physician. Treatment was given for 14 days or until prior hospital 
discharge. CT scan to exclude intracranial hemorrhage (ICH) was to be 
performed before randomization where possible, and was mandatory in 
comatose patients. A non-comatose patient could be randomized before CT 
scan only if there was likely to be a long delay in getting the CT scan and the 
physician considered the stroke most likely to be ischemic. For those allocated 
active treatment, the initial doses could be given while CT was being arranged, 
but treatment was stopped if ICH was found. 
Classification 
On the basis of the neurological symptoms at study entry, patients were 
categorized by means of a computer algorithm according to the criteria of 
Bamford et a! into one of the following clinical syndromes: total anterior 
circulation stroke (TACS), partial anterior circulation stroke (P ACS), posterior 
circulation stroke (POCS), lacunar anterior circulation stroke (LACS), or 
other.27 
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Outcome measures 
Protocol-specified primary outcomes were death from any cause within 14 days 
and death or dependency at 6 months. Protocol-specified secondary outcomes 
were: symptomatic intracranial hemorrhage within 14 days (including 
symptomatic hemorrhagic transformation of the original infarct) as confirmed 
by CT, magnetic resonance imaging or necropsy; ischemic stroke (including 
any recurrent stroke of ischemic or unknown type), major extracranial 
hemorrhage, and other major clinical event such as pulmonary embolism within 
14 days. There were no specific criteria to define a recurrent ischemic stroke, 
so that the decision on whether or not recurrent stroke had occurred was left to 
the judgment of the responsible physician. 
Analysis and statistical methods 
The protocol specified two main analyses for the primary outcomes, namely 
"inunediate heparin" (low or medium dose) vs. "avoid heparin" and "inunediate 
aspirin" vs. "avoid aspirin". In these analyses we have also compared medium 
vs. low dose heparin vs. "avoid heparin". In the factorial design, half of the 
heparin and control patients were allocated aspirin, and since there was no 
interaction between aspirin and heparin, 26 we combined the aspirin and no 
aspirin groups for the purpose of these analyses. All analyses were "intention-
to-treat" and thus patients were included in the analysis in the group to which 
they were allocated, irrespective of their compliance with trial treatment. 
Analysis of total numbers of patients affected was done by chi-square tests and 
chi -square tests for trend. 
Results 
At study entry, a total of3,169 (17%) patients were in AF and 15,282 were not 
in AF. The mean delay between the stroke and randomization was 18.7 hours 
in patients with AF, versus 20.4 hours in those without (difference in means 1.7 
hours, 95% CI 1.2 to 2.2). 
Compliance with the allocated treatment was good; only 6% of patients with AF 
and 8% of patients without AF received heparin despite being allocated to the 
"avoid heparin" group. Compliance with aspirin allocation was equally good 
across all treatment groups. 
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Table 1 Baseline characteristics in stroke patients with and without atrial fibrillation (AF), 
recorded at the time of randomization 
AF NoAF OR(95% Cl)* 
Number of patients 3169 15282 
Age (mean, years) 77.8 70.6 7.2 (6.9-7.6) t 
Female sex 1779 (56%) 6823 (45%) 1.6 (1.5-1.7) 
Symptoms noticed on waking 854 (27%) 4552 (30%) 0.9 (0.8-1.0) 
Impaired consciousness 1166 (37%) 3039 (21 %) 2.4 (2.2-2.6) 
Subtype of stroke 
TACS 1155 (36%) 3252 (21%) 2.1 (2.0-2.3) 
PACS 1310 (41%) 6166 (40%) 1.0 (1.0-1.1) 
LACS 409 (13%) 4014 (26%) 0.4 (0.4-0.5) 
POCS 289 (9%) 1809 (12%) 0.8 (0.7-0.9) 
Other 6 (0.2%) 41 (0.3%) 0.7 (0.3-1.7) 
Had pre-randomization CT scan 1968 (62%) 10434 (68%) 0.8 (0.7-0.8) 
Infarct on pre-randomization CT scan 1 1127 (57%) 4915 (47%) 1.5 (1.4-1.7) 
* Odds ratio (OR) and 95% confidence interval (CI). An OR greater than one indicates that the 
characteristic is more conm10n in patients with AF; If the 95% CI does not include unity, the result is 
significant at the 5% level or greater 
t This is the difference between the two means with 95% confidence intervals, not an odds ratio 
t Among those who had a pre-randomization CT-scan 
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Table 1 Baseline characteristics in stroke patients with and without atrial fibrillation (AF), recorded 
at the time of randomization, continued 
AF NoAF OR(95% Cl)* 
Final diagnosis of initial event 
leading to randomization 
L~chemic stroke 2865(90%) 13813 (90%) 1.0 (0.9-l.l) 
Hemorrhagic stroke 79(2%) 490 (3%) 0.8 (0.6-1.0) 
Stroke of unknown type 172(5%) 592 (4%) 1.4 ( 1.2-1. 7) 
Not a stroke/unknown 53(2%) 387 (3%) 0.7 (0.5-0.9) 
j: Among those who had a pre-randomization CT scan 
Table 1 summarizes the principal baseline characteristics of the patients. Compared to patients without AF, 
patients with AF were more likely to: be female (56% vs. 45%), old (mean age 78 years vs. 71 years), and have 
impaired consciousness (37% vs. 21%). The initial stroke was more often a large infarct with the clinical deficits 
suggesting involvement of the entire tetTitory of the middle cerebral artery (TACS) (36% vs. 21%). Lacunar stroke 
was less common among patients with AF (13% vs. 26%). Correspondingly, infarction on the pre-randomization 
CT scan in was more often seen in patients with AF (57% vs. 47%). Since the study design petmitted 
randomization while CT was being arranged, inevitably, in a few patients, it was discovered that the event leading 
to randomization was a hemorrhagic stroke (AF 2%, not AF 3%). Treatment was stopped after the CT scan in such 
cases. 
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The risk of recunent ischemic stroke within 14 days was low and not significantly altered by the presence or 
absence of AF (Table 2): 123 (3.9%) and 500 (3.3 %) in patients with and without AF, respectively. Symptomatic 
intracranial hemmThage within 14 days occuned significantly more often in AF patients: 39 (1.2%) vs. 109 (0.7%). 
A total of 534 (17%) AF patients died within 14 days compared with 1149 (8%) patients without AF (OR 2.5, 95% 
CI 2.2 to 2.8). Table 3 shows that AF patients were more likely to die from neurological damage from the initial 
stroke or from pneumonia, coronary heart disease or pulmonary embolism, and fiom early recurrent stroke. 
Table 2 Events within 14 days in patients with and without atrial fibrillation (AF), all treatment groups combined 
AF NoAF OR(95% CI)* 
Number of patients 3169 15282 
Fatal or non-fatal recUITent ischemic stroke 123 (3.9%) 500 (3.3%) 1.2 (1.0-1.5) 
Fatal or non-fatal symptomatic intracranial 39 (1.2%) 109 (0.7%) 1.7 (1.2-2.5) hemonhage 
Fatal or non-fatal recutTent ischemic stroke or 161 (5.1%) 603 (4.0%) 1.3 ( 1.1-1.6) 
symptomatic intracranial hemonhage 
Fatal or non-fatal recunent ischemic stroke or 630 (19,9%) 1548 (10.1 %) 2.2 (2.0-2.4) 
symptomatic intracranial hemonhage or death 
Death from any cause 534 (16.9%) 1149 (7.5%) 2.5 (2.2-2.8) 
* Odds ratio (OR) and 95% confidence interval (CI) 
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Table 3 Causes of death within 14 days in stroke patients with and without atrial fibtillation (AF), all treatment 
groups combined 
AF NoAF OR(95% Cl)* 
Number of patients 3169 15282 
Neurological damage 11-om initial stroke 305 (9.6%) 557 (3.6%) 2.9 (2.5-3.4) 
Recunent stroke, ischemic or unknown 42 (1.3%) 131 (0.9%) 1.7 (1.2-2.4) 
Recunent stroke, hemorrhagic 6 (0.2%) 32 (0.2%) 1.0 (0.4-2.4) 
Pneumonia 85 (2.7%) 180 (1.2%) 2.5 (2.0-3.3) 
Coronary heati disease 44 (1.4%) 92 (0.6%) 2.6 (1.8-3.7) 
Pulmonmy embolism 21 ( 0.7%) 50 (0.3%) 2.3 (1.4-3.8) 
Other vascular or unknown 26 (0.8%) 84 (0.5%) 1.7 (l.l-2.6) 
Non vascular 5 (0.2%) 23 (0.2%) 1.2 (0.4-3.1) 
Total 534 (16.9%) 1149 (7.5%) 
*Odds ratio (OR) and 95% confidence interval (CI), using those 'not dying' as a comparator 
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Table 4 Effect of heparin in different doses on events within 14 days and outcome at six months in patients with atrial 
fibrillation (AF)* 
Heparin Heparin No heparin P-value P-value 12,500 IU 5,000 IU overall X2 x2 trend 
Number randomized 784 773 1612 
Events within 14 days 
Recurrent stroke of ischemic 18 (2.3%) 26 (3.4%) 79 (4.9%) 0.006 0.001 
or unknown type 
Symptomatic ICH 22 (2.8%) 10 (1.3%) 7 (0.4%) <0.0001 <0.0001 
RecmTent stroke or 39 (5.0%) 36 (4.7%) 86 (5.3%) 0.8 0.6 
symptomatic ICH 
Recun·ent stroke, symptomatic 147 (18.8%) !50 (19.4%) 333 (20.7%) 0.5 0.3 
ICH, or death 
Outcome at six months 
Dead ji-om any cause 305 (38.9%) 292 (37.8%) 630 (39.1%) 0.8 0.8 
Dead or dependent 612 (78.1 %) 609 (78.8%) 1266 (78.5%) 0.9 0.8 
ICH= intracranial hemorrhage 
*Within each of these groups, half of the patients were randomly assigned to aspirin 300 mg once daily 
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The frequency of various events, subdivided by heparin allocation, are shown in 
table 4. The three treatment groups were comparable with respect to baseline 
characteristics (data not shown) and, within each group, half of the patients 
were randomly allocated to aspirin. However, there was no evidence of an 
interaction effect between aspirin and heparin, and patients receiving aspirin are 
therefore not excluded from the analysis. The proportion of AF patients with 
fatal or non-fatal events within 14 days allocated to UFHI2,500 IU, 5,000 IU 
and to "avoid heparin", respectively, were: stroke of ischemic or unknown type 
2.3%, 3.4%, 4.9% (p=O.OOl); symptomatic intracranial hemorrhage 2.8%, 1.3%, 
0.4% (p<O.OOl); and any recurrent stroke or death 18.8%, 19.4%, and 20.7% 
(p=0.3). So, despite a clear and dose-dependent reduction in ischemic strokes 
among patients allocated heparin, this advantage was offset by a similar sized 
increase in hemorrhagic strokes in the heparin allocated groups. Consequently, 
there was no net difference in death or the event "death or dependency six 
months after the stroke". 
A small proportion (3%) of patients included (among those first scanned after 
randomization) turned out to have an intracranial hemorrhage. We therefore 
repeated the analysis restricted to patients known to have non-hemorrhagic 
stroke. The results of this analysis were remarkably similar to those in table 4. 
Discussion 
These data from the International Stroke Trial confmn the fmdings from other 
studies that patients with AF have a case fatality that is about twice as high as 
the case fatality in patients without AF (17% versus 8% after two weeks). In 
IST, patients with AF were, compared with those not in AF, on average older, 
had more co-morbidity and more severe strokes, and these factors are likely to 
have contributed to the higher case fatality in AF. On the other hand, recurrent 
stroke (ischemic/unknown or hemorrhagic) occurred equally often in patients 
with and without AF, and although slightly more patients with AF died from a 
fatal recurrent stroke of ischemic or unknown type, early recurrences could not 
explain the worse outcome in patients with AF. The most common cause of 
early death in patients with AF was neurological damage from the initial stroke, 
as might be anticipated, since they had more severe strokes, with a 
predominantly corticallocalization.11•17•19·21 •28 
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Absolute risk of early recurrent stroke in AF 
The overall risk of early recurrent stroke of ischemic or unknown type in 
patients with AF was lower than reported in earlier studies, and not significantly 
different from the group without AF, which is in agreement with some previous 
studies, 3-5.1 6•17·24 but disagrees with several others. 6·10•11.14 One explanation for 
the different estimates might be different selection of patients. However, about 
one sixth of the patients in IST were in AF, which is very similar to that found 
in community-based incidence studies of stroke. This suggests that our patients 
are likely to be reasonably representative of patients with acute ischemic stroke 
and AF, so factors related to patient selection may not be the explanation. Other 
explanations for the low estimate of the incidence of recurrent ischemic stroke 
among AF patients could be methodological: recurrent stroke was not a primary 
measure of outcome in the trial; the trial did not apply a rigid definition of 
recurrent ischemic stroke, but relied on the clinical judgment of local 
investigators. The effect of this may have been to count only severe recurrent 
strokes and hence we may have under-ascertained mild recurrent strokes. The 
high early case fatality (about 30%) after recurrent stroke tends to confirm the 
hypothesis that only severe recurrences were reported. Furthermore, since 
patients could be randomized up until 48 hours after onset of symptoms, some 
very early recurrences may have been missed. 
Effect of different heparin doses on risk of recurrence 
We found that, although the higher heparin dose was associated with the fewest 
recurrent ischemic strokes, the clear dose-related trend to benefit was offset by a 
significant and dose-dependent increase in the risk of hemorrhagic stroke. 
These trends were also seen after exclusion of the small number of patients with 
intracranial hemorrhage at randomization (who were first scanned after 
randomization), and there was no evidence of benefit from heparin on death or 
disability at six months. 
Part of the apparent effects of heparin on recurrent ischemic stroke and 
symptomatic hemorrhage could be due to an observer bias. Since the trial was 
open, there may have been systematic bias operating against heparin by an 
increased attention to bleeding in patients allocated heparin, especially the 
higher dose. However, this does not apply to outcome at 6 months, as this was 
effectively blinded. Also, the short-term effects of heparin were similar to those 
in other placebo-controlled trials, such as the TOAST study, a placebo-
controlled trial of intravenous heparinoid in acute ischemic stroke, in which the 
subgroup of patients with cardioembolic stroke also showed no evidence of 
benefit from anticoagulation.29 
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Implications for practice 
What then are the consequences of these analyses for the trea1ment of patients 
with AF in the acute phase of ischemic stroke? Firstly, the risk of major 
recurrent stroke is lower than many clinicians fear. Secondly, the risk of 
bleeding complications with the higher heparin dose is a cone=. A recent 
combined analysis of the 40,000 randomized patients in the IST and Chinese 
acute stroke trial (CAST) showed that trea1ment with aspirin reduces the risk of 
recurrent ischemic stroke within 14 days by 30%, and the effect is similar in the 
presence or absence of AF.30 For many patients presenting with acute ischemic 
stroke and atrial fibrillation, aspirin offers a safe and effective option for 
preventing early recurrent stroke in the frrst week or two after stroke onset. For 
patients who remain in AF and have no contraindications, oral anticoagulation 
with target INR 2.0-3.0 is likely to be the most effective secondary prevention. 13 
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General discussion 
Chapter 10 
The findings of this thesis 
Two strategies for treatment of acute ischemic stroke were explored in this 
thesis: 
1. The safety and efficacy of diaspirin cross-linked hemoglobin (DCLHb) 
2. The safety and efficacy of heparin in patients with atrial fibrillation 
(AF) 
The following are the main findings: 
• DCLHb was neither safe nor efficacious for the treatment of acute stroke. 
More serious adverse events and deaths occurred in DCLHb-treated 
patients than in controls, and outcome scale scores were worse. 
• DCLHb prevented the decrease in blood pressure (BP) that normally 
occurs in the first days after stroke. Although clinical outcome was worse 
in patients treated with DCLHb, this was not caused through adverse effect 
on the heart and the pressor effect by itself was well tolerated. 
• Infusion of DCLHb was associated with a dose-dependent increase in 
plasma ET -1 concentration, which was correlated with the rise in blood 
pressure. We suggest that the pressor effect was caused, at least in part, by 
ET-1. 
• Acute ischemic stroke patients with AF have a higher risk of early death, 
which can be explained by older age and larger infarcts, but not by a higher 
risk of early recurrent ischemic stroke, although slightly more patients with 
AF died from a fatal recurrent stroke. 
• Paroxysmal AF was commonly found in patients with acute ischemic 
stroke and was effectively discovered by 84-h Holter-ECG recording and 
slightly less effectively by repeated ECG' s. The result of a single Holter-
ECG during the first 24 hours was nil. 
• In patients with AF the absolute risk of early recurrent stroke is low, and 
there is no net advantage to treatment with heparin in the acute phase. 
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Treatment of acute ischemic stroke with DCLHb 
In our phase II study, treatinent with DCLHb was an independent predictor of 
worse outcome. Our study showed no obvious reason for the failure of this 
drug. The pressor effect of DCLHb on itself was well tolerated. None of the 
patients showed signs of hypertensive encephalopathy or hemorrhagic 
transformation of the infarct. Neither did DCLHb cause myocardial ischemia or 
congestive heart failure. Two patients had an adverse event, which was 
possibly drug-related: one of fatal brain and pulmonary edema, the other of 
transient renal and pancreatic insufficiency. Levels of endothelin-1 (ET-1, a 
potent vasoconstrictor) were dose-dependently increased in response to DCLHb 
and correlated with increments in blood pressure (BP). 
At the time we were evaluating DCLHb as a neuroprotective agent in stroke, it 
was also tested as a resuscitative fluid in patients with traumatic hemorrhagic 
shock in an American multicenter, phase III, randomized, controlled, single-
blinded efficacy trial.' At 28 days, 24 of the 52 (46%) patients infused with 
DCLHb died, versus 8 of the 46 (17%) patients infused with saline (p = .003). 
The 28-day morbidity rate, as measured by the multiple organ dysfunction 
score, was 72% higher in the DCLHb group (p = .03). Why DCLHb adversely 
affected outcome was not clear. When these results became known, the 
European trauma trial, which by then had enrolled 117 patients, was suspended 
and these results have not been published. Soon hereafter, the manufacturer, 
Baxter Healthcare Corporation, announced that it had decided to focus its 
research-and-development efforts in oxygen-carrying therapeutics, on 
genetically engineered hemoglobin molecules. This decision ended the 
company's clinical development ofDCLHb. 
Unfortunately, there is no obvious reason for the failure of DCLHb. In 
experimental studies addressing infarct size, animals were given various doses 
of DCLHb to achieve hemodilution up to 9%. After this treatinent, temporary 
ligation of the middle cerebral artery resulted in a smaller infarct size2·3 and 
increased cerebral blood flow4 compared with animals receiving albumin. The 
beneficial effects were most profound when DCLHb was given in a manner that 
induced its hypertensive response.' Further studies showed that the mechanism 
of infarct reduction might be through scavenging of NO in brain tissue.' 
However, the relevance of these pre-clinical models to clinical efficacy can be 
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questioned. Apart from the obvious dissimilarities between man and rat, 
efficacy was judged by reduced infarct size in animal studies as opposed to 
reduced death and dependency/disability in human stroke trials. Also the 
timing and dosing schedule was quite different. In most animal experiments, a 
highly favorable response was found after a single high dose exchange 
transfusion, either before or within one hour after initiation of ischemia. 2•3 After 
our study had fmished, such high doses were found to be safe in patients 
undergoing coronary by-pass surgery.7 Another problem may have been failure 
of the drug to reach the ischemic area because of arterial occlusion. The 
cerebral artery occlusion was temporary in most animal stroke models, 2•3•5 but 
this is not necessarily the case in humans. 
The effect on BP, although seemingly beneficial in animal stroke studies, may 
have contributed to study failure. Elevation of BP is not necessarily bad. 
However, it is only useful if it is accompanied by increased blood flow. For 
example, tissue perfusion can be improved by chronotropic or inotropic agents. 
Contrary to this mechanism, agents that elevate BP by peripheral 
vasoconstriction do so at the expense of raising peripheral resistance, so that 
capillary blood flow may decrease. The additional oxygen-carrying capacity 
provided by administering the hemoglobin solution could then be completely 
offset by the increased resistance to flow. 
Many studies were carried out to determine which of the abovementioned 
mechanisms to raise BP predominated. Invariably, the increase in BP was not a 
result of volume changes, but a direct pharmacological effect.'·" Using 
microspheres to estimate regional blood flow in anesthetized rats, infusion of 
DCLHb caused an increase in MAP, cardiac output, stroke volume and 
peripheral resistance, while blood flow to the heart, gastrointestinal tract, 
mesentery, pancreas and skin increased, apparently at the expense of increased 
resistance and lower flow to the musculoskeletal system and liver. Blood flow 
to the brain was not affected. 12"14 In hemorrhaged rats, resuscitation 
experiments showed that when the volume of DCLHb was 50% of the volume 
of shed blood, perfusion to vital organs such as the heart and brain exceeded 
pre-hemorrhage levels. 15•16 In a swine model of non-lethal hemorrhagic shock, 
infusion of DCLHb caused dose-dependent increase of cardiac output and 
improved base excess and lactate concentrations, two indices of global 
perfusion, more rapidly and to a greater extent than Ringer's Lactate.17 In brief, 
DCLHb elevated pressure as well as cardiac output and tissue perfusion. 
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In the phase I study, a single infusion of DCLHb (25, 50, or 100 mg!kg) in 
healthy volunteers was safe and weii tolerated. 18 A dose-related increase in 
blood pressure occurred without evidence of decreased peripheral perfusion as 
measured by laser Doppler flowmetry, pulse oximetry, or toe temperature. 
DCLHb was tested as a hemoglobin substitute in several phase II and III trials. 
34 patients undergoing elective repair of an abdominal aortic received DCLHb: 
50, 100 and 200 mg kg/kg i.v. DCLHb produced an increase in MAP of 
approximately 25%, with smaii decreases in cardiac index and calculated 
oxygen delivery.19 The effects on oxygen consumption were minimal. In 
another phase II randomized, placebo-controiied, single-blind, cross-over trial, a 
30-minute infusion of25, 50, or 100 mg!kg DCLHb or placebo was evaluated in 
18 subjects receiving chronic hemodialytic therapy." The maximum increase in 
systolic blood pressure from baseline increased significantly with DCLHb dose 
compared with placebo. There were no adverse events. In a phase II, 
prospective, observational study 14 criticaiiy ill patients requiring vasopressor 
therapy to maintain MAP were administered 100 ml boluses of 10% diaspirin 
cross-linked hemoglobin, up to a maximum of 500 ml. Reduction in 
norepinephrine requirements was used as the main end point to assess the 
efficacy of DCLHb as a vasopressor. Again DCLHb demonstrated a marked 
vasopressor action, aiiowing norepinephrine requirements to be reduced. Heart 
rate, central venous pressure, mean pulmonary arterial pressure, systemic 
vascular resistance index, and urine output did not demonstrate any significant 
changes from preinfusion values. However, pulmonary vascular resistance 
index increased and cardiac index and oxygen delivery index decreased 
significantly.21 In a phase III randomized, controiied trial DCLHb was tested as 
an alternative to blood transfusion after cardiac bypass surgery.7 209 were 
determined to require a blood transfusion and were randomized to receive up to 
three 250-ml infusions of DCLHb (n = 104) or three units of packed 
erythrocytes (n = I 05). Primary efficacy end points were the avoidance of 
blood transfusion through hospital discharge. Administration of DCLHb 
aiiowed a significant number (19%) of cardiac surgery patients to avoid 
exposure to erythrocytes postoperatively. Mortality was similar between the 
DCLHb (6 of 104 patients) and the control (8 of 105 patients) groups. The 
hemodynamic effects of DCLHb included slightly greater increase in systemic 
and pulmonary vascular resistance with associated increases in systemic and 
pulmonary arterial pressures compared with packed red blood ceiis. Cardiac 
output values decreased more in the DCLHb group patients. To summarize, 
DCLHb produced an increase in MAP. Contrary to most animal studies, this 
was however, generaiiy accompanied by decreased cardiac index and calculated 
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oxygen delivery, 19'21 and increased systemic and pulmonary vascular 
resistance,7 but this did not appear to affect the patients' clinical condition. 
Acute ischemic stroke and hemorrhagic shock patients are in dire need of 
oxygen, either locally or systemically. As there was no specific adverse effect 
that appeared to cause damage and considering the information we now have on 
the vasoconstrictor effects of DCLHb it is tempting to hypothesize that both 
populations were adversely affected by vasoconstriction and subsequent lack of 
oxygen. 
In our population, DCLHb caused a rise in BP that was accompanied by a 
decrease in heart rate and increase in ET-1. This would suggest that the pressor 
effect is not caused by a positive chronotropic effect on the heart, but possibly 
through vasoconstriction by ET -1. Since this was a study testing the 
pharmacological effects of DCLHb in stroke patients, we could not administer 
ET-1 antagonists to prove that the pressor effect is caused by ET-1. The 
circumstantial evidence from many other studies, however, is compelling. 15·22.25 
The increased ET-1 levels may have contributed to the ischemic damage 
through the potent vasoconstrictor effect of ET-1.26 On the other hand, there is 
also evidence that a systemic increase in endothelin causes a vasodilator effect 
in the brain?7 The NO binding effect of DCLHb could also have caused 
vasoconstriction in the cerebral vessels. Inhibition of NO has been shown to 
cause vasoconstriction and decreased blood flow in the middle cerebral artery .28 
Suggestion for fUture research 
The hemodynamic response caused by DCLHb increases vascular resistance, 
and probably eliminates its potential as a neuroprotective agent in acute 
ischemic stroke. Newer, possibly genetically engineered, hemoglobin solutions 
that overcome this limitation should fare better in clinical development. 
Treatment of acute ischemic stroke in the presence of AF 
with heparin 
The International Stroke Trial (IST) showed no benefit of treatment with 
subcutaneous unfractionated heparin (UFH, 12.500 or 5000 IU twice daily) on 
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death or dependency at 6 months nor on the other primary outcome measure of 
death within 14 days.Z9 Patients allocated to heparin had significantly fewer 
recurrent ischemic strokes within 14 days but this was offset by a similar-sized 
increase in hemorrhagic strokes. It is generally assumed that the overall results 
of a clinical trial are applicable to all patients in the trial, or in other words, that 
the relative treatment effect in individual patients is similar to the overall trial 
result. We aimed to investigate whether this was true for the subset of 3169 
patients with atrial fibrillation (AF) randomized in IST. 
Methodological issues concerning subgroup analyses 
Caution is required when performing subgroup analysis, but in this case there 
were sound clinical arguments to consider the subgroup of patients with AF 
more closely. Five primary prevention studies in patients with AF3a-34 and one 
on secondary prevention35 showed that the long-term benefit of anticoagulants 
for secondary prevention of stroke greatly outweighs that of aspirin.35 The 
European Atrial Fibrillation trial (EAFT), however, did not provide information 
on risk/benefit ratio of anticoagulation in the early period after onset of 
symptoms. There has been only one trial that focused on treatment with 
anticoagulants in the acute phase of ischemic stroke associated with AF.36 A 
total of 449 patients were randomized. The authors concluded that while the 
data could not provide any evidence that dalteparin is superior to aspirin, the 
study could not exclude the possibility of smaller, but still worthwhile effects of 
either of the trial drugs. The trial was also not large enough to reliably estimate 
a significant increase in cerebral hemorrhage on dalteparin. Our IST subgroup 
represents by far the largest group of acute ischemic stroke patients with AF 
treated with anticoagulants. The variable AF was recorded at baseline. 
Clinicians might have excluded some patients with AF from randomization, 
because they believed them to require anticoagulation. However, about one 
sixth of the patients in IST were in AF, which is very similar to that found in 
community-based incidence studies of stroke. This suggests that our patients 
are likely to be reasonably representative of patients with acute ischemic stroke 
andAF. 
The effect of heparin on recurrent stroke in patients with AF or SR during the 
first 14 days 
Among stroke patients with AF, heparin during the first 14 days stroke reduced 
the absolute risk for recurrent stroke by 2.1% (medium-dose heparin: 2.6%; 
low-dose heparin: 1.5% vs. aspirin: 1.2% ). Heparin increased the risk of 
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hemorrhagic stroke by 1.6% (2.4% in the medium-dose heparin:2.4%; low-dose 
heparin 0.7%) vs. 0.3% by aspirin. Among patients in sinus rhythm (SR) the 
absolute risk reduction was only 0.7% (without dose-dependency) and the 
increase in symptomatic ICH was also 0.7% and higher in the medium-dose 
(1.4%) than the low-dose regimen (0.3%). Aspirin prevented 1.1% more 
ischemic strokes at the cost of only 0.1% more intracranial bleeds than 
treatment without aspirin. To summarize, there was no net advantage of heparin 
among patients with AF, because the higher benefit on recurrent ischemic stroke 
was counterbalanced by an increase in intracranial hemorrhages. The low-dose 
heparin regimen had a better risk/benefit ratio than the medium-dose regimen. 
Comparison with other studies 
In EAFT, the secondary prevention trial, treatment with anticoagulants reduced 
the risk of recurrent stroke from 12%/year to 4%/year, while none of the patients 
on anticoagulant treatment suffered an intracranial bleed.35 The striking 
difference in the incidence of intracerebral hemorrhage may be explained by the 
timing of the treatment and the size of the infarcts. In EAFT, patients were 
recruited in the first 3 months after stroke and not many were randomized 
within the first 14 days, when the risk of intracerebral hemorrhage is the 
highest. The larger size of the infarcts in IST could also very well have 
contributed to the high number of bleedings. In EAFT, only TIA' s and minor 
disabling infarcts were randomized. Treatment was unblinded in both trials, but 
coagulation times were monitored in EAFT, which could also have contributed 
to the very low risk of bleeding. 
In HAEST, the only acute stroke trial concentrating on patients with AF, 
double-blind treatment with low-molecular-weight heparin (LMWH, dalteparin 
100 IU/kg s.c. twice daily) was tested against aspirin in 449 patients." 
Coagulation times were not monitored. The primary measure of outcome, the 
frequency of recurrent ischemic stroke during the first 14 days, was 8.5% 
(19/224) in dalteparin-allocated patients vs. 7.5% (17/225) in aspirin-allocated 
patients. There was no increased risk of symptomatic cerebral hemorrhage 
(6/224 vs. 4/225) or symptomatic and asymptomatic cerebral hemorrhage 
(26/224 vs. 32/225). Neither did dalteparin have an effect on progression of 
symptoms within the first 48 hours. 
The 14 day event rate of ischemic stroke was much higher in HAEST than in 
IST: 7.5% vs. 3.3%. Again, patient selection in IST may have played a role. 
Clinicians may not have randomized patients, whom· they believed to have a 
154 
General discussion 
high risk of stroke recurrence or a clear indication for anticoagulation. Other 
explanations for the low estimate of the incidence of recurrent ischemic stroke 
could be methodological: in IST recurrent stroke was not a primary measure of 
outcome in the trial; the trial did not apply a rigid defmition of recurrent 
ischemic stroke, but relied on the clinical judgment of local investigators, and 
patients were not rigidly monitored which may have led to underreporting of 
mild recurrent strokes. The high early case fatality (about 30%) after recurrent 
stroke tends to confirm the hypothesis that only severe recurrences were 
reported. Furthermore, since patients could be randomized up until 48 hours 
after onset of symptoms vs. 30 hours in HAEST, some very early recurrences 
may have been missed. 
Although the net result of HAEST was the same as in our subgroup of AF 
patients, dalteparin did not seem to have a stronger effect on the prevention of 
ischemic strokes or the occurrence of intracranial hemorrhage as compared to 
aspirin. There are several factors that could have contributed to this difference. 
Firstly, very severe (thus large) strokes were excluded from HAEST, which 
could have lessened the risk of bleeding. Furthermore, the specific types of 
heparin used (LMWH vs. UFH) may have influenced the bleeding risk. Indeed, 
several trials in other areas of vascular medicine have shown that LMWH is 
superior to UFH in their risk/benefit ratio, in that it is associated with lower risk 
of hemorrhage and more powerful antithrombotic effects than standard 
unfractionated heparin (UHF)."·" Nevertheless, this has not been definitely 
confirmed in several medium-sized stroke studies!0-42 Finally, the unblinded 
nature of treatment in IST raises the question of a systematic bias against 
heparin, namely, an increased attention to bleeding when patients were on 
heparin. 
Conclusions 
In the 3169 patients with AF from IST, the medium-dose heparin regimen was 
clearly more effective in preventing early recurrent stroke than the low-dose 
heparin regimen or than aspirin, but it was also the most hazardous, considering 
the steep increase in intracerebral hemorrhage. UFH (12.500IU) can produce a 
highly variable anticoagulant response, both inter- and intraindividual!y!' 
Compared with UFH, LMWH's produce a more predictable anticoagulant 
response such that they can be given subcutaneously once or twice daily without 
monitoring.44 However, both UFH and LMWH 36 have not been found to be 
useful in improving outcome in AF patients with (major) ischemic stroke. 
Further trials with anticoagulation are not warranted in this group of patients. 
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AF patients with a TIA or rapidly resolving minor ischemic stroke should be 
treated with anticoagulants innnediately after the event on the basis of the 
EAFT results. 35 
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Stroke is a major cause of death and an important cause of hospital admission 
and long-term disability in Western countries. The only known effective 
treatment, thrombolysis with recombinant tissue plasminogen activator, can be 
applied to only a small percentage of patients. 
In this thesis, two types of treatment for acute ischemic stroke, both studied in 
randomized controlled trials, are described. Firstly, we evaluated the safety, 
efficacy and pharmacodynamics of the use of a hemoglobin solution, diaspirin 
cross-linked hemoglobin (DCLHb, HemAssist®) in patients with acute 
ischemic stroke. Secondly, we studied the effect of heparin in patients with 
acute ischemic stroke in combination with atrial fibrillation (AF) entered in a 
large clinical study, the International Stroke Trial (IST). We had specific 
interest in the prevention of early stroke recurrence. 
Chapter 1 is the introduction to this thesis and describes the contents of the 
other chapters. 
Chapter 2 describes the rationale for using DCLHb and heparin in the 
treatment of acute stroke. 
DCLHb is a purified cell-free human hemoglobin solution, and was originally 
developed as a blood substitute. After DCLHb was discovered to enhance 
oxygen delivery while increasing blood pressure and organ perfusion, animal 
stroke studies were undertaken and showed favorable results. This eventually 
led to the start of our safety study: DCLHb in Acute Ischemic Stroke (DIAS). 
The pressor response observed after infusion of DCLHb is not a unique 
property of DCLHb, but rather a general property of hemoglobin solutions. 
Several studies performed to elucidate the mechanism of the pressor effect of 
DCLHb are described. The main conclusions are that DCLHb primarily 
interacts with the peripheral vascular autoregulatory system, rather than the 
central nervous system. DCLHb has been shown to interact with nitric oxide 
NO and to induce contraction of vascular smooth muscle cells. Studies in rats 
have shown that infusion of DCLHb leads to an increase of ET -I levels along 
with an increase in BP. This pressor effect was significantly attenuated by 
pretreatment with a ET -receptor antagonist, thus providing evidence for the 
hypothesis that the pressor effect is mediated, at least in part, through the 
increase ofET-llevels. 
Heparin is regularly administered to stroke patients, regardless of the lack of 
convincing evidence of safety or efficacy. Heparin is given to promote early 
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clot lysis and to prevent thromboembolic events such as early stroke recurrence. 
Since the recurrence rate is presumed by some to be even larger in patients with 
atrial fibrillation (AF), clinicians are even more inclined to treatment with 
heparin in ischemic stroke in the presence of AF. In this part of chapter 2 the 
evidence on the safety and efficacy of heparin in acute stroke is reviewed, and 
the conclusion is that there is only one group of stroke patients in which the 
beneficial effects of heparin are uncontroversial. In the EAFT patients with 
non-rheumatic AF and recent TIA or minor stroke, anticoagulant treatment 
reduces the risk of recurrent stroke by two thirds. However, the EAFT does not 
provide information on the balance between the risk and benefit of 
anticoagulant therapy in the early period after onset of symptoms. 
To our knowledge there has been only one study that focused solely on 
treatment with anticoagulants in the acute phase of an ischemic stroke in the 
presence of AF. In the HAEST study Berge et a! investigated whether 
treatment with low-molecular weight heparin (LMWH) is superior to aspirin for 
the prevention of recurrent stroke during the frrst 14 days in patients with AF. 
Treatment was started within 30 hours of stroke onset. The authors concluded 
that while the data could not provide any evidence that LMWH is superior to 
aspirin in this setting, the study could not exclude the possibility of smaller, but 
still worthwhile effects of either of the trial drugs. The trial was also not large 
enough to reliably estimate a significant increase in cerebral hemorrhage on 
dalteparin. 
Since 3169 patients with AF were randomized in the IST, we decided to study 
this subgroup in more detail. Even though this is a subgroup analysis, we 
considered it worthwhile still since many questions regarding AF in association 
with acute ischemic stroke are unanswered. 
Chapter 3 describes the design, conduct and main results of the DIAS trial. 
This was a multi-center, randomized, single-blind, controlled, dose-fmding, 
safety trial consisting of3 parts. Twelve doses of25, 50 and lOOmg/kg DCLHb 
or equal volumes normal saline were administered over 72 hours to 85 patients 
with acute ischemic stroke in the anterior circulation, within 18 hours of 
symptom onset. The primary objective of this study was to evaluate the safety 
of DCLHb in patients with acute ischemic stroke. DCLHb caused a rapid rise 
in mean arterial blood pressure. The pressor effect was not accompanied by 
complications. Dose-dependent increases of lactate dehydrogenase (LDH), 
creatine kinase (CK), bilirubin and aspartate aminotransferase (AST) were 
found. These laboratory abnormalities were clinically asymptomatic and 
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disappeared within a week. Two patients, in the 100 mg!kg group, had an 
adverse event which was possibly drug-related: one of fatal brain and 
pulmonary edema, the other of transient renal and pancreatic insufficiency. 
Jaundice (yellow discoloration of skin and sclerae without evidence of liver 
insufficiency) and hemoglobinuria were minor adverse drug reactions that 
predominantly occurred in the 100 mg!kg group. Although patients in the 
DCLHb group tended to have more severe strokes at baseline than the control 
group, multivariate logistic regression analysis showed that a severe stroke at 
baseline (odds ratio (OR) 20.9;confidence interval (CI) 4.1-102.4) and treatment 
with DCLHb (OR 3.9; CI 1.4-12.0) were independent predictors of a worse 
outcome (Rankin 3-6) at 3 months. In conclusion, outcome scale scores were 
worse in the DCLHb group and more serious adverse events and deaths 
occurred in DCLHb-treated patients than in controls. 
BP is often elevated in the acute phase of stroke. Lowering BP is commonly 
discouraged as this may adversely affect outcome. As the DIAS trial was to our 
knowledge the first to elevate BP in a randomized controlled fashion, we took a 
more detailed look at the pressor effect of DCLHb, in chapter 4. DCLHb (25, 
50 and 100 mg/kg, n=lO, 10 and 20, respectively) or placebo (n=45) was 
infused intravenously every 6 hours for 72 hours. We measured BP and heart 
rate every 15 minutes. Safety was further monitored by repeated physical and 
neurological examinations and by CT and MRI scans. 
DCLHb caused a rapid rise in mean BP from 113±14 at baseline to 129±21, 
135±11 and 135±24 for the 25, 50 and lOOmg!kg respectively, versus. 
109±16nunHg in controls. The duration of this effect on BP was dose-
dependent. The pressor effect was not accompanied by complications such as 
hemorrhagic transformation of the infarct, brain edema or hypertensive 
encephalopathy and there was no excess need for anti-hypertensive treatment. 
However, clinical outcome at 3 months was worse in the treatment group. 
Even though the pressor effect by itself was well tolerated, clinical outcome, 
described in chapter 3, was worse in patients treated with DCLHb. Further 
studies should therefore try and evaluate other methods of induced hypertension 
and explore their clinical efficacy. 
For more than 50 years it has been known that hemolyzed blood can increase 
BP. Although pre-clinical studies suggest that this pressor response is due to 
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interaction of hemoglobin with endothelium-derived vasoactive substances, its 
mechanism in humans is unknown. We investigated the involvement of 
endothelin-1 (ET -1) in the BP response to DCLHb. This is described in 
chapter 5. These data were only collected for the patients randomized in 
Rotterdam. 
DCLHb in a dose increasing fashion (25, 50 and 100 mg/kg, n=8, 8 and 11, 
respectively) or placebo (n=26) was infused intravenously every 6 hours for 72 
hours to patients with an acute ischemic stroke. BP and heart rate (every 15 
minutes) and plasma concentrations ofET-1, catecholamines, renin, vasopressin 
and atrial natriuretic peptide (before and 24 and 66 hours after the start of 
infusions) were measured. 
In the placebo group, mean arterial pressure (MAP) of 112 (109-115) rnmHg 
(mean and 95%CI) at baseline decreased spontaneously by 11.4 (5.4 -17.5) and. 
12.5 (5.4-19.5) rnmHg after 24 and 66 hours, respectively. This decrease in 
MAP was attenuated in patients treated with DCLHb, reaching statistical 
significance in the highest dose group. Plasma ET-1 concentration decreased 
slightly in the placebo group from 4.2 (3.1-5.3) pg/ml (median and range) at 
baseline to 2.4(1.9-3.7) pg/ml after 24 hours (p=0.0044) and 2.8 (1.9-3.7) pg/ml 
after 66 hours (p=0.0042), but increased dose-dependently in response to 
DCLHb infusion. With the highest dose of DCLHb, plasma ET -1 concentration 
rose from 4.8 (0.1-7.8) pg/ml at baseline to 21.2 (13.4-53.2) pg/ml after 24 
hours (p<O.OOl) and to 27.6 (11.9-47.8) pg/ml after 66 hours (p<O.OOl). 
Increments in plasma ET-1 concentration and in MAP were correlated (r=0.30, 
p=0.02). Other vasoactive hormones were not affected by DCLHb infusion. 
Infusion of DCLHb in patients with acute ischemic stroke is associated with a 
dose-dependent increase in plasma ET-1 concentration. We suggest that this 
increase prevents the natural decrease in BP in these patients. 
DCLHb was not beneficial when given to patients with acute ischemic stroke, 
whilst it was clearly hemodynamically active. In chapter 6, we wanted to 
determine whether the adverse effect of DCLHb on outcome was mediated 
through adverse effects on the heart. Blood pressure and heart rate were 
measured every 15 minutes. Continuous ECG monitoring was performed during 
84 hours. Standard 12 lead ECG's were made at entry, after 24 hours and once 
between day 3 and 7. Patients were checked for adverse events on a daily basis. 
Plasma levels of creatine kinase (CK), lactate dehydrogenase (LDH) including 
sub-fractions were determined regularly. 
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DCLHb caused a rapid rise in mean arterial blood pressure that was not 
accompanied by complications or excess need for anti-hypertensive treatment. 
Cardiac functions as assessed by ECG's, Holter registration, and physical 
examination were not affected. Cardiac adverse events, such as heart failure, 
dysrhythmias occurred equally in both groups. Dose-dependent increases of 
LDH and CPK were found, but without an increase in CK-MB or LDH-1 sub-
fractions. We conclude that the adverse effect of DCLHb on clinical outcome 
was not caused through adverse effect on the heart. 
Chapter 7 provides the introduction to the second part of this thesis and 
discusses early recurrence of stroke, one of the feared complications in the acute 
phase of ischemic stroke. The frequency of early recurrent stroke varies in 
different studies and is often believed to be higher in patients with a potential 
cardiac source of embolism. This chapter reviews the definition and 
epidemiology of early recurrent stroke, tries to identify risk factors for early 
stroke recurrence and focuses on the benefits and risks of antithrombotic 
therapy in the prevention of this complication. 
The diagnosis of early recurrent stroke is not always easy in patients with acute 
ischemic stroke, since up to 20% of patients show spontaneous fluctuations, 
some of which may be caused by repeated embolism, but many have other 
causes, including systemic disorders. The risk of recurrent stroke seems to be 
higher in patients entered in clinical trials than in population based studies or 
stroke data banks. The aggregate results of randomized clinical. trials of heparin 
in acute ischemic stroke suggest that this treatment reduces the risk of early 
recurrence by about one quarter, but also that this benefit is completely offset by 
an equal risk of hemorrhage. Present data neither suggest a clear subgroup, in 
particular those with cardioembolic stroke, with a higher risk of early 
recurrence, nor one that specifically benefits from early treatment with 
anticoagulants. Findings from two large trials show that aspirin is safe and 
effective in reducing death and early recurrence, preventing I 0 events per 1000 
patients treated. 
Atrial fibrillation (AF), both continuous and paroxysmal (P AF), constitute a 
major risk factor for stroke. The most effective way to diagnose P AF in acute 
stroke patients without a history of AF is still uncertain. In chapter 8 we 
167 
Summary 
compare the yield of 84-hour Holter-ECG recording with that of a single Holter-
ECG during the first 24 hours and of repeated ECG' s during the first 7 days. 
We prospectively studied 85 patients with ischemic stroke in the anterior 
circulation of less than 18 hours duration by means of continuous ECG 
monitoring during 84 hours within the setting of the DIAS-trial. Medical 
history, including AF, was assessed from patients, general practitioners and 
available hospital information. Standard 12 lead ECG's were made at entry, 
after 24 hours and once between day 3 and 7. The patients with AF were 
divided in 2 groups: with or without a history of AF. 
Twenty-one patients had AF, including 11 with a history of AF. Eight of 21 
patients had PAF. Five of these 8 patients did not have a history of AF. Seven 
of 8 patients with P AF were identified by 84-hour Holter-ECG recording, 5 by 
repeated ECG's, and none by Holter-ECG recording during the first 24 hours 
only. It is concluded that P AF is commonly present in patients with acute 
ischemic stroke, and often newly discovered. It can be most effectively 
identified by 84-h Holter-ECG recording and only slightly less effectively by 
repeated ECG's. The yield ofHolter-ECG monitoring during the frrst 24 hours 
only is extremely low. 
In chapter 9 we investigated the apparently high risk of early death after an 
ischemic stroke among patients with atrial fibrillation (AF), identified the main 
factors associated with early death, and assessed the effect of treatment with 
different doses of subcutaneous unfractionated heparin (UFH) given within 48 
hours. We studied the occurrence of major clinical events within 14 days 
among 18,451 patients from IST, firstly for all treatment groups combined and 
then, among patients with AF, we examined the effects of treatment with 
subcutaneous UFH started within 48 hours and continued till 14 days after 
stroke onset. 
3,169 (17%) patients were in AF. A total of784 patients were allocated to UFH 
12,500 IU sc bid, 773 to UFH 5,000 IU sc bid, and 1612 to "no heparin". 
Within each of these groups, half of the patients were randomly assigned to 
aspirin 300 mg once daily. Compared with patients without AF, patients with 
AF were more likely to be: female (56% vs. 45%), older (mean 78 vs. 71 yrs), 
have an infarct on the pre-randomization CT (57% vs. 47%), and have impaired 
consciousness (37% vs. 21%). The initial ischemic stroke type was more often 
a large artery infarct (36% vs. 21 %). A lacunar stroke syndrome was less 
common (13% vs. 26%). Death within 14 days was commoner in patients with 
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AF (17% vs. 8%) and more often attributed to neurological damage from the 
initial stroke (10% vs. 4%). The frequency of recurrent ischemic or undefined 
stroke was not significantly different (3.9% vs. 3.3%). The proportion of AF 
patients with further events within 14 days allocated to UFH 12,500 IU 
(n=784), UFH 5,000 IU (n=773) and to "avoid heparin" (n=l612) respectively, 
were: ischemic stroke 2.3%, 3.4%, 4.9% (p=O.OOl); hemorrhagic stroke 2.8%, 
1.3%, 0.4% (p<O.OOOl); and any stroke or death 18.8%, 19.4% and 20.7% 
(p=0.3). No effect of heparin on the proportion of patients dead or dependent at 
6 months was apparent. 
Acute ischemic stroke patients with AF have a higher risk of early death, which 
can be explained by older age and larger infarcts, but not by a higher risk of 
early recurrent ischemic stroke, although slightly more patients with AF died 
from a fatal recurrent stroke of ischemic or unknown type (1.3% vs. 0.9%). In 
patients with AF the absolute risk of early recurrent stroke is low, and there is 
no net advantage to treatment with heparin. These data do not support the 
widespread use of intensive heparin regimens in the acute phase of ischemic 
stroke associated with AF. 
The results of the studies reported in this thesis are discussed in chapter 10. It 
is concluded that: 
I. The hemodynamic response caused by DCLHb increases vascular 
resistance, and probably eliminates its potential as a neuroprotective agent 
in acute ischemic stroke. 
2. In the 3169 patients with AF from IST, the medium-dose (12.500 IU) 
heparin regimen was clearly more effective in preventing early recurrent 
stroke than the low-dose heparin regimen or than aspirin, but it was also 
the most hazardous, considering the steep increase in intracerebral 
hemorrhage. UFH can produce a highly variable anticoagulant response, 
both inter- and intraindividually. LMWH's produce a more predictable 
response. However, both UFH and LMWH have not been found to be 
useful in improving outcome in AF patients with ischemic stroke. Further 
trials with anticoagulation are not warranted in this group of patients. AF 
patients with a TIA or rapidly resolving minor ischemic stroke can be 
treated with anticoagulants immediately after the event on the basis of the 
European Atrial Fibrillation Trial results. 
169 

Samenvatting 
Samenvatting 
172 
Samenvatting 
Het herseninfarct is een belangrijke doodsoorzaak in de Westerse wereld en 
aanleiding tot langdurige ziekenhuisopnames invaliditeit. De enige tot nog toe 
bekende effectieve behandeling, trombolyse met recombinant tissue 
plasminogen activator, kan slechts op een klein dee! van de patienten met een 
infarct worden toegepast. 
In dit proefschrift worden twee behandelingen voor het acute herseninfarct, 
beide getest in gerandomiseerde gecontroleerde studies, beschreven. Als eerste 
werden de veiligheid, werkzaamheid en farmacodynamiek van een hemoglobine 
oplossing, Diaspirin Cross-linked Hemoglobin (DCLHb, HemAssist®), 
onderzocht in een multicenter trial van patienten in de acute fase van het 
herseninfarct. Ten tweede, hebben we het effect van heparine bestudeerd bij 
patienten met een acuut herseninfarct in combinatie met boezemfibrilleren bij 
patienten uit een grote studie, de International Stroke Trial (IST). We waren 
vooral gelnteresseerd in de preventie van vroege recidief infarcten. 
Hoofdstuk 2 beschrijft de ratio achter het gebruik van DCLHb en heparine bij de 
behandeling van het acute herseninfarct. 
DCLHb is een gezuiverde, celvrije, humane hemoglobine oplossing, en is 
oorspronkelijk ontwikkeld als een bloedvervangend product. Nadat duidelijk 
werd dat DCLHb zuurstofaanvoer bevordert, terwijl het zowel de bloeddruk als 
de orgaanpersfusie doet toenemen, werden studies verricht in dierexperimentele 
herseninfarctrnodellen. De gunstige resultaten hiervan hebben uiteindelijk 
geleid tot de start van onze fase II (veiligheid) studie: DCLHb in Acute 
Ischemic Stroke (DIAS). Het bloeddrukverhogende effect dat na infusie van 
DCLHb is geen unieke eigenschap van DCLHb, maar een eigenschap van 
hemoglobine oplossingen in het algemeen. Verscheidene studies verricht om 
het mechanisme van het bloeddrukverhogende effect van DCLHb te ontrafelen 
worden beschreven. De voomaamste conclusie is dat DCLHb inwerkt op het 
perifere vasculaire autoregulatoire systeem, en niet op het centrale zenuwstelsel. 
Er is aangetoond dat er interactie is tussen DCLHb en nitric oxide (NO) en zo 
contractie van vasculaire gladde spierweefsel cellen veroorzaakt. Studies bij 
ratten hebben aangetoond dat infusie van DCLHb leidt tot verhoogde 
endotheline (ET-1) spiegels alsmede een toename van de bloeddruk. Dit 
bloeddrukverhogend effect werd duidelijk verzwakt door voorbehandeling met 
een ET -receptor antagonist, aldus bewijs verschaffend voor de hypothese dat 
het bloeddrukverhogend effect in elk geval deels wordt veroorzaakt, door de 
verhoogde ET -1 spiegels. 
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Heparine wordt geregeld toegediend aan patienten met een infarct, ondanks het 
gebrek aan overtuigend bewijs voor de veiligheid of effectiviteit van deze 
behandeling. Heparine wordt o.a. gegeven om vroege lysis van de thrombus te 
bewerkstelligen en om thrombo-embolische complicaties zoals vroege 
recidieven te voorkomen. Aangezien de recidiefkans soms hoger wordt geacht 
bij patienten met atrium fibrillatie (AF), zijn clinici bij een infarct in 
aanwezigheid van AF nog meer geneigd over te gaan op behandeling met 
heparine. In dit dee! van hoofdstuk 2 wordt een overzicht gegeven van het 
bewijs betreffende de veiligheid en effectiviteit van heparine in de acute fase 
van het infarct. De conclusie is dat er slechts een groep van infarct patienten is, 
waarbij het heilzame effecten van heparine onomstotelijk is vastgesteld: in de 
Europese Atrium Fibrillatie Trial (EAFT) bleek behandeling met orale 
antistolling bij patienten met niet-reumatisch AF en een recente TIA of niet 
invaliderend herseninfarct de kans op een recidief infarct met twee derde te 
reduceren. Maar de EAFT verschaft geen data over de balans tussen de voor-
en nadelen van antistolling in de acute fase na het ontstaan van de symptomen. 
Voor zover mij bekend, is er slechts een studie geweest die zich heeft 
geconcentreerd op behandeling met antistolling in de acute fase van het 
herseninfarct in aanwezigheid van AF. In de HAEST studie hebben Berge et a!. 
onderzocht of behandeling met gefractioneerde heparine ( dalteparine) beter is 
dan aspirine om recidief infarcten gedurende de eerste 14 dagen te voorkomen 
bij patienten met AF. Er werden 449 patienten gerandomiseerd. De 
behandeling werd binnen 30 uur na aanvang van symptomen · gestart. De 
auteurs concludeerden dat hoewel de data geen bewijs leverden dat LMWH 
beter is dan aspirine in deze groep van patienten, de mogelijkheid van een 
kleiner, maar toch nog steeds klinisch waardevolle effect van een beide 
middelen niet kon worden uitgesloten. Ook was de trial niet groot genoeg om 
een betrouwbare schatting te geven van een eventueel verhoogd risico op 
hersenbloedingen door dalteparine. 
Aangezien er 3169 patienten met AF waren gerandorniseerd in de International 
Stroke Trial (IST), hebben wij besloten deze groep uitgebreider te bestuderen. 
Hoewel het een subgroep analyse betreft, is het waardevol omdat er nog vee! 
vragen rond AF in associatie met een acuut infarct onbeantwoord zijn. 
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In hoofdstuk 3 worden de opzet, uitvoering en de hoofdresultaten van de DIAS 
trial beschreven. Dit was een multi-center, gerandomiseerde, enkelblinde, 
placebogecontroleerde, fase II studie bestaande uit 3 delen. Gedurende een 
periode van 72 uur werden twaalf doseringen van 25, 50 of lOOmg/kg DCLHb 
of eenzelfde volume fysiologische zoutoplossing werden toegediend aan 
patienten met een infarct in de voorste circulatie. Behandeling werd binnen 18 
uur na ontstaan van de symptomen gestart. Het prirnaire doe! van de studie was 
te bepalen of toediening van DCLHb aan patienten met een infarct veilig is. 
DCLHb veroorzaakte een snelle stijging van de bloeddruk. Deze verhoging van 
de bloeddruk ging niet gepaard met complicaties en werd goed verdragen. De 
plasmaconcentratie van lactaat dehydrogenase (LDH), creatine kinase (CK), 
bilirubine and aspartaat aminotransferase (AST) waren dosisafhankelijk 
verhoogd. Deze laboratoriumafwijkingen waren asymptomatisch en verdwenen 
binnen een week. Twee patienten, beide uit de I 00 mg/kg groep, hadden een 
'adverse event' dat mogelijk gerelateerd was aan DCLHb. Het betrof een 
patient met fataal hersen- en longoedeem, en een met voorbijgaande nier- en 
pancreasinsufficientie. Geelzucht (gele verkleuring van huid en slerae, zonder 
aanwijzingen voor leverinsufficientie) en hemoglobinurie waren minor 'adverse 
drug reactions', die voornamelijk optraden in de 100 mg/kg groep. Hoewel de 
patienten in de DCLHb groep ertoe negen ernstiger infarcten bij baseline te 
hebben, toonde multivariate logistische regressie analyse aan dat een ernstige 
infarct bij binnenkomst (odds ratio (OR) 20.9;confidence interval (CI) 4.1-
102.4) en behandeling met DCLHb (OR 3.9; CI 1.4-12.0) onafhankelijke 
voorspellers waren van een slechte uitkomst (Rankin 3-6) op 3 maanden. 
Concluderende waren de uitkomst schalen slechter in de DCLHb groep en er 
traden meer 'serious adverse events' en doden op bij patienten behandeld met 
DCLHb dan bij controle patienten. 
De bloeddruk is vaak verhoogd in de acute fase van het herseninfarct. Verlagen 
van de bloeddruk wordt in het algemeen afgeraden aangezien dit het herstel 
mogelijk negatief kan be'invloeden. Aangezien de DIAS trial voor zover ik 
weet de eerste studie was, waarin de bloeddruk op een gerandomiseerde 
gecontroleerde manier werd verhoogd, hebben we het pressor effect van 
DCLHb in hoofdstuk 4 wat uitgebreider bestudeerd. DCLHb (25, 50 and 100 
mg/kg, n=lO, 10 and 20, respectievelijk) of placebo (n=45) werd intraveneus 
toegediend, iedere 6 uur gedurende 72 uur. Behandeling werd binnen 18 uur na 
het ontstaan van de symptomen begonnen. De bloeddruk en hartfrequentie 
werden iedere 15 minuten gemeten. Voorts werd herhaaldelijk algemeen 
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lichamelijk en neurologisch onderzoek verricht en werden CT- en MRI-scans 
gemaakt. 
DCLHb veroorzaakte een snelle stijging van de gemiddelde arteriele bloeddruk 
van 113±14 op baseline naar 129±21, 135±11 en 135±24mrnHg voor de 25, 50 
and 1 OOmg/kg groepen respectievelijk, versus. 1 09±16mrnHg in de controle 
groep. De duur van dit effect op de bloeddruk was dosisafhankelijk. Het 
pressor effect werd niet vergezeld door complicaties zoals hemorrhagische 
transformatie van het infarct, hersenoedeem, hypertensieve encephalopathie of 
toename van het gebruik van anti-hypertensiva gebruikt. Echter, de klinische 
uitkomstvariabelen waren slechter in de behandelde groep. 
Hoewel het pressor effect op zich goed getolereerd, was de klinische uitkomst, 
besproken in hoofdstuk 3, slechter bij de patienten behandeld met DCLHb. 
Toekomstige studies zouden andere methodes van gefuduceerde hypertensie 
moeten bestuderen en de klinisch effect hiervan moeten evalueren. 
Al meer dan 50 jaar is bekend dat gehemolyseerd bloed de bloeddruk kan 
verhogen. Hoewel dierexperimentele studies suggereren dat de verhoging van 
de bloeddruk wordt veroorzaakt door interactie van hemoglobine met uit het 
endotheel afkomstige vaso-actieve substanties, is het mechanisme bij de mens 
onbekend. Wij onderzochten de betrokkenheid van endotheline-1 (ET-1) bij het 
bloeddrukverhogende effect van DCLHb. Dit wordt beschreven in hoofdstuk 
5. Deze data zijn aileen verzameld bij de patienten geran.domiseerd in 
Rotterdam. 
In een gerandomiseerde fase II studie, werd DCLHb in verschillende doseringen 
(25, 50 and 100 mg/kg, n=8, 8 and 11, respectievelijk) of placebo (n=26) 
intraveneus toegediend, iedere 6 uur gedurende 72 uur aan patienten met een 
acuut herseninfarct. De bloeddruk en hartfrequentie (iedere 15 minuten) en 
plasma concentraties van ET -1, catecholamines, renine, vasopressine and atriaal 
natriuretisch peptide (v66r en 24 en 66 uur na het starten van de infusies) 
werdengemeten. 
In de placebo groep, daalde de gemiddelde arteriele bloeddruk (MAP) van 112 
(109-115) mrnHg (gemiddelde en 95%BI) bij baseline spontaan met 11.4 (5.4-
17.5) en 12.5 (5.4-19.5) mrnHg na 24 en 66 uur, respectievelijk. Deze daling 
van de MAP was verminderd bij patienten behandeld met DCLHb. Dit verschil 
was statistisch significant in de groep die de hoogste dosering DCLHb ontving. 
Plasma ET-1 concentraties daalden Iicht in de placebo groep van 4.2 (3.1-5.3) 
pg/ml (mediaan en range) bij baseline naar 2.4(1.9-3.7) pg/ml na 24 uur 
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(p=0.0044) en 2.8 (1.9-3.7) pg/ml na 66 uur (p=0.0042), maar stegen 
dosisafhankelijk als reactie op de DCLHb infusies. Bij de hoogste dosering van 
DCLHb, steeg de plasma ET-1 concentratie van 4.8 (0.1-7.8) pg/ml bij baseline 
naar 21.2 (13.4-53.2) pg/ml na 24 uur (p<0.001) en naar 27.6 (11.9-47.8) pg/ml 
na 66 uur (p<0.001). De toename van de plasma ET-1 concentratie en van de 
MAP waren gecorreleerd (r=0.30, p=0.02). De concentraties van de overige 
vasoactieve hormonen werden niet beinvloed door DCLHb. 
Infusie van DCLHb bij patienten met een acuut herseninfarct gaat gepaard met 
een dosisafhankelijke stijging van de plasma ET-1 concentratie. Wij doen de 
suggestie dat deze toename de natuur1ijke daling van de b1oeddruk bij deze 
patienten tegengaat. 
Patienten met een acuut herseninfarct hadden geen baat bij toediening van 
DCLHb, terwijl het wei duidelijk hemodynamisch actief was. In hoofdstuk 6, 
wilden we uitzoeken of het negatieve effect van DCLHb op de uitkornst werd 
veroorzaakt door een negatief effect op de cardiale functies. Continue Holter-
ECG monitoring werd verricht gedurende 84 uur. Standaard ECG' s werden 
gemaakt bij opname, na 24 uur en een keer tussen dag 3 en 7. Patienten werden 
dagelijks gecontroleerd op 'adverse events'. Plasma concentraties van creatine 
kinase (CK), !actaat dehydrogenase (LDH) inclusief subfracties werden op vaste 
tijden bepaald. 
DCLHb veroorzaakte een snelle stijging van de gemiddelde arteriele bloeddruk, 
die niet gepaard ging met complicaties of een overmaat aan behandeling met 
anti-hypertensiva. Cardiale functies, gemeten door middel van ECG's, Holter 
registraties, en lichamelijk onderzoek waren niet aangedaan. Cardiale 'adverse 
events', zoals hartfalen en arrhythmieen kwamen even vaak voor in beide 
groepen. De plasmaconcentraties van LDH en CPK stegen dosisafhankelijk, 
maar zonder een toename van de cardiale subfracties, CK-MB en LDH-1. De 
conclusie is dat de slechtere uitkomst van de patienten behandeld met DCLHb 
niet veroorzaakt werd door een negatief effect op de functie van de hart. 
Hoofdstuk 7 is de introductie tot het tweede dee! van dit proefschrift en 
bespreekt vroege recidief infarcten, een van de gevreesde complicaties in de 
acute fase van het herseninfarct. De frequentie van vroege recidieven varieert 
in verschillende studies en er wordt vaak aangenomen dat deze hoger is bij 
patienten met een potentiele cardiale emboliebron. In dit hoofdstuk worden de 
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definitie en epidemiologie van vroege recidief infarcten besproken, wordt 
gepoogd risicofactoren voor vroege recidief infarcten te identificeren en worden 
de kosten en baten van anti-trombotische therapie voor de preventie van deze 
complicatie tegen elkaar afgewogen. 
De diagnose vroeg recidief infarct is niet altijd gemakkelijk bij patienten met 
een acuut herseninfarct, aangezien tot 20% van de patienten spontane fluctuaties 
vertonen. Een dee! van deze fluctuaties wordt veroorzaakt door een recidief 
embolus, maar velen hebben een andere oorzaak, bijvoorbeeld een metabole 
stoomissen. Het risico van een recidief infarct !ijkt hoger te zijn bij patienten 
die gemcludeerd zijn in klinische trials dan in populatie studies of stroke data 
banken. Het aggregaat van de resultaten van gerandomiseerde klinische studies 
van heparine bij het acute herseninfarct suggereert dat deze behandeiing het 
risico van een vroeg recidief met ongeveer een kwart doet verminderen, maar 
dat dit voordeel volledig teniet wordt gedaan door een even grote verhoging van 
de kans op een intracerebrale bloeding. De huidige data suggereren noch een 
duidelijke subgroep, m.n. die met een cardioembolisch infarct, met een hoger 
risico op een vroeg recidief infarct, noch een subgroep die we! baat zou hebben 
bij vroege behandeling met anticoaguiantia. Het enige tot nog toe effectief 
gebieken middel om voege recidief infarcten te voorkomen is aspirine. De 
bevindingen van twee grote studies tonen aan dat behandeling met aspirine 
gedurende de eerste 14 dagen na het herseninfarct 10 vroege recidief infarcten 
en doden per 1000 behande!de patienten voorkomt. 
Atrium fibrilleren (AF), zowel continu als paroxysmaal (P AF), is een grote 
risicofactor voor een infarct. Het is nog onduidelijk wat de meest effectieve 
manier is om P AF te diagnosticeren bij patienten met een acuut herseninfarct 
zonder een voorgeschiedenis van AF. In hoofdstuk 8 wordt de additionele 
diagnostische opbrengt van langdurige Holter-ECG monitoring in de acute fase 
van herseninfarct om P AF op te sporen, vergeleken met herhaalde ECG' s 
gedurende de eerste week en Holter-ECG gedurende de eerste 24 uur. 
Wij bestudeerden prospectief 85 patienten met een herseninfarct in de voorste 
circulatie binnen 18 uur na het begin van de symptomen d.m.v. continue ECG 
monitoring gedurende 84 uur in de setting van de DIAS-trial. De 
voorgeschiedenis, waaronder AF, werd afgenomen van patienten, hun 
huisartsen en de beschikbare geautornatiseerde informatie van het ziekenhuis. 
Standaard ECG' s werden gemaakt bij opname, na 24 uur en nog een keer tussen 
dag 3 en 7. De patienten met AF werden onderverdeeld in 2 groepen: met of 
zonder AF in de voorgeschiedenis. 
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Eenentwintig patienten hadden AF, waarvan 11 bekend we gens AF in de 
voorgeschiedenis. Acht van deze 21 patienten hadden P AF. Bij 5 van hen was 
AF nooit eerder geconstateerd. Zeven van de 8 patienten met P AF werden 
gei:dentificeerd d.m.v. 84-uur Holter-ECG, 5 d.m.v. herhaalde ECG's, en niet 
een door Holter-ECG registratie gedurende de eerste 24 uur. Er wordt 
geconcludeerd dat P AF regelmatig voorkomt bij patienten met een acuut 
herseninfarct, en vaak een nieuwe bevinding is. De meest effectieve 
opsporingsmethode is die d.m.v. 84-uurs Holter-ECG registratie en de 
herhaalde ECG's zijn slecht iets minder effectief. De opbrengst van Holter-
ECG monitoring gedurende de eerste 24 uur is extreem laag. 
In hoofdstuk 9 hebberi we het hoge kans op vroege dood na een herseninfarct 
bij patienten met AF bestudeerd, de belangrijkste factoren geassocieerd met 
vroege dood gei:dentificeerd, en het effect van behandeling met verschillende 
doseringen subcutaan toegediende heparine geevalueerd. Wij onderzochten het 
optreden van 'major clinical events' binnen 14 dagen onder 18.451 patienten uit 
de International Stroke Trial (IST), in eerste instantie voor aile 
behandelingsgroepen gecombineerd. V ervolgens bestudeerden we onder 
patienten met AF, het effect van behandeling met ongefractioneerde heparine 
(UFH) begonnen binnen 48 uur na start van de symptomen en voortgezet tot en 
met 14 dagen ema. 
3.169 (17%) patienten hadden AF. In totaal kregen 784 patienten behandeling 
met UFH 12.500 IE sc 2 dd toegewezen, 773 UFH 5.000 IE sc 2dd, en 1612 
kregen 'geen heparine'. Binnen a! deze groepen kreeg de helft van de patienten 
op gerandomiseerde wijze 300mg aspirine per dag. Vergeleken met patienten 
zonder AF, waren patienten met AF vaker: vrouw (56% vs. 45%), ouder 
(gemiddeld 78 vs. 71 jaar), hadden een infarct op de pre-randomisatie CT-scan 
(57% vs. 47%), en een gedaald bewustzijn (37% vs. 21 %). Ret initiele 
herseninfarct was vaker een corticaal infarct (36% vs. 21 %). Lacunaire 
syndroom kwam minder vaak voor (13% vs. 26%). Dood binnen 14 dagen 
kwam vaker voor bij patienten met AF (17% vs. 8%) en werd vaker 
toegeschreven aan neurologische schade van het oorsprorikelijke infarct (10% 
vs. 4%). De frequentie van recidiefherseninfarct ofniet nader gespecificeerde 
beroerte was niet significant anders (3.9% vs. 3.3%). 
De proportie van AF patienten met 'major clinical events' events binnen 14 
dagen per behandelingsgroep was als volgt; UFH 12.500 IE (n=784), UFH 
5.000 IE (n=773) en 'geen heparine' (n=l612) respectievelijk: herseninfarct 
2.3%, 3.4%, 4.9% (p=O.OOl); hersenbloeding 2.8%, 1.3%, 0.4% (p<O.OOOl); en 
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hersenbloeding, -infarct of dood 18.8%, 19.4% and 20.7% (p=0.3). 
Behandeling met heparine had geen effect op de proportie patienten die op 6 
dood of afhankelijk op tijdstip 6 maanden. 
Concluderend stellen we dat patienten met een acuut herseninfarct in 
combinatie met AF een hager risico hebben op vroege dood. Dit kan worden 
verklaard door hun oudere leeftijd en grotere infarcten, maar niet door een 
grotere kans op een recidief herseninfarct, hoewel iets meer patienten met AF 
overleden als gevolg van een recidief beroerte met een ischemische of 
onbekende oorzaak (1.3% vs. 0.9%). Bij patienten met AF is het absolute risico 
op een vroeg recidief infarct laag, en er is geen netto voordeel van behandeling 
met heparine. Deze data ondersteunen het wijdverbreide gebruik van intensieve 
heparine regimes in the acute fase van het herseninfarct bij aanwezigheid van 
AFniet. 
De resultaten van de studies gepresenteerd in dit proefschrift worden besproken 
hoofdstuk 10. Er wordt geconcludeerd dat: 
I. DCLHb een bloeddrukverhoging veroorzaakt die hoogstwaarschijnlijk 
gepaard gaat met een verhoogde vaatweerstand. Hierdoor is DCLHb niet 
bruikbaar als neuroprotectivum voor patienten met een acuut 
herseninfarct. 
2. Onder de 3169 patienten met AF uit deIST, was de medium-dose (12.500 
IU) heparine duidelijk effectiever in het voorkomen van vroege recidief 
infarcten dan de !age dosering heparine en dan aspirine, maar het was ook 
de meest riskante behande1ing, gezien de forse toename van 
hersenb1oedingen. Het is bekend dat ongefractioneerde heparine een zeer 
variabe1 effect heeft op de stalling, zowe1 inter- a1s intraindividueel. 
Laagmo1eculaire heparines geven een meer voorspelbaar effect Maar, van 
zowel ongefractioneerde heparine a1s van 1aagmo1eculaire heparines is 
aangetoond dat deze niet effectief zijn om de uitkomst van patienten met 
een herseninfarct en AF te verbeteren. Verdere studies met heparine in 
deze groep patienten bieden weinig perspectief. AF patienten met een 
TIA of een snel herstellend minor stroke moeten op basis van de resultaten 
van de European Atrial Fibrillation Trial direct met anticoagulantia 
worden behandeld. Voor aile andere patienten is aspirine de beste optie. 
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